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1. Introduction 
1.1 Rett syndrome 
1.1.1 Story and Clinical aspects: symptomatology, 
neurobiology, biochemical alterations and variants  
Rett syndrome (RTT) [OMIM 312750] is a rare neurodevelopmental 
disorder, that almost exclusively affects females with a incidence of 1 in every 
10,000 births, characterized by severe behavioural and physiological 
symptoms (Rett, 1966; Hagberg et al., 2002; Ricceri et al., 2012). RTT was 
reported for the first time by Dr. Andreas Rett, paediatric neurologist: he 
studied the clinical cases of two female children showing an unusual 
compulsive behaviour and physical and cognitive deficits, symptomatology 
very similar to patients with Autism. He started to investigate deeply on this 
strange symptoms finding 22 cases of this new disorder in Europe, publishing 
results in 1966 (Rett, 1966) without impacting the scientific community until 
1983, when Dr. Hagberg described 35 clinical cases displaying the Rett’s 
described symptomatology (Hagberg et al., 1983; Hagberg, 1985).  
One essential feature of RTT is the apparently normal perinatal 
development until about 6-18 months of age, when RTT patients start a 
regression period, losing their acquired cognitive, social, and motor skills and 
develop a wide variety of symptoms (Hagberg, 2002) (Fig. 1). Indeed, most of 
the severe symptoms in RTT are not quite detectable in the first stage of the 
disorder. After the first “normal development” phase, at 6 months of age starts 
the “developmental stagnation” phase, characterized by microcephaly, growth 
arrest and hypotonia. Already after the first year of life, child enters in a phase 
called “rapid regression”, phase where child loses the hands skills, the speech, 
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the social interaction, developing all autistic features, including severe mental 
retardation. Moreover, the child displays hands stereotypies, breathing 
impairments and seizures. Despite everything there are more and more 
evidences supporting the absence of this regression phase, suggesting that 
already from the first days of life, some morphological and biochemical 
alterations are just detectable in RTT patients (Cosentino et al.,  in preparation). 
After this phase of rapid regression, about three years of age the clinical picture 
goes to a “stationary stage” characterized by scoliosis defect and the anxiety 
behaviour onset accompanied by a late motor deterioration leading to motor 
rigidity and Parkinsonian features that will accompanied child for all life, 
causing complications often deadly (Chahrour and Zoghbi, 2007).  
Classic RTT is caused in about 90–95% of cases mutations in the X-
linked MECP2 gene, which encodes the methyl CpG-binding protein 2 
(MECP2), a multifunctional protein that binds to methylated DNA and mainly 
acts as a key transcriptional regulator (Guy et al., 2011). This protein was 
identified in 1992 by Dr. Adrian Bird and colleagues (Meehan et al., 1992). 
Only 7 years later, mutations in MECP2 were associated to be the most 
important cause of RTT (Amir et al., 1999).  Most of the mutations arise de 
novo in the paternal germline and many times involve a C to T transition at 
CpG dinucleotides (Trappe et al., 2001). A wide range of mutations occurs on 
MECP2 gene; eight missense and nonsense mutations in about 70% of cases, 
small C-terminal deletion in about 10% of cases and complex rearrangements 
in about 6% of cases (Christodoulou and Weaving, 2003).  
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Fig.1: Developmental phases in the Rett syndrome: at each phase corresponds a 
wide range of symptoms (Chahrour and Zoghbi, 2007)  
After the first initial description and characterization of RTT, to better 
define its neuro-biology and pathology features at the end of 80’s many 
neuroimaging and neuropathological studies have been carried out on RTT 
patients. The head growth deceleration and cognitive decline suggested 
alterations in neocortex, whereas gait disturbances involved extrapyramidal 
and cerebellar dysfunction. Actually, there is a generalized brain atrophy (12-
34% reduction in brain weight and volume in RTT patients (Armstrong, 2005)) 
involving cerebrum and cerebellum (Nomura et al., 1985; Reiss et al., 1993; 
Armstrong, 2005). Contrary to what was expected, no evidence of neuronal 
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loss was detected (Armstrong et al., 1995), suggesting the absence of a 
neurodegeneration over time. However, from RTT post-mortem brain studies 
several changes in neurons synaptic growth and architecture regarding the 
number of dendrites as well as the presence of regions without dendritic spines 
were observed (Belichenko et al., 1994). Post-mortem studies characterizing 
different brain regions cell types, have tried to correlate cells alterations and 
symptoms occurrence (Leontovich et al., 1999). In addition, several 
neurochemical alterations in RTT patients were also reported, mainly related 
to cholinergic and dopaminergic systems (Brucke et al., 1987; Wenk et al., 
1993).  Nevertheless, all these results suggest a fundamental role for MeCP2 
in neuronal maturation and maintenance. Considering that the reported 
alterations are linked with a lacking general brain growth and functionality, 
several studies focused on the levels of neurotrophic factors in cerebrospinal 
fluid and serum, using them as markers of pathogenesis too. Indeed, low 
concentrations of cerebrospinal fluid nerve growth factor (NGF) that acts on 
cholinergic neurons of the basal forebrain and high level of glutamate were 
reported in patients with RTT. In particular, the forebrain is more severely 
affected in RTT than the other cortical areas. These data suggested that 
alterations in RTT dendritic development could be the consequence of 
cholinergic deficiency and of NGF/glutamate imbalance (Calamandrei et al., 
2001; Riikonen, 2003). In addition, RTT brain post mortem studies showed a 
reduced quantity of dopamine, serotonin and noradrenaline and higher levels 
of markers associated to bioaminergic metabolism (Lekman et al., 1989). 
These results were confirmed in studies on brain of RTT mouse models, in 
which the same alterations were detected (Viemari et al., 2005; Panayotis et 
al., 2011). 
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To complicate the clinical picture, the presence of different mutations 
leads to different phenotype-genotype correlations with severe symptoms and 
alterations. MeCP2 mutations involving the nuclear localization signal (NLS) 
or early truncated mutations cause a severe phenotype, whereas C-terminal 
deletion lead to milder phenotype with prolonged life-span (Smeets et al., 
2005; De Filippis et al., 2010). In all reported cases of classic RTT, the 
syndrome was caused by the partial or complete loss of MeCP2 functions, 
including DNA binding and protein-protein interactions. From the first RTT 
description, several atypical forms have been described. These variants range 
from milder phenotype with a later age of onset to more severe clinical 
symptomatology. This high variability in the phenotype shown by females 
RTT patients is due to the phenomenon of casual inactivation of the X-
chromosome, which is altered in some patients (Renieri et al., 2003; Weaving 
et al., 2005). Moreover, somatic mosaicism in females with MECP2 alterations 
is another source of variability (Bourdon et al., 2001). The wide clinic 
heterogeneity reporting in RTT patients allowed the description of four major 
RTT variants:  
1) The “forme fruste” (“Worndown form”): it is characterized by a 
later age of symptoms onset, with the hypothetical regression phase 
starting between 1 to the 3 years of age, and less severe stereotyped 
hands movements.  
2) The congenital form: it is the most severe variant, lacking the 
“apparently normal development” period with the first seizure 
episode at 6 months of age. Most of the symptoms appear already 
from the first day of life. The gene involved in this form is FOXG1, 
codifying for the transcriptional repressor “winged-elix”, important 
for telencephalons development (Ariani et al., 2008). 
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3) The Zappella variant (Preserved speech variant): the essential 
feature of this form is the ability of the patients to speak some few 
words, even if often out of context. In addition, the head size can 
be considered normal and the stereotypic hands movement are 
absent. However, patients display a severe kyphosis and are often 
overweight (Zappella et al., 2001). 
4) CDKL5 deficiency disorder (CDD) or Hanefeld variant (early 
infantile epileptic encephalopathy type 2): comparing it with 
classical RTT, in this variants the main diagnostic symptom is the 
early-onset seizures, occurring by the 6 month of life, accompanied 
with several RTT-like features (Hanefeld, 1985b, a). In this variant, 
no alteration in MECP2 gene are present; mutation of gene 
codifying for Cyclin-Dependent Kinase-Like 5 (CDKL5), 
previously known as serine/threonine kinase 9 (STK9) (Montini et 
al., 1998) leads to the Hanefeld variant, that will change its name in 
CDKL5 deficiency disorder. 
CDKL5 deficiency disorder (CDD) 
CDD is a severe X-linked neurodevelopmental disease characterized 
by severe mental retardation, generalized developmental delay (symptoms in 
common with RTT) and the typical early-onset intractable seizures. It is caused 
by mutation of CDKL5 gene, leading to CDKL5 protein with altered 
functionality. This protein is highly expressed in the brain in physiological 
condition. CDD affects mostly females and, after the first descriptions 
reporting most of the symptomatology of RTT, was initially termed Hanefeld 
variant of RTT. The first described mutations were reported in 2003 by Dr. 
Vera Kalscheuer which identified CDKL5 gene disruption by a breakpoint on 
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the X-chromosome, in two different girls displaying infantile spasms and 
severe developmental delay (Kalscheuer et al., 2003). The interest for CDKL5 
is growing because there are many patients affected by RTT symptomatology, 
but they were negative to MeCP2 testing (Weaving et al., 2004). Subsequent 
studies allowed the identification of intragenic CDKL5 alterations in girls 
showing early onset seizures (Weaving et al., 2004).  
Many works have tried to understand the relationship between MeCP2 
and CDKL5. Mutations in both genes are involved in the genesis of 
neurodevelopmental and behavioural impairments, whereas the characteristics 
of the linked-epilepsy are different (Guerrini and Parrini, 2012). Despite that, 
MeCP2 and CDKL5 are widely co-expressed in the brain and both activated 
during neuronal maturation (Rusconi et al., 2008). Moreover, it has been 
demonstrated that CDKL5 can bind and phosphorylate MeCP2 in vitro, and 
that MeCP2 exerts a precise regulation of CDKL5 gene expression (Mari et 
al., 2005; Bertani et al., 2006). Finally, both proteins can bind DNA 
methyltransferase I, suggesting a participation to common pathway 
(Kameshita et al., 2008).  
As mentioned, the clinical features in CDD are the early-onset seizures, 
severe mental retardation and gross motor impairment. In 2010, the diagnostic 
criteria for atypical RTT were published (Neul et al., 2010) and included five 
specific diagnostic items: seizures onset before 5 months of age, infantile 
spasms, refractory myoclonic epilepsy, seizures onset before regression and 
decreased of typical RTT features. Considering the diverse profiles displayed 
by RTT and CDKL5, in 2013 it has been proposed to consider the two 
disorders separately (Fehr et al., 2013). 
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Despite extensive effort understanding RTT and, recently CDD, how 
mutations in MECP2 and CDKL5 lead to the symptomatology of RTT/CDD is 
still unknown. Moreover, no effective therapy is currently available for these 
devastating disorders.  
1.1.2 MECP2 (gene location and protein structure and 
function, regulation and mutations in classic RTT) 
The methyl-CpG binding protein 2 (MECP2; OMIM 300005) gene is 
located at q28 on the human X chromosome. It is long about 76kb and it is 
localized on X chromosome antisense strand and has been demonstrated to go 
through X inactivation in human and mice (D'Esposito et al., 1996). The gene 
is flanked by Interleukin-1 Receptor Associated Kinase gene (IRAK1) and by 
the Red Opsin gene (RCP) (Fig. 2). It was localized for the first time in mouse 
in 1994, in a region equivalent to region 28 of the human X-chromosome long 
arm (Quaderi et al., 1994). MECP2 encodes for the homonym protein 
(MeCP2), which belongs to a large family of DNA-binding proteins that bind 
5-methylcytosine residue in CpG dinucleotides. In 1999, MeCP2 has been 
identified as clear etiological factor in more than 95% of RTT cases (Amir et 
al., 1999).  
Primary transcript (pre-mRNA) encloses four exon regions (exon 1-2-
3-4) and three intronic regions, leading to two main splicing variants; the first 
encloses the exons 1-3-4 codifying for MeCP2e1 isoform (486 amino acids) 
(in human MeCP2B), the second one encloses exons 1-2-3-4, but it uses the 
translation starting codon AUG on exon 2 to encodes the MeCP2e2 isoform 
(498 amino acids) (in human MeCP2A) (Kriaucionis and Bird, 2004; 
Mnatzakanian et al., 2004). Region 3’UTR differs in length in the two main 
transcripts containing multiple polyadenylation sites leading to functional or 
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not functional transcripts (Kriaucionis and Bird, 2004) (Fig 2) MeCP2B seems 
to be more prevalent in brain, thymus and lungs (Kriaucionis and Bird, 2004), 
whereas MeCP2A is highly expressed in fibroblast and lymphoblast 
(Mnatzakanian et al., 2004). Expression level of MeCP2 changes during the 
development, raising higher levels during embryonal development, short post-
natal decrease following by an increase during the growth (Shahbazian et al., 
2002; Pelka et al., 2005). The functional significance of these temporal 
fluctuations is still unknown.  
 
Fig.2: Methyl-CpG binding protein 2 gene (MECP2) 
(a) MECP2 gene is located at q28 on the human X chromosome and is flanked by 
Interleukin-1 Receptor Associated Kinase gene (IRAK1) and by the Red Opsin gene 
(RCP); (b) primary transcript of MeCP2 and (c) the two splicing variants (Liyanage 
and Rastegar, 2014)  
MeCP2 is a very plenty nuclear protein that weights about 53kDa 
belonging to Methyl Binding Protein family (Lewis et al., 1992) (Fig.3). 
MeCP2 was defined as member of protein family of Intrinsically disordered 
proteins (IDP) as MeCP2 is lacking secondary and tertiary structures (Fig. 4) 
and like other IDP can interact with a wide variety of complexes and nucleic 
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acids (Adams et al., 2007). The methyl CpG binding domain (MBD), forming 
by a short α/β tertiary structure, is highly conserved in all proteins of this family 
and in MeCP2 starts from position 92 to 176. This domain is fundamental for 
the DNA binding: it recognizes and binds methyl groups on 5’ position of CpG 
cytosines leading to chromatin compacting and transcription repression. 
Besides MBD, MeCP2 contains a transcriptional repression domain (TRD), 
which extends from position 215 to 326, and several DNA binding domains in 
not methylated positions, such as three domains able to bind the DNA in the 
zones full of AT sequences (A-T hook domains) and two sites of chromatin 
binding (Fig.4) (Nan et al., 1996; Ghosh et al., 2010; Baker et al., 2013). TRD 
domain interacts with repressor complexes NCoR/SMRT and Sin3a/HDAC. 
Inside the TRD there is the Nuclear localization site (NLS), which allows the 
transport in the nucleus, and one of the AT-hooks. 
 
Fig 3: MeCP2 domains; MeCP2 is characterized by an aminoacidic sequence (498 
amino acids) which are divided in domains. Protein starts with N-terminal domain 
(NTD; pink) followed by methyl CpG binding domain (MBD; blue), transcriptional 
repression domain (TRD; green) and C-terminal domain (CTD, purple); DNA binding 
domains include the AT-Hooks (purple outline) and MDB (in brown and blue). 
Chromatin interaction domains include the DNA-binding domain (orange) and the 
Binary chromatin-binding sites (light brown). Modified by (Ausio et al., 2014) and 
(Rastegar et al., 2009).  
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MeCP2 binds the NCoR/SMRT complex by TRD terminal residues 
(285-319), forming the NCoR/SMRT interaction domains (NID). When 
mutations occurs in this site, the MeCP2 repressor role fails (Lyst et al., 2013). 
Regarding the Sin3a/HDAC complex, no clear information is available about 
its interaction with MeCP2. It is known that this complex contributes to 
MeCP2 repression activity interacting directly with Sin3a-MeCP2 
(TRD/CTD) or indirectly through NCoR/SMRT complex and the histone- 
deacetylases (HDACs) and the histone Methyl transferases (HMTs) (Nan et 
al., 1998; Samaco and Neul, 2011; Lyst and Bird, 2015). 
 
Fig.4: Secondary and tertiary structure of MeCP2 and Post Translational 
Mutations (PTM) 
(A) Tertiary structure of MDB, obtained by crystallographic studies; (B) MeCP2 
secondary structures with the possible secondary structures that can be assumed by 
the protein and the PTMs with the involved aminoacidic residues (modified by Ausio 
et al., 2014) 
MeCP2 was thought to act mainly as transcriptional repression factor, 
which binds the dinucleotides CpG, leading to further chromatin compacting 
(Lewis et al., 1992). Subsequent studies have clearly showed that MeCP2 can 
both activate and repress transcription and can also globally regulate chromatin 
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remodelling (Horike et al., 2005) (Chahrour et al., 2008) (Fig. 5). MDB domain 
is able to interact and bind the 5’Methyl Cytosines (5mC) and the 5’-hydroxy 
Methyl Cytosines (5hmC) (Szulwach et al., 2011). When MeCP2 binds target 
genes CpG methylated, its TRD domain recruits the corepressor Sin3a, the 
HDAC 1 and 2 associated with it, and the NCoR/SMRT complex (Heinzel et 
al., 1997; Nan et al., 1998). The MeCP2 transcriptional repressor activity leads 
to the chromatin compacting, promoting the nucleosome clustering, both by 
deacetylation HDAC-mediated and direct interaction between CTD and the 
chromatin (Nikitina et al., 2007). Moreover, it has been demonstrated a direct 
interaction between MeCP2 and the nuclear receptor co-repressor (NCoR), 
which composes the NCoR/SMRT complex. NCoR is a transcriptional 
repressor which recruits the HDACs and other repressors to down-regulate 
target genes. It has been demonstrated that MeCP2 stably interacts with NCoR 
and that TRD mutations could compromise the bind between MeCP2 and the 
complexes disrupting their repression function on promotors genes MeCP2-
regulated (Kokura et al., 2001; Lyst et al., 2013). 
Of note, besides the transcriptional repression activity, MeCP2 can acts 
as transcriptional activator, directly or indirectly. This role needs to be 
explored deeper: it has been showed an interaction between MeCP2 and the 
transcriptional repressor CREB1 at the promoter of an activated target but not 
a repressed target, suggesting a possible transcriptional activator function, but 
the reason of this interaction remains unclear (Chahrour et al., 2008)(Fig.5).  
MeCP2 may also act as splicing regulator. The RNA-binding protein 
“Y-box-binding protein 1” (YB1), one of the main components of 
ribonucleoproteins controlling the pre-mRNA in mRNA processing, has been 
identified as MeCP2 partner. Indeed, when MeCP2 is absent, the splicing of 
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some transcripts results altered leading to transcripts aberrant forms (Young et 
al., 2005). 
 
Fig.5: Different MeCP2 functions (modified by Lyst and Bird, 2015)  
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MeCP2 mutations and RTT mouse model 
Several efforts have been made to understand the role of MeCP2 in the 
brain and in the developing brain. Indeed, many studies on post mortem brain 
of RTT patients have demonstrated the MeCP2 involvement in the central 
nervous system (CNS) development and neuronal maturation (Armstrong, 
2005) and in dendritic morphology (Armstrong, 2002; Chapleau et al., 2009), 
signs which contribute to the neuropathology of RTT. 
Two research groups demonstrated that one of the MeCP2 targets are 
the methylated CpG sites near the promoter III region of Bdnf in rats and near 
the promoter IV region of Bdnf in mice (Chen et al., 2003; Martinowich et al., 
2003) suggesting that the Bdnf gene is under MeCP2 transcriptional control. 
BDNF is a member of the neurotophin family of growth factors having critical 
roles in neuronal survival and differentiation in early development and in 
modulation of synaptic plasticity in adult brain. 
As mentioned above, MeCP2 mutations have been documented in more 
than 95% of RTT cases and in the recent years more than 2000 pathogenic 
mutations have been reported in females with RTT (Amir et al., 1999; Weaving 
et al., 2005; Lyst and Bird, 2015) among which: 
- 8 mutations, among missense and nonsense, finding in 70% of RTT 
patients: 
- Total or partial deletion of the CTD, in about 10% of RTT cases; 
- Complex gene rearrangements finding in 6% of the patients. 
Using genotype-phenotype correlation studies, it has been showed that 
mutations involving the NLS and nonsense mutations (creators of premature 
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STOP codon) lead to more severe phenotype compared to the phenotype 
derived from mutation on CTD (Calfa et al., 2011).  
 
Fig. 6: Main mutations occurring in the MeCP2 (Liyanage and Rastegar, 2014) 
Mutations on MDB and the TRD determine a very severe phenotype , 
because they affect the DNA binding and the correct recruitment of repressor 
factors (Ebert et al., 2013; Lyst et al., 2013) (Fig. 6-7). In particular, three 
important missense mutations on residues R106, R133 and T158 are found on 
MBD, compromising MeCP2 primary function and destabilizing the 
methylated DNA binding (Kucukkal et al., 2015). The fourth missense 
mutation is on R306 residue, in the TRD, which destabilizes DNA binding thus 
not allowing NCoR/SMRT binding. (Lyst and Bird, 2015). C-terminal 
deletions lead to less severe phenotype because they eliminate only the 
phosphorylation site S421, important for protein regulation and turnover, 
maintaining the principal functions (Thambirajah et al., 2009). The patients 
display all RTT symptomatology but with a less severe phenotype (Bebbington 
et al., 2010). In addition, Arg270X mutation on TRD resulting in a truncated 
protein is associated with increased mortality (Cuddapah et al., 2014). 
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Fig.7: Different MeCP2 mutations lead to different complexes or DNA binding 
impairments (modified by Lyst and Bird, 2015) 
The discovery of a monogenic origin for classical RTT (Amir et al., 1999), 
initially led to the creation of mice models carrying mutations in the Mecp2 
gene. The first RTT mouse was the MeCP2-null and was described in 2001 
(Chen et al., 2001; Guy et al., 2001). In the case of Guy et al., their mouse 
model lacks exons 3 and 4 (hemizygous males; -/Y), leading to MeCP2 block 
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expression in whole organism (MeCP2Bird). Chen et al. generated a full 
knockout (KO) by the targeting deletion of exon 3 (MeCP2Jae), a conditional 
KO in which embryonic MeCP2 expression was blocked only in the brain 
(CNS KO) and a conditional KO in which MeCP2 expression was blocked 
only in the postmitotic neurons in the forebrain (Forebrain KO). All models 
displayed the same pathological traits similar to RTT patients. Heterozygous 
Female MeCP2-null mice (MeCP2 +/-) show the same alterations but with a 
later stage of onset. Subsequently, considering that MeCP2 mutations can 
occur in the C-terminal too, a model bears a truncating mutation on the gene 
exon 4, leading to the expression of a protein truncated at amino acid 308, was 
created (MeCP2-308) (Shahbazian et al., 2002). This model appears associated 
with a milder phenotype and prolonged life-span in comparison with KO mice.  
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1.1.3 CDKL5 (gene location and protein structure and 
function, mutations in patients) 
The cyclin-dependent kinase-like 5 gene (CDKL5), is located on the X-
chromosome in the Xp22 region and was identified in 1998 and initially called 
Serine threonine Kinase 9 (STK9)(Montini et al., 1998) Mutations on CDKL5 
have been associated with a form of epileptic encephalopathy classified as 
early infantile epileptic encephalopathy 2. The human CDKL5 gene is long 
about 240kb, composed of 24 exons: exons 1, 1a and 1b are untranslated, 
whereas the coding sequence are contained within exons 2-21. Moreover, 
CDKL5 is characterized by different isoforms and splicing variants 
(Kalscheuer et al., 2003; Williamson et al., 2012). The 107 kDa isoform 
(CDKL5107) is the predominant isoform in human and in mouse brain, 
suggesting it to be of primary pathogenic importance for CDD (Williamson et 
al., 2012). CDKL5 protein contains a serine/threonine kinase domain in its N-
terminal and belongs to a large superfamily of homologous proteins which 
conserve the kinase domain of 250-300 amino acids. Mutations in this gene 
were found in epileptic patients and in 2003 Dr. Vera Kalscheuer suggested 
STK9 as the etiological key of X-linked infantile spasm (Kalscheuer et al., 
2003), a pathology characterized by early onset seizures and mental retardation 
(symptoms of the CDD) and caused in the most of cases by mutation in the 
aristaless-related homebox gene (ARX), located on the Xp21.3-p22.1 (same 
CDKL5 region).  
The CDKL5 belongs to the CMGC family of serine-threonine kinases 
(cyclin-dependent kinases (CDKs), mitogen-activated protein kinases 
(MAPK), glycogen synthase kinases (GSK) and CDK-like kinases) 
characterized by a N-terminal catalytic domain (amino acid 13-297). This 
catalytic domain contains the ATP-binding region (amino acid 14-47), the 
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serine-threonine kinase active site (amino acid 127-144) and a Thr-Xaa-Tyr 
motif (TEY) (amino acid 169-171), site of a possible auto phosphorylation 
(Bertani et al., 2006). Unlike other protein of its family, CDKL5 has an unusual 
long C-terminal tail of more than 600 amino acids containing signals for 
nuclear import (NLS) and export (NES), which could be involved in the 
cellular localization of protein and either the catalytic activity (Bertani et al., 
2006; Rusconi et al., 2008) (Fig.8). 
 
Fig.8: Schematic representation of CDKL5 (Bienvenu and Chelly, 2006) 
CDKL5 function seems to be critical in the CNS by regulating different 
molecular pathways, involving the synaptic function, structure and plasticity. 
Unfortunately, the lack of mouse model for Cdkl5 functions does not allowed 
to clarify the fair situations. Despite all, many studies tried to explain the real 
role of CDKL5, adding year by year several pieces. The CDKL5 protein 
shuttles between cytoplasm and nucleus, where exerts different functions 
(Fig.9). 
Using RNA interference (RNAi) to downregulate CDKL5 in cultured 
cortical rat neurons, Cdkl5 has been demonstrated to be critically involved in 
the regulation of neuronal morphogenesis through mechanisms involving Rac1 
(Chen et al., 2010) (Fig.9), a protein belonging to the Rho GTPase family, a 
group of low-molecular-weight guanine nucleotide binding proteins with a 
well-established role as regulators of actin cytoskeleton dynamics (Etienne-
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Manneville and Hall, 2002) leading to formation and maturation of neuronal 
spines (Tolias et al., 2011). The loss of Cdkl5 influences mice neuronal 
morphogenesis by deregulating BDNF-Rac1 signalling pathway (Chen et al., 
2010), suggesting that Cdkl5 has a role in the maintaining of the neuronal 
function during life. Recently, different authors have reported that Cdkl5 
phosphorylates amphiphyn 1 (AMPH1), brain specific protein involved in 
neuronal transmission (Sekiguchi et al., 2013) exclusively at Ser293. This 
phosphorylation does not occur if a mutation is present in the CDKL5 catalytic 
domain. Interestingly , mice lacking AMPH1 display severe cognitive deficits 
and seizures, suggesting its involvement in the CDD pathogenesis (Sekiguchi 
et al., 2013).  
Possible link between Cdkl5 and MeCP2 
Link between MeCP2 and Cdkl5 has been described in vitro (Mari et al., 
2005; Bertani et al., 2006), suggesting a possible link between RTT and CDD. 
However, considering that Cckl5-mediated MeCP2 phosphorylation is weak 
(Kameshita et al., 2008), is not plausible that MeCP2 and Cdkl5 linked-
activities are due to only this phosphorylation. Indeed, it is well known that 
DNA methyltransferase 1 (DNMT1) and netrin-G1 ligand (NGL-1) are 
phosphorylated by Cdkl5 (Kameshita et al., 2008) (Fig.9): DNMT1 has the 
function to maintain the DNA CpG methylations after the replication and it is 
well known its interaction with MeCP2 suggesting Cdkl5 critical role in 
controlling gene expression (Kameshita et al., 2008); NGL-1 is involved in 
synapse formation and maturation, indirectly suggesting Cdkl5 involvement in 
spine and synapses development (Ricciardi et al., 2012).  
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Fig. 9: CDKL5 functions in cytoplasmatic and nuclear environment 
(A) in the cytoplasm CDKL5 regulates actin cytoskeleton and dendritic arborisation, 
using the interaction with Rac1; (B) degradation is the pathway to regulate levels of 
CDKL5 in the cytoplasmic compartment; (C) in the nucleus, CDKL5 regulates 
epigenetic events by interacting with MeCP2 and DNMT1 (Kilstrup-Nielsen et al., 
2012) 
Pathogenic CDKL5 mutations and CDD mouse models 
As in RTT, in CDD is present a relationship between CDKL5 mutations 
and phenotype showed. All reported cases of CDD are sporadic. From the first 
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CDKL5 identified mutation (Kalscheuer et al., 2003), a wide range of 
pathogenic mutations have been described, reaching over a hundred of CCD 
patients types (Fig.10).  
 
Fig.10: Pathogenic CDKL5 mutations 
Mutations can involve the catalytic domain (the blue exons) or the C-terminal region 
(the white exons). The green and the red parts show different versions of the protein 
(isoforms). Mutations reported on the upper part of the figure represent deletions or 
frameshift mutations, whereas in fuchsia and black respectively are reported below 
the gene and represent the missense and nonsense mutations (Kilstrup-Nielsen et al., 
2012). 
These mutations include missense and nonsense mutations, deletions, 
frameshifts and aberrant splicing. Missense mutations re localized in the N-
terminal domain, compromising the kinase activity of CDKL5. These kinds of 
mutations are associated with a more severe phenotype. On the contrary, 
patients bearing missense mutations on the ATP binding site display less 
severe symptomatology. Conversely, truncating mutations can occur anywhere 
on the gene. Many pathogenic alterations involve the C-terminal part of the 
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gene: stop-codons mutations in the C-terminal lead to a milder clinical picture 
compared to mutations in the catalytic domain (Bahi-Buisson et al., 2012).  
To understand the mechanisms at the disorder basis, two mouse models 
have been generated. The first Cdkl5 KO mouse models a mutation site found 
in CDD and was generated in 2012 (Wang et al., 2012), deleting Cdkl5 exon 
6. This mutation generates a premature termination codon causing an early 
truncation of Cdkl5 in its N-terminal kinase domain, disrupting its 
functionality. As in RTT, the deriving genotypes are: homozygous females (-
/-), heterozygous females (+/-) and hemizygous males (-/Y), which are until 
now, the most used. These mice displayed most of the symptomatology 
described in CDD patients, such as motor defects, sociability deficits, cognitive 
dysfunction. At the same time, another Cdkl5 KO mouse model was created 
by germline deletions of exon 4 of a Cdkl5 conditional KO allele produced by 
standard gene targeting in embryonic stem cells (Amendola et al., 2014) and 
displayed a wide range of CDD symptoms. 
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1.2 Serotoninergic system in 
neuropsychiatric disorders 
1.2.1 General background 
5-hydroxytryptamine (5-HT) or Serotonin is a monoamine 
neurotransmitter, conserved in many species (Marston et al., 2011), which it is 
found in many tissues: 95% of the body’s serotonin is produced in the 
enterochromaffin (EC) cell, in the digestive tract (Gershon, 2004). In the CNS, 
serotonin synthesising cells are found in the dorsal and median raphe nuclei of 
the brain stem, giving rise to descending and ascending projections to every 
part of the brain (Fig. 11). 
 
Fig. 11: The neurons of the raphe nuclei are the main source of 5-HT in the brain, 
projecting to every part of the brain 
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Serotonin is synthetized from tryptophan, which is introduced by diet 
in the organism (Fig. 12). The L-Tryptophan is converted to 5-hydroxy-L-
Tryptophan (5-HTP) by tryptophan 5-hydroxylase (Tph). The two isoforms of 
the enzyme, Tph1 and Tph2, are located respectively in the EC cells and in the 
central and enteric neurons (Yu et al., 1999; Walther et al., 2003). The final 
step is the conversion of 5-HTP to serotonin by aromatic L-amino acid 
decarboxylase (Fig.11). Once formed, serotonin gets transported into vesicles 
by vesicular monoamine transporter (VMAT), which will release it via 
exocytosis into the synaptic cleft where serotonin can bind its receptors (Fig. 
13). Serotonin receptors are divided into seven major classes (5-HT1 to 5-HT7), 
which have multiple subtypes (e.g. 5-HT2A, 5-HT2B, and 5-HT2C). Except for 
5-HT3, which is a ligand-gated ion-channel, the 5-HT receptors are G-protein-
coupled, with signal transduction mediated by either stimulation or inhibition 
of cAMP synthesis (Gray and Roth, 2001). When the serotonin exerted its 
function in the synaptic cleft, the residual content goes through a reuptake 
process by Na+/Cl- dependent transporter called Serotonin Reuptake 
Transporter (SERT) (Fuller and Wong, 1990). Moreover, serotonin can be 
degraded primarily by monoamine oxidase A (MAOA) into 5-
hydroxyindolacetic acid (5-HIAA) or metabolized into melatonin (Fig.12).  
Dysfunction in serotoninergic system has been implicated in many 
neuropsychiatric conditions, as schizophrenia, major depression disorder, 
anxiety disorders, Alzheimer’s and Parkinson’s disease (Geldenhuys and Van 
der Schyf, 2011; Maron et al., 2012; Eggers, 2013; Andrews et al., 2015; Politis 
and Niccolini, 2015). 
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Fig. 12: Serotonin synthesis from diet-introduced L-tryptophan (Fidalgo et al., 
2013) 
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Fig. 13: Representative scheme of the serotonin functions, from synthesis to 
metabolism.  
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1.2.2 Serotonin receptor 7 (5-HT7R): an innovative therapeutic 
target for RTT  
Among the seven serotonin receptors family, the 5-HT7R is one of the 
most recently discovered (Bard et al., 1993). The 5-HT7R gene is located on 
human chromosome 10q23.3 – q24.3 and encodes for a protein of 445 amino 
acids (Bard et al., 1993). This receptor belongs to the family of G-protein 
coupled receptors (GPCRs), the largest and most diverse superfamily of 
transmembrane receptors, functioning as signal-transducer by translating 
extracellular stimuli into intracellular responses resulting in multiple 
physiological and pathophysiological responses (Thompson et al., 2008). All 
GPCRs contain an extracellular amino-terminus, seven membrane spanning α-
helices and an intracellular carboxyl-terminus. The 5-HT7R exerts this its 
function by two different signalling pathways. The canonical is the activation 
of Gs-protein which can activate different adenylyl cyclase (AC) isoforms 
(Shen et al., 1993). This activation leads to cAMP production which in turn 
activates protein kinase A (PKA), which induces phosphorylation of different 
target proteins. In this way, 5-HT7R stimulation, will activates the 
neuroprotective extracellular signal-regulated kinases (ERK1/2) and Akt 
(protein kinase B) pathways (Errico et al., 2001; Johnson-Farley et al., 2005), 
involved in cytoskeleton formation  and in gene transcription (Fig. 14). The 
secondary pathway concerns the activation of the Gα12- protein, of which 
members of Rho GTPases (Rho, Rac and Cdc42) are the main downstream 
effectors. It has been demonstrated that Rho GTPase positive stimulation leads 
to activate gene transcription via transcription factor serum response factor 
(SRF) and to stimulate neurite outgrowth and synaptogenesis (Kvachnina et 
al., 2005; Kobe et al., 2012; Speranza et al., 2013) (Fig.14). 
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Fig. 14: Schematic representation of signalling pathways regulated by the 5-
HT7R. On the left part of the picture are represented effects mediated by Gs-protein. 
On the right part, are represented the effects mediated by Gα12- protein. 
Abbreviations: AC-Adenylyl cyclase; cAMP-cyclic adenosine monophosphate; PKA-
protein kinase A; ERK-Extracellular signal-regulated kinases; Akt-Protein kinase B; 
Hsp90-Heat shot shock protein 90; GEF-Guanine nucleotide exchange factor; SRF-
Serum response factor; SRE-Serum response element (Guseva et al., 2014).  
The 5-HT7R is widely express in all CNS (Hedlund and Sutcliffe, 2004) 
and it has been demonstrated its important role in the control of many 
physiological functions, such as circadian rhythms, thermoregulation, learning 
and memory, and its involvement in psychiatric disorders, such as Alzheimer’s 
disease, depression, schizophrenia, anxiety, cognitive disturbances and pain 
(reviewed in Gellynck et al., 2013). 
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1.3 Endocannabinoid system in 
neuropsychiatric disorders 
1.3.1 General background 
The endocannabinoid system (ECS) is a complex neuromodulator 
system found in all vertebrate classes, involved in the regulation of numerous 
physiological functions (Kano et al., 2009). This “machine” is driven by 
endocannabinoids (eCBs), lipid mediators derived from arachidonic acid. The 
complexity of the system is due to the presence of many receptors, mediators 
and enzymes, which make this field not yet fully explored. Cannabinoid 
receptor type 1 (CB1), encoded by CNR1, was the first discovered guanine-
nucleotide-binding-protein (G protein)-coupled receptor (GPCR) of the ECS 
(Devane et al., 1988). As the most of the GPCR, CB1 is formed by 473 amino 
acids, possessing seven transmembrane domains connected by three 
extracellular and three intracellular loops, an extracellular N-terminal tail, and 
an intracellular C-terminal tail (Shao et al., 2016). The second canonical ECS 
receptor is the CB2, encoded by CNR2, discovered for the first time in the 
immune cells (Munro et al., 1993), is formed by 360 amino acids and possesses 
the common structure of the GPCRs. The discoveries of these two receptors 
was due to the studies on the Δ9 – tetrahydrocannabinol (THC), the active 
principle of Cannabis sativa, which is fully and/or partial agonist of CB1 and 
CB2 receptors, gifted of psychostimulant effects on CNS, identified by (Gaoni 
and Mechoulam, 1964). Despite CB1 receptors are the most abundant 
receptors in the mammalian brain (Matsuda et al., 1990), they are also present 
in the peripheral tissues (Pagotto et al., 2006). CB2 are expressed mainly in the 
immune system cells, but recently was found to be present also in the brain and 
in the peripheral tissue (Gong et al., 2006; Juan-Pico et al., 2006; Ofek et al., 
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2006). CB1 and CB2 couple with G protein type Gi/o and their stimulation can 
activate mitogen activated protein kinases (MAPK), such as extracellular 
signal regulate kinase 1 and 2 (ERK1/2), and inhibit adelite cyclase (AC) and 
PKA signalling (Dalton et al., 2009). 
The presence of these two receptors in the organisms suggested the 
existence of endogenous ligands, the endocannabinoids (eCBs). Starting from 
nineties, until now, the most active eCBs are Anandamide 
(arachidonoylethanolamide; AEA) and 2-arachidonoylglycerol (2-AG), which 
can mimic the action of Δ9 – tetrahydrocannabinol (THC), in several biological 
processes. eCBs, together with enzymes involved in their meta- and 
catabolism, and the two receptors, they form the ECS (Fig.15). eCBs are 
released “on demand” when intracellular Ca2+ concentration is elevated 
through the action of different enzymes, actors of the ECS itself: N-acyl 
phosphatidylethanolamine-specific phospholipase D (NAPE-PLD), the main 
synthesizing enzyme of AEA (Okamoto et al., 2004) and diacylglycerol lipase 
(DAGL), responsible of 2-AG synthesis (Bisogno et al., 2003). Regarding the 
catabolism of eCBs, mainly two enzymes degraded AEA and 2-AG, Fatty acid 
amide hydrolase (FAAH)(Cravatt et al., 1996) and Monoacylglycerol lipase 
(MAGL)(Dinh et al., 2002) respectively (Fig. 15).  
Recently, many works have provided evidences for the existence of 
additional receptors forming the ECS. The new receptors are: transient receptor 
potential (TRP) channels and G-coupled protein receptor GPR55, the leading 
candidate for the CB3 receptor name, receptors which can be bound by AEA 
and/or 2-AG. 
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Fig. 15: Schematic representation of the ECS; eCBs derived from the arachidonic 
acid (AA). Anandamide (AEA) is produced from the hydrolysis of the corresponding 
N-acyl-phosphatidyl-ethanolamine (NAPE) by NAPE selective phospholipase D 
(NAPE-PLD) enzyme. After completing its task, it goes to degradation process 
mediated by fatty acid amide hydrolase 1 (FAAH). 2-Arachidonoyl-ethanolamine (2-
AG) is produced from the hydrolysis of diacylglycerols (DAGs) by diacylglycerols-
lipases (DAGL). 2-AG degradation process seems to be catalysed by 
monoacylglycerol lipase (MAGL). Solid arrows: transformation in active metabolites; 
dashed arrows: transformation in inactive metabolites. Abbreviation: AA, arachidonic 
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acids; AGs, 2-acylglycerols; DAGs, diacylglycerols, ER, endoplasmic reticulum; 
GPRs, orphan G-protein-coupled receptors; MAPK, mitogen-activated protein 
kinases; PIP2, phosphoinositide bisphosphate; PKA, protein kinase A; PLCβ, 
phospholipase Cβ; PPARs, peroxisome proliferator-activated receptors; TRPs, 
transient receptor potential channels; VGCCs, voltage-gated calcium channels (Di 
Marzo et al., 2015). 
In the recent years, evidence of ECS involvement in numerous 
behavioural and physiological processes is constantly increasing. Moreover, 
ECS deregulation has been associated with many neuropsychiatric disorders 
particularly in affective disturbances such as anxiety and depression (Micale 
et al., 2013; Jenniches et al., 2016), mental disorder such as schizophrenia 
(Leweke et al., 2012; Clarke et al., 2017), neurodegenerative disorders 
associated with cognitive and motor dysfunctions such as Alzheimer’s disease, 
Huntington’s disease and Parkinson’s disease (Dowie et al., 2009; Pisani et al., 
2011; Maroof et al., 2014) and Autism Spectrum disorder (Chakrabarti et al., 
2015; Servadio et al., 2016). Moreover, many of the symptoms correlated with 
the pathologies above mentioned, had been improved modulating the eCBs. 
Modulation can run through enzymes inhibitors or molecules directly acting 
on eCBs receptors; regarding FAAH inhibitors, in rodents, daily orally 
administered of ST4070, decreased anxious behaviour measured in elevated 
plus-maze and in the light/dark test (Marco et al., 2015) and still in rodents, 
once daily dose of URB597 elicits antidepressant effects, in chronically 
stressed animals (Bortolato et al., 2007); moreover, CB2 receptor agonist 
JWH-133 was tested in a genetic mouse model of Alzheimer's in which 
induced cognitive improvement (Aso et al., 2013). Of note, pathologies cited 
above have in common many symptoms characterizing RTT and detectable in 
available mouse models (Ricceri et al., 2013; De Filippis et al., 2014). 
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1.3.2 Cannabis sativa extracts as innovative therapeutic 
approaches 
In the last twenty years, Cannabis sativa has been the subject of many 
debates, regarding its use as medical treatment, especially due to the 
psychotropic effect exerts on CNS. In 1964 THC, the main compound of 
Cannabis, was isolated from hashish (Gaoni and Mechoulam, 1964). Most 
THC psychotropic effects are mediated through agonistic actions at the 
cannabinoid receptors, especially CB1, which activation lead to the cascade 
events mentioned before. Pioneering studies tested THC treatment in order to 
increase the ECS response and ameliorates pathology symptoms (e.g. anxiety) 
(Berrendero and Maldonado, 2002). However, CB1 agonists may cause 
psychotropic side effects, like those reported with cannabis use in the 
recreational area. To avoid these undesirable effects, most recent preclinical 
studies focussed on the identification of molecules that modulates the ECS 
without the psychotropic effects of THC. The focus has shifted on non-
psychotropic molecules contained in Cannabis; despite more of 120 
substances, until now, few non-psychotropic phitocannabinoids (phCBs) had 
been tested as novel drugs (Morales et al., 2017). These phCBs are contained 
in cannabis in different percentages depending on the growing conditions, 
location and plant variety or chemotype. The most abundant phCBs in the plant 
are THC, cannabinol (CBN), cannabidiol (CBD), cannabigerol (CBG), 
cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabidivarin 
(CBDV) (Fig. 16) 
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Fig. 16: Most studied phytocannabinoids (phCBs)  
These compounds exerts multiple actions trough mechanisms which are 
only partially related to modulation of the ECS (Pertwee, 2008). Indeed, several 
studies elucidate the ability of phCBs to exerts pharmacological effects via 
different pathways such as TRP channels (De Petrocellis et al., 2008), 
peroxisome proliferator-activated receptor γ (PPARγ) (Vallee et al., 2017), 
GPR55 (Ryberg et al., 2007; Vigli et al., 2018), 5-HT1A (Espejo-Porras et al., 
2013), the adenosine membrane transporter phospholipase A2 (Evans et al., 
1987), modulation of Ca2+homeostasis (Drysdale et al., 2006; Ryan et al., 
2009), often displaying weak affinity and/or real CB1 and CB2 antagonism 
(Thomas et al., 2005; Thomas et al., 2007).  
Among the available phCBs, CBD has been more deeply studied. 
Several works highlighted the efficacy of CBD, in the treatment of muscular 
spasms and rigidity, combining it in 1:1 ratio with THC (GW pharmaceutical 
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Sativex is the first drug FDA approved for the symptomatologic treatment of 
Multiple Sclerosis) (Di Marzo, 2011), epilepsy (Gw pharmaceutical Epidiolex 
drug FDA approved for epilepsy treatment) (Gobira et al., 2015; Devinsky et 
al., 2018), mood disorders (Linge et al., 2016) and Alzheimer’s disease (Cheng 
et al., 2014a; Cheng et al., 2014b); because of its numerous and different 
application diseases, the interest for CBD is constantly increasing. Interestingly 
CBD shows weak affinity for CB1 and CB2 receptors, but antagonistic 
properties on GPR55 receptor and agonistic properties on TRPV1 receptors in 
mice and rats (De Petrocellis et al., 2008; Iannotti et al., 2014; Kaplan et al., 
2017). 
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1.4 Current pharmacological approaches for the treatment 
of Rett Syndrome and CDKL5 Deficiency Disorder 
Despite numerous efforts have been made studying RTT and CDD 
etiopathogenesis, no cure for these disorders is available. In both the diseases, 
medical management is essentially symptomatic and supportive, also including 
psychosocial support for the families. Regarding RTT, there are many 
evidences/projections predicting that RTT patients will live into adult life. 
These data make it clear that it will be needed to plan an accurate therapeutic 
plan for RTT girls (Kirby et al., 2010). As we just mentioned, RTT patients, 
besides the severe mental retardation, suffer of many disturbs leading to a wide 
variety of symptoms.  
Sleep is often disrupted in RTT girls, which can have difficult falling 
to sleep or frequent awakenings during night (Piazza et al., 1990). The causes 
of the disturb and be multiple. Indeed, gastrointestinal dysfunctions, such as 
constipation or gastroesophageal reflux disease (GERD), causing pain, are 
another of the disturbs present in RTT and it should be considered as causes of 
sleep disturbances. Sleep disturbances are treated using Trazodone, a serotonin 
receptor modulator, which is safe to initiate sleep. Moreover Melatonin, last 
metabolism product of serotonin (see 1.2.1) which is important to maintain 
circadian cycles, has been shown to be effective in the initial phase of sleep of 
RTT patients, increasing their sleep duration (McArthur and Budden, 1998). 
Beneficial effects for sleep maintenance have been showed using L-carnitine, 
amino acid required for energy metabolism (Ellaway et al., 2001). Instead, for 
the gastrointestinal dysfunctions, several drugs can be used in RTT. Laxatives 
(polyethylene glycol 3350 and magnesium hydroxide) can be used to treat and 
prevents constipation. For the GERD, which may cause pain due to 
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oesophageal mucosal damage, can be treated with antiacids (calcium 
carbonate) and proton-pump-inhibitor (PPIs).  
RTT patients, due to lack of ambulation and inadequate diet, are victims 
of very frequent bone fractures and reduced bone mass. Osteopenia, the 
reduced bone mineralization, could be caused by low levels of vitamin D which 
was reported in RTT patients (Roende et al., 2011). When vitamin D is lacking, 
supplementation with diet is required. Moreover, to treat this disturb, 
bisphosphonates could be used to inhibit bone resorption and increasing the 
density of mineralized bone. However, these drugs have many side effects, 
including osteonecrosis and gastrointestinal pain.  
Cardiac dysfunction and breathing abnormalities, are two 
characteristics symptoms in RTT. Cardiac prolonged QT interval, a delay of 
timing between ventricle depolarization and repolarization, is a prominent 
feature in RTT patients, which can increase the risk of sudden death, one of 
the problems reported in RTT (Sekul et al., 1994). For the management of this 
disturb, beta-blockers are recommended, but further studies are needed to 
clarify the real efficacy in RTT. The breathing dysfunctions, such as apnoea, 
hypoxia, hyperventilation, could be correlated with the prolonged QT interval 
and the cardiac disturbs. Unfortunately, no treatments for breathing 
irregularities was effective yet in RTT patients.  
Majority of RTT individuals have some type of seizure disorder. Many 
options are available to alleviate seizures episodes, such as valproate, 
lamotrigine, carbamazepine. Levetiracetam is useful in RTT cases suffer of 
drug-resistant seizures (Specchio et al., 2010; Krajnc et al., 2011). 
On the behavioural side, RTT girls suffer of mood disturbances 
including anxious and fearful behaviours. The most successful treatment for 
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anxiety and mood disturbances is the use of selective serotonin reuptake 
inhibitors (SSRIs), which increase serotonin levels in the synaptic cleft and are 
the elective therapy for this disturbs.  
Most of the symptoms in CDD are similar to symptoms displayed in 
RTT, having in common the pharmacological treatments too. However, 
considering that the essential feature of CDD is the early onset of severe 
seizure episode, most of the disease management is for the treatment of 
epilepsy, having, unfortunately, limited effectiveness. Indeed, there is no 
single best anticonvulsant medication or combination for children with CDD. 
Besides the classical anticonvulsant drugs, already mentioned for RTT, other 
approaches have been tried to alleviate the seizures in CDD refractory 
epilepsy. Left cervical Vagus nerve stimulation (VNS) has been demonstrated 
being generally safe and effective treatment for CDD epilepsy. in addition, 
mood and behavioural improvements too have been described in CDD patients 
(Lim et al., 2018). The other innovative approach is the ketogenic diet (KD) 
introduced in the 1920s as a treatment option for refractory epilepsy in 
children. This diet brings elevated level of ketone bodies in the blood, a state 
known as ketosis, leads to a reduction in the frequency of epileptic seizures. It 
has been showed that in CDD this diet is a useful tool to control the seizures 
episodes (Lim et al., 2017).  
Besides the approved pharmacological treatments, several preclinical 
studies have been carried to extend the possible pharmacological treatments to 
cure at least RTT and CDD symptomatology. In RTT, promising results have 
been obtained using molecules mimicking BDNF’s effects. This idea has been 
formulated because BDNF protein levels were found to be lower in brain 
samples of MeCP2 mutant mice (Chang et al., 2006) The administration of 
BDNF is not useful, due to the low penetrant power through the blood-brain-
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barrier (BBB). However, are available molecules able to mimic the effects of 
BDNF, such as BDNF-mimetics (LM22A-4) or increase its levels, such as 
AMPAkines. Mimicking the BDNF effects with LM22A-4 rescued breathing 
abnormalities in heterozygous female MeCP2 mutant mice (Schmid et al., 
2012); instead systemic administration of AMPAkines improved breathing in 
Mecp2 mutant mice by increasing BDNF in brain stem (Lauterborn et al., 
2009). Unlike the BDNF, Insulin-like Growth factor-1 (IGF-1) crosses the 
BBB. It has been showed that daily administration of the active tri-peptide 
fragment of IGF-1 improved motor function, breathing abnormalities and 
cardiac irregularities in MeCP2 mutant mice (Tropea et al., 2009) and 
modulated the synaptic plasticity and morphology (Landi et al., 2011). A 
clinical trial is currently underway to determine administration to verify if 
administration of Mecasermin (synthetic analog of IGF-1) could improve RTT 
health and symptoms.  
In CDD, few pharmacological preclinical studies are available in 
literature. One of this has reported an abnormal hippocampal development and 
neuronal maturation, accompanied by increased activity of GSK-3β, inhibitory 
regulator of many neurodevelopmental processes (Fuchs et al., 2014) Using 
the GSK-3β inhibitor SB216763 it has been showed a fully hippocampal 
development and behavioural deficits rescue in a CDD mouse model (Fuchs et 
al., 2014; Fuchs et al., 2015). In addition, considering the beneficial effects of 
IGF-1 administration in RTT mice, Della Sala and colleagues (2016) have tried 
IGF-1 administration in a CDD mouse model. Authors found that systemic 
administration of IGF-1 restored spine density and spine elimination rate and 
that this beneficial effect was detectable 20 days after the end of treatment 
(Della Sala et al., 2016). 
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1.4.1 5-HT7R selective agonist LP-211  
As mentioned above, 5-HT7R, is the most recently discovered G-
coupled serotonin receptor. This is involved in neurophysiological phenomena 
like regulation of circadian rhythm, mood, cognition, learning and synaptic 
plasticity. Moreover, it has been associated with different neuropsychiatric 
disorders like depression, anxious behaviour, schizophrenia and recently with 
Rett syndrome (De Filippis et al., 2014; De Filippis et al., 2015). After the 
receptor characterization, many studies tried to synthetize molecules able to 
selectively modulate the 5-HT7R. One of the most interesting was LP-211 (Fig. 
17), an arypiperazinic derivate that can bind and activate the 5-HT7R which is, 
until now, the most powerful available agonist. This molecule was chosen 
because is characterized by high penetrant power through the BBB and high 
selectivity on the 5-HT7R (Hedlund et al., 2010; Leopoldo et al., 2011). Like 
arypiperazinic derivatives in general, metabolism of LP-211 includes N-
dealkylation of the aliphatic chain attached to the piperazine nitrogen, resulting 
in the formation of 1-(2-diphenyl) piperazine (RA-7). This potentially active 
metabolite rapidly enters the brain achieving higher concentrations than in 
plasma (Hedlund et al., 2010). 
 
Fig. 17: LP-211 chemical structure 
LP-211 showed a Ki value of 15nM at human cloned 5-HT7R. This 
affinity profile seems preferable compared to that of 8-OH-DPAT, which has 
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been reported to have Ki = 467nM at the human cloned 5-HT7R and Ki = 3.8nM 
at human cloned 5-HT1AR. The selectivity of LP-211 against 5-HT1BR, 5-
HT2BR, 5-HT2CR and 5-HT5AR is modest, whereas significantly higher 
selectivity is observed for the subtypes 5-HT1AR, 5-HT1DR, 5-HT2AR and 5-
HT6R. Finally, LP-211 does not significantly bind at 5-HT3R and 5-HT1ER 
receptors or at SERT. Interestingly, RA-7 appears to be a potent ligand for the 
human 5-HT7R with a Ki (1.4nM), approximately 10-fold lower than the 
corresponding value for LP-211 (Hedlund et al., 2010). 
Efficacy of LP-211 rescuing RTT symptomatology in mouse model 
was previously demonstrated. In these previous experiments MeCP2-308 male 
mice (see 1.1.2) received 7 daily intraperitoneal injections of saline solution or 
LP-211 solution and then behavioural and molecular profile were evaluated. It 
has been demonstrated that LP-211 rescued anxiety like behaviour, improved 
motor coordination and increased novelty preference (De Filippis et al., 2014). 
The potential therapeutic efficacy of LP-211 emerged by molecular assays too, 
reversing RTT molecular alteration about cell cytoskeleton dynamic with 
reversion of abnormal activation of PAK and Cofilin, and about the protein 
synthesis, reversing abnormal activation of ribosomal protein S6, a 
downstream target of mTOR and S6 kinase, both in hippocampal tissue (De 
Filippis et al., 2014). Of note, these LP-211 beneficial effects were detectable 
until 2 months after the end of treatment in MeCP2-308 heterozygous female 
mice (De Filippis et al., 2015). Moreover, LP-211 treatment exerted beneficial 
effects on the mitochondrial dysfunction evaluated in two female RTT mice 
models (MeCP2-null(Bird) and MeCP2-308) (Valenti et al., 2017).  
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1.4.2 Phytocannabinoid Cannabidivarin (CBDV)  
Cannabis, both sativa and indica, contains about 120 substance called 
phCBs (Morales et al., 2017). Besides THC and CBD, most of the phCBs are 
not well characterized and just few of them showed a potential as 
pharmacological treatment in preclinical studies. Another promising phCB is 
Cannabidivarin (CBDV) (Fig.18), the n-propyl analog of CBD. Recent 
evidences suggest that in vitro and in vivo treatment with CBDV in mouse and 
rat exerts anticonvulsant effects (Hill et al., 2012) and prevents neuronal 
hyperexcitability in cells (Iannotti et al., 2014). However, the studies focussed 
on this compound are still very limited and the mechanisms of action of CDBV 
have not been clarified so far. Current evidence suggest that CBDV may show 
weak affinity for CB1 and CB2 receptors, and presents both agonistic 
properties on transient receptor potential (TRP) channels receptors and 
antagonistic properties on the GPR55 receptor (Hagberg et al., 2002; Anavi-
Goffer et al., 2012; Iannotti et al., 2014; Rosenthaler et al., 2014).  
 
Fig. 18: Cannabidivarin chemical structure 
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1.5 Aims of the thesis 
Considering previous evidences and lack of fully functional 
pharmacological treatment, the aim of this thesis was to evaluate two new 
drugs, LP-211 and CBDV, in highly validated MeCP2 and CDD mouse 
models.  
The first aim of this thesis is to extend previous works evaluating LP-
211 treatment in a female mouse model of RTT adding new behavioural task 
and new molecular analysis (Chapter 2); moreover, considering the analogies 
between RTT and CDD, for the first time we evaluated LP-211 treatment in a 
validated male mouse model of CDD (Chapter 3). To accomplish these aims, 
we followed the previous treatment experimental schedules (De Filippis et al., 
2014; De Filippis et al., 2015) and then we evaluated the presence of 
behavioural and molecular deficits in both models and the LP-211 effects 
thereon. The second aim of this thesis is to identify for the first time the effects 
of three different daily intraperitoneal doses of CBDV treatment on a highly 
validated mouse model of RTT (hemizygous male MeCP2-308 mice) (Chapter 
4). Of note, a clinical trial is currently in progress aimed at evaluating the 
potential efficacy of a treatment with CBDV on children affected by Autism 
Spectrum Disorder (clinicaltrial.gov, NCT03202303), giving to CBDV an 
highly translational power. 
Despite LP-211 and CBDV, as well as their relative targets, are 
structurally different, recent evidence suggests a link between serotoninergic 
and endocannabinoid systems (Haj-Dahmane and Shen, 2011). Since both 
systems have been associated to the symptomatology of RTT, an evaluation of 
the effects of the above-mentioned drugs on RTT mouse models would be of 
great interest for this research field.   
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2.1 Abstract 
Rett syndrome (RTT) is a rare neurodevelopmental disorder caused by 
mutations in the MECP2 gene in about 95% of cases and no cure is available 
for this disorder. MECP2 mainly exerts transcriptional regulatory functions, 
directly interacting with nucleosomes or acting as a platform for recruitment 
of recruit histone deacetylase (HDAC)-containing co repressor complexes. 
How mutations in the MeCP2 gene lead to the neurobehavioural features of 
RTT is still not clear and there is no cure for this devastating disorder. In the 
present study we demonstrate that stimulation of the serotonin receptor 7 (5-
HT7R) with the agonist molecule LP-211 (0.25 mg/kg once/day for 7 days) 
rescues the altered histone H3 acetylation levels in the cortex and hippocampus 
of heterozygous MeCP2-308 female mice, a RTT mouse model bearing a C-
terminal truncating mutation on the MeCP2 gene (RTT mice). Moreover, the 
LP-211 treatment restored the abnormal protein levels of NCoR and HDAC3 
in RTT mouse cortex. A normalization of the carotid pulse distension and a 
rescue of the aberrant sociability in RTT female mice treated with LP-211 were 
also uncovered, thus extending previous findings and adding further support to 
the translational value of this promising pharmacological approach for RTT.  
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2.2 Introduction 
The serotonin receptor 7 (5-HT7R) is one of the most recently 
discovered serotonin receptor (Bard et al., 1993). The 5-HT7R is widely 
expressed throughout the central nervous system (Hedlund and Sutcliffe, 2004; 
Romano et al., 2014) and plays an important role in the control of many 
physiological functions, such as circadian rhythms, thermoregulation, learning 
and memory (Canese et al., 2014; Meneses, 2014; Volpicelli et al., 2014). The 
receptor belongs to the family of G-protein coupled receptors (GPCRs), 
functioning as signal-transducer by translating extracellular stimuli into 
intracellular responses resulting in multiple physiological and 
pathophysiological responses (Thompson et al., 2008). In particular, the 5-
HT7R stimulation activates several pathways involved in synaptic plasticity 
and cognition (Ciranna and Catania, 2014; Stiedl et al., 2015; Zareifopoulos 
and Papatheodoropoulos, 2016), such as protein kinase A (PKA), which 
induces activation of the neuroprotective extracellular signal-regulated kinases 
(ERK1/2) and cyclin-dependent kinase 5 (Cdk5) pathways (Guseva et al., 
2014; Volpicelli et al., 2014; Costa et al., 2018). Aberrant 5-HT7R signalling 
has been involved in a number of psychiatric disorders, such as Alzheimer’s 
disease, depression, schizophrenia and anxiety disorders (Gellynck et al., 2013; 
Naumenko et al., 2014; Ivachtchenko et al., 2016). Moreover, recent evidence 
suggest that the stimulation of the central 5-HT7R signalling as a new 
therapeutic strategy in X-linked neurodevelopmental disorders characterized 
by intellectual disability such as Fragile X syndrome (Costa et al., 2018) and 
CDKL5 Deficiency Disorder (Vigli et al., 2018b).  
In this context, we have demonstrated that repeated systemic treatment 
with LP-211, a brain penetrant selective agonist which binds with high affinity 
at the human cloned 5-HT7R (Leopoldo et al., 2008; Hedlund et al., 2010; 
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Leopoldo et al., 2011), substantially rescues the neurobehavioral phenotype of 
a mouse model of Rett Syndrome (RTT; OMIM 312750) (De Filippis et al., 
2014; De Filippis et al., 2015a). RTT is a rare neurodevelopmental disorder 
characterized by severe behavioural and physiological symptoms (Rett, 1966; 
Hagberg et al., 2002; Ricceri et al., 2012). RTT almost exclusively affects 
females with an incidence of 1 in every 10,000 births. Patients present a wide 
variety of symptoms including autistic features, social interaction deficit, 
mental retardation, stereotyped hand movements, seizures and breath 
impairments. 
Classic RTT is caused in about 90–95% of cases by mutations in the X-
linked MECP2 gene located on Xq28 (Amir et al., 1999), which encodes the 
methyl CpG-binding protein 2 (MECP2), a multifunctional protein that binds 
to methylated DNA and mainly acts as a key transcriptional regulator (Guy et 
al., 2011). MECP2 mainly exerts transcriptional regulatory functions, directly 
interacting with nucleosomes via its methyl-CpG–binding domain (MBD) or 
acting as a platform for recruitment of numerous protein partners via its a 
transcriptional repression domain (TRD), leading to chromatin compaction 
and transcriptional repression (Lyst et al., 2013). Historically, the repressive 
MeCP2 activity was thought to be primarily promoted through the recruitment 
of SIN3α/HDACs complex and the consequent de-acetylation of histones 
(Jones et al., 1998; Nan et al., 1998). Major interest in the last few years has 
been however attracted by the histone deacetylase (HDAC)-containing 
co-repressor complex NCoR/SMRT/HDACs, which binds the TRD terminal 
residues (285-319) of MeCP2 (Lyst et al., 2013). Despite numerous efforts 
have been made in this field, how mutations in the MeCP2 gene lead to the 
neurobehavioural features of RTT is still not clear and there is no cure for this 
devastating disorder. Indeed, most of the MeCP2 mutations in RTT patients 
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occurs in the MDB, disrupting the MeCP2 binding with DNA leading to severe 
phenotype (Amir et al., 1999). Mutations in TRD also occur in RTT patients, 
that could compromise the repression function of NCoR/SMRT/HDACs on 
MeCP2-regulated genes (Kokura et al., 2001; Lyst et al., 2013), suggesting a 
pathogenic role in RTT (Shahbazian et al., 2002; Guy et al., 2011). In this line, 
an hyperacetylation of the histone H3 was found in the brain of MeCP2-308 
male mice bearing a truncating mutation on the MeCP2 gene, leading to the 
expression of a protein truncated in the TRD at amino acid 308 (Shahbazian et 
al., 2002). Alterations in chromatin accessibility for transcriptional regulators 
and consequent alterations in gene transcription may thus occur in the brain of 
this RTT mouse model, explaining at least in part the altered RTT phenotype 
(Shahbazian et al., 2002).  
In the present study we have further explored the therapeutic efficacy 
of repeated systemic treatment with the 5HT7R agonist LP-211 in MeCP2-308 
mice (Shahbazian et al., 2002). Our previous studies have demonstrated that 
repeated systemic treatment with LP-211 (0.25 mg/kg once/day for 7 days) 
rescues several RTT-related behavioural alterations in MeCP2-308 mouse 
model restoring motor deficits, cognitive impairments and anxious profile and 
restoring altered proteins synthesis and synaptic plasticity (De Filippis et al., 
2014; De Filippis et al., 2015a). Treatment efficacy was confirmed in 
symptomatic MeCP2-308 heterozygous female mice, the genetic and 
hormonal milieus that more closely resemble those of RTT patients. Moreover, 
we demonstrated that the LP-211 treatment restores mitochondria functions in 
the brain of heterozygous female mice from two highly validated mouse 
models of RTT (MeCP2-308 and MeCP2-Bird mice) (Valenti et al., 2017). 
Notably, the beneficial effects of LP-211 treatment on behavioural, molecular 
and brain mitochondrial defects were evident out up to 2 months after the last 
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injection, thus suggesting long-lasting effects of LP211 exposure on RTT-
related impairments (De Filippis et al., 2015a).  
Considering the wide variety of beneficial effect which LP-211 exerted 
in RTT mice (De Filippis et al., 2014; De Filippis et al., 2015a; Valenti et al., 
2017), we reasoned that LP-211 treatment may have restored abnormal histone 
acetylation in RTT mouse brain (Shahbazian et al., 2002). To test this 
hypothesis, in the present study heterozygous fully symptomatic female 
MeCP2-308 female mice and wt littermates were treated with LP-211 (0.25 
mg/kg once/day intraperitoneal (i.p.) injection for 7 days) or control (veh) 
solution, following previous treatment schedules (De Filippis et al., 2014; De 
Filippis et al., 2015a). The histones acetylation and the level of co-repressors 
proteins were evaluated in mouse brain to verify whether they are altered in 
RTT and LP-211 treatment effects thereon. In addition, to extend and support 
our previous results demonstrating widespread behavioural effects of the LP-
211 treatment, physiological parameters, such as carotid distension, breath 
frequency and hearth rate, and sociability were evaluated in experimental mice, 
considering that in human RTT patients breath impairments and aberrant social 
behavior are present (Katz et al., 2009; Kaufmann et al., 2012).   
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2.3 Materials and methods 
2.3.1 Subjects 
The experimental subjects were 1-year old MeCP2-308 heterozygous 
female mice (RTT) [B6.129S-MeCP2tm1Heto/J, stock number: 005439; 
backcrossed to C57BL/6J mice for at least 12 generations from the Jackson 
Laboratories (USA)] and wild-type (wt) littermates. The MeCP2-308 model 
bears a truncating mutation, leading to the expression of a protein truncated at 
amino acid 308(Shahbazian et al., 2002; De Filippis et al., 2014; De Filippis et 
al., 2015a).  
Mice were housed in 2-3 groups in polycarbonate transparent cages 
(33X13X14 cm) with sawdust bedding and kept on a 12-h light-dark schedule 
(lights off at 8:00 am). Temperature was maintained at 21 ±1 C° and relative 
humidity at 60± 10%. Animals were provided ad libitum with tap water and a 
complete pellet diet (Altromin, Germany). All experimental procedures were 
conducted in conformity with the European Directive 2010/63/EU and the 
Italian legislation on animal experimentation, D.Lgs. 26/2014 and formally 
approved by Italian Ministry of Health. 
2.3.2 Genotyping  
DNA has been prepared from a small tail-tip biopsy taken at 21–28 
days of age, as previously described De Filippis et al., 2010). The MeCP2 
alleles have been identified by PCR using two sets of primers. Primer set 1 (5′ 
primer: 5′-AAC GGG GTA GAA AGC CTG-3′ and 3′ primer: 5′-ATG CTC 
CAG ACT GCC TTG -3′) yields a product of 396 bp identifying the wildtype 
allele. Primer set 2 (5′ primer same as for primer set 1 and 3′ primer: 5′- TGA 
TGG GGT CCTCAG AGC -3′) yields a product of apparent size 318 bp 
identifying the null allele. PCR products were electrophoresed through a 2% 
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NuSieve 3:1 agarose gel (Cambrex Bio Science, Rockland, ME, USA) 
containing 0.5 μg/mL ethidium bromide, and examined under UV light. 
2.3.3 Drug and Treatment 
LP-211 was prepared following the same synthetic procedure described 
in(Leopoldo et al., 2008). The compound was dissolved in a vehicle solution 
of 1% dimethyl sulfoxide (DMSO) in saline (0.9% NaCl). RTT mice and wt 
littermate controls were randomly assigned to be daily intra-peritoneally (ip) 
injected (between 9.00 and 11.00 am) for 7 consecutive days with either LP-
211 (0.25 mg/kg) or vehicle (1% of DMSO in saline) (veh). The following 
sample size was used for the behavioural tasks: MouseOx: wt, veh = 11; wt, 
LP-211 = 10; Het, veh = 6; Het, LP-211 = 8; Three chamber: wt, veh = 9; wt, 
LP-211 = 8; Het, veh = 5; Het, LP-211 = 7. 
To test whether LP-211 can counteract RTT related abnormalities when 
they are fully manifested, RTT mice were treated at about 12 months of age, 
in which RTT mice are fully symptomatic (De Filippis et al., 2014; De Filippis 
et al., 2015a). 
2.3.4 In vivo testing 
Mice were experimentally naïve at the start of the test battery. All in 
vivo testing took place during the dark phase of the L/D cycle and was carried 
out by experimenters blind to mouse genotypes and treatments. Behavioural 
testing started 1 month after the end of the i.p. treatment, according to the 
schedule described in (De Filippis et al., 2015a). In particular, physiological 
parameters were evaluated on the day 35 of the schedule; the Three-Chamber 
Social test was performed on day 41 of the schedule (see Figure 1A for 
experimental design and treatment schedule). The brains of the experimental 
mice were collected two months after the last i.p. injection, based on previous 
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data suggesting long-term effects of a seven-day-long treatment with LP-211 
(De Filippis et al., 2015a).  
 
Fig. 1: (A) Experimental schedule 
2.3.4.1 Three chambered social test 
Sociability and social recognition were assessed in the three-chambered 
test, as previously described (Smith et al., 2007; Vigli et al., 2018a). The test 
consists of 4 consecutive phases of 10 minutes during which each mouse is 
individually placed in the apparatus: Phase 1 (S1): mice can freely explore the 
central chamber of the apparatus; Phase 2 (S2): mice can explore the three 
empty chambers; Phase 3 (S3): mice can explore either the chamber containing 
an empty small wire cage or the other one containing a conspecific kept under 
an identical small wire cage; Phase 4 (S4): an unfamiliar mouse is located 
under the cage wire which was empty during S3. Allocation of mouse partners 
to specific chambers was counterbalanced within each experimental group. 
Time spent exploring the mouse versus the empty wire cage during S3 is 
considered as an index of sociability. Time spent exploring the unfamiliar 
mouse versus the familiar one during S4 is considered as an index of memory 
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of the social stimuli. Naïve C57 adult male mice were used as partners in this 
test. They were first habituated to the small wire cages in the test environment 
for 2 consecutive days before the testing day. After each animal was tested, the 
three-chamber apparatus and the wire cages were thoroughly cleaned with 70% 
ethanol. 
2.3.4.2 Physiological parameters measurement 
The non-invasive MouseOx Apparatus (STARR Life Sciences, 
Holliston, Ma, USA) allows the measure of the Oxygen Saturation 
(% = percentage of hemoglobin saturated by O2), Heart rate (bpm = number of 
beats per minute) and Breath Rate (brpm = number of breaths per minute) and 
the Pulse Distention (μm = distention of the blood carotid artery due to a 
cardiac pulse). Experimental subjects were habituated to the collar clip placing 
a blank collar on the neck for 12h the day before the test. On the testing day, 
blank collar was removed from the neck of the animal and substituted with the 
infrared pulse oximeter clip connected to the instrument. Physiological 
parameters were recorded for 10 minutes as reported in previous studies 
(Bittolo et al., 2016). 
2.3.5 Molecular analysis 
2.3.5.1 Protein extraction 
Histone proteins from mice cortex and hippocampus were extracted 
using the EpiQuik™ Total Histone Extraction Kit (EpiGentek), according to 
the manufacturer’s instructions, in presence of Proteases Inhibitor Cocktail 
(PIC 1X, Sigma) and 1mM Phenyl methyl sulfonyl fluoride (PMSF). Total 
histone proteins were collected and quantified by Bradford Assay (Bio-Rad) at 
595 nm with a microplate-reader Appliskan TM (Thermofisher). Total Histone 
extracts were aliquoted and stored the at –80°C until use. 
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To analyse endogenous proteins, cortex and hippocampus samples 
were lysed in RIPA buffer (50 mM pH 7,4 Tris HCl, 150 mM NaCl, 1.0% NP-
40, 0.5% deoxycholic acid (NaDOC), 0.1% SDS, 1 mM EDTA, 5mM NaF, 1 
mM Na3VO4) supplemented with 1X PIC and 1 mM PMSF. Briefly, small 
tissue pieces resuspended in RIPA buffer were homogenized through at least 
20-30 strokes in a Dounce homogenizer and incubated on ice for 30 min with 
gentle stirring. Protein extracts were obtained by centrifugation at 14000 rpm 
for 10 min at 4°C.  The supernatants were collected and the proteins 
concentration was determined by Bradford Assay, as described above. The 
extracts were aliquoted and stored the at –80°C. 
2.3.5.2 Western Blot (WB) 
Histone and endogenous protein extracts were resolved by gel 
electrophoresis on a 4–20% polyacrylamide gradient PROTEAN® TGX Stain-
Free™ protein gel (Bio-Rad) and transferred onto a PVDF membrane (Biorad) 
by Trans-Blot® Turbo™ Transfer System (Bio-Rad). Membranes were 
blocked in 5% milk in TBST for 1 hour at room temperature, and then 
incubated with indicated antibodies: polyclonal anti-Di-Methyl Histone H3 
(Lys9) (1:1000) (Cell Signaling), polyclonal anti-acetyl-Histone H3 (1:500-
1:1000) (Millipore), polyclonal anti-H3 (1:1500), polyclonal anti-SIN3α 
(1:500), monoclonal anti-MeCP2 (1:500) (Sigma)or polyclonal anti-MeCP2 
(1:500), polyclonal anti-NCoR (1:500) (abcam®), monoclonal anti-HDAC1 
(1:500), monoclonal anti-HDAC3 (1:500), monoclonal anti-GAPDH (1:5000), 
monoclonal anti-actin (1:5000) (Santa Cruz Biotechnology). The proteins were 
visualized by chemiluminescence detection with LuminataCrescendo Western 
HRP substrate (Millipore) using ChemiDoc™ MP System (Bio-Rad), and 
densitometric analyses were performed with ImageLab software (Bio-Rad) 
and normalized to a reference protein. 
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2.3.6 Statistical analysis 
Behavioural data were analysed with two-way ANOVA models, using 
statistical software (Statview v 5.0) including genotype and treatment as 
between-subject factors and repeated measurements as within-subject factor. 
The alpha level was set to 5%. The Levene test was applied to confirm the 
equality of variance. The presence of outliers was verified using Grubbs 
method. Post-hoc comparisons were performed by Tukey HSD, even in the 
absence of statistically significant interactions (Wilcox, 1987).  For the western 
blot analyses, data were analysed with one-way ANOVA models, using 
statistical software (Graphpad Prism v. 6.0) Experiments were repeated at least 
three times. Post-hoc comparisons were performed by Bonferroni post hoc test; 
p values <0.05 were regarded as significant. 
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2.4 Results 
2.4.1 In vivo testing results 
2.4.1.1 Three chambered social test 
The three chambered social test was performed to evaluate sociability 
skill in RTT mice and LP-211 effects thereon. The analysis of the S3 phase 
highlighted a statistically significant genotype difference, with RTT mice 
showing an aberrant hyper preference for the social stimulus (versus the empty 
cage) in comparison to wt controls [Fig. 1B; p < 0.05 after post-hoc comparison 
on Genotype*Treatment interaction F(1,25)= 9.888 p = 0.004]. Importantly, the 
LP-211 treatment rescued this social deficit in RTT mice, restoring wt-like 
levels of the social preference [Fig. 1B; p < 0.05 after post-hoc comparison on 
Genotype*Treatment interaction]. From the S4 analysis, no genotype or 
treatment effects were highlighted (data not shown). 
Fig. 1: LP-211 treatment rescues social defects in RTT female mice. (B) The three-
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chamber social task highlighted aberrant sociability in RTT mice, measured as % of 
time spent with the social stimulus, in comparison to wt controls. This abnormal 
behaviour was restored by LP-211 treatment, that restored to wt-like levels the % of 
time spent with social stimulus in RTT mice. Data are mean ± SEM. Statistical 
significance was calculated by two-way ANOVA with Tukey’s post hoc test.  
p < 0.01; **, p < 0.05, *  
2.4.1.2 Physiological parameters 
The MouseOx was applied to evaluate the presence of cardiac and 
breath impairments in RTT mice. A genotype difference was found on Pulse 
distention parameter, with RTT mice showing a lower carotid artery distention 
in comparison with wt controls [Fig. 1C; p < 0.05 after post-hoc comparison 
on Genotype*Treatment interaction F(1,31)= 4.506 p = 0.042]. Furthermore, 
LP-211 treatment increased pulse distention dysfunction in RTT mice, 
restoring carotid artery distention at the same level of wt controls [Fig. 1C; p 
< 0.05 after post-hoc comparison on Genotype*Treatment interaction]. No 
genotype differences were found as for SpO2, Hearth rate and Breath rate and 
the LP-211 treatment did not affect these parameters. 
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Fig. 1: LP-211 treatment rescues pulse distention in RTT female mice. (C) it has been 
possible to detect a defective pulse distention in RTT mice compared to wt littermates 
was found through the MouseOx apparatus. LP-211 treatment rescued this defective 
parameter in RTT mice, increasing levels of pulse distention. Data are mean ± SEM. 
Statistical significance was calculated by two-way ANOVA with Tukey’s post hoc 
test. p < 0.01; **, p < 0.05, * 
2.4.2 Molecular results 
2.4.2.1 LP-211 treatment normalizes the abnormal acetylation level of 
histone H3 in RTT mouse cortex and hippocampus 
To clarify the possible relationship between MeCP2 and alterations in 
histone H3 modifications in RTT, we analyzed acetylation of the lysine 9 on 
the histone H3 (K9H3) in cortex and in hippocampus of RTT mice. We found 
that RTT mice showed lower levels of cortical histone H3 acetylation 
compared to wt mice (Fig.2A p < 0.01 after post-hoc comparison),whereas the 
hippocampus of RTT mice was characterized by hyperacetylation of histone 
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H3 (Fig.2B; p < 0.01 after post-hoc comparison). LP-211 treatment normalized 
histone H3 acetylation levels in both brain areas of RTT mice in comparison 
to veh treated RTT mice (Fig.2A,B; p < 0.01 and p < 0.05 for LP-211 effect in 
cortex and hippocampus respectively, after post-hoc comparison). 
 
Fig. 2: LP-211 treatment normalizes cortical and hippocampal histone H3 acetylation 
level in RTT female mice. Cortical and hippocampal histone H3 acetylation levels 
were evaluated by western blot analysis. RTT mice showed a histone H3 
hyperacetylation in cortex (A) and a histone H3 hypoacetylation in the hippocampus 
compared to wt (B); in both brain regions, LP-211 treatment normalizes histone H3 
acetylation levels, restoring them to wt levels (A-B). Data are mean ± SEM. Statistical 
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significance was calculated by one-way ANOVA with Bonferroni post hoc test.  
p < 0.01; **, p < 0.05, * 
2.4.2.2 LP-211 treatment influences cortical and hippocampal levels of 
MeCP2 complexes proteins in RTT mouse model 
We assessed whether NCoR/HDAC3 and SIN3α/HDAC1 have 
different protein levels in the cortex and in the hippocampus of RTT mice and 
whether LP-211 was able to modulate them.  
In the cortex of RTT mice we found a significant increase of NCoR and 
HDAC3 protein level up to 50% compared with WT mice (Fig.3A,B; NCoR: 
p < 0.05 and HDAC3: p < 0.05 after post-hoc comparison). LP-211 
administration markedly reduced the levels of both proteins in comparison 
with RTT mice, thus restoring wt-like levels (Fig.3A,B ; p < 0.05 and p < 0.05 
for LP-211 effect in cortical levels of NCoR and HDAC3 respectively, after 
post-hoc comparison). 
On the contrary, no genotype difference was highlighted for SIN3α 
levels (Fig. 3D); HDAC1 showed a slight decrease, just missing statistical 
significance (Fig. 3C). LP-211 treatment increased HDAC1 and SIN3α protein 
levels selectively in RTT mouse cortex (Fig.3C,D ; p < 0.05 and p < 0.01 for 
LP-211 effect in cortical levels of HDAC1 and SIN3α respectively, after post-
hoc comparison). 
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Fig. 3: LP-211 treatment normalizes altered cortical levels of NCoR and HDAC3 and 
increases levels of SIN3α and HDAC1 in RTT female mice. Western blot analyses 
highlighted increased levels of the NCoR (A) and HDAC3 (B) in the cortex of RTT 
mice compared to wt littermates. No genotype differences emerged analyzing HDAC 
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1 and SIN3α levels (C-D); in the cortex of RTT female mice LP-211 treatment 
restored normal levels of NCoR (A) and HDAC3 (B), in comparison to veh treated 
RTT mice and increased levels of HDAC 1 and SIN3α (C-D). Data are mean ± SEM. 
Statistical significance was calculated by one-way ANOVA with Bonferroni post hoc 
test. p < 0.01; **, p < 0.05, * 
In the hippocampus of RTT mice we found a significant decrease of 
NCoR protein levels (Fig.4A; p < 0.01 after post-hoc comparison). LP-211 
treatment did not rescue this alteration. No alterations in RTT mice were found 
considering the levels of HDAC3, HDAC1 and SIN3α levels. However, in 
RTT mice, LP-211 treatment increased HDAC3 and SIN3α levels (Fig.4B,D; 
HDAC3: p < 0.05 and SIN3α: p < 0.05 after post-hoc comparison).  
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Fig. 4: LP-211 treatment modulates hippocampal levels of SIN3α and HDAC3 in RTT 
female mice. Western blot analyses highlighted lower levels of the NCoR (A) in the 
hippocampus of RTT mice compared to wt littermates. No genotype differences 
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emerged analyzing HDAC3, HDAC 1 and SIN3α, levels (B-C-D); in the 
hippocampus of RTT female mice LP-211 treatment increase levels of SIN3α (B) and 
HDAC3 (D), in comparison to veh treated wt mice. Data are mean ± SEM. Statistical 
significance was calculated by one-way ANOVA with Bonferroni post hoc test.  
p < 0.01; **, p < 0.05, * 
2.5 Discussion 
The present study extends previous results about the treatment effects 
of the 5-HT7R agonist LP-211 in a fully symptomatic mouse model of RTT 
syndrome (12 months of age) (De Filippis et al., 2014; De Filippis et al., 
2015a), showing a normalization of the carotid pulse distension and a rescue 
of the aberrant sociability in female RTT mice. Moreover, we found for the 
first time a normalization of the altered histone H3 acetylation and NCoR and 
HDAC3 levels in the cortex of LP-211 treated RTT mice. Present results 
provide further support on the therapeutic efficacy of the LP-211 treatment for 
RTT and shed some light on the molecular mechanisms underlying the 
reported beneficial effects of LP-211. 
Social impairments are a common symptom characterizing RTT. 
Alterations in social behaviors have been widely studied, reporting mild to 
severe impairments that are consistent with reports in RTT girls (Ricceri et al., 
2012). Contrary to what expected, we found an aberrant sociability in fully 
symptomatic MeCP2-308 female mouse model at 9-12 months of age, showing 
an increase social preference, that was completely rescued by LP-211 
treatment. Indeed, previous studies demonstrated the presence of defective 
sociability in MeCP2-308 female and male mice respectively at 2 or 5 months 
of age, showing low social preference (Woods et al., 2012; Vigli et al., 2018a). 
However, another work reported an increase social behaviour displayed by 3 
months old MeCP2-308 male mice measured in the same task using a slightly 
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different protocol (Pearson et al., 2012). Even though several studies have 
reported the presence of sex and/or age difference when measuring the 
sociability (Greenberg et al., 2013; Shoji et al., 2016), altogether these results 
suggest that the old age of the experimental mice or the sex of the animals may 
not sufficient to explain the hyper-sociability we uncovered in the present 
study. Further studies are thus needed to clarify the mechanisms leading to 
social deficit in RTT. 
Cardiorespiratory dysfunctions occurring in RTT patients in the late 
stage of the disorder, are responsible for 26% of deaths (Rohdin et al., 2007) 
and these alterations are also detectable in mouse models (Johnson et al., 2015; 
Bittolo et al., 2016). Using the MouseOx, we recorded, for the first time in this 
RTT mouse model, several cardio circulatory parameters. We found a severe 
pulse distention impairment in RTT mice. This alteration suggests that carotid 
stenosis may occur in this RTT mouse model, possibly as a result of a sort of 
occlusion or vasculopathy leading to a decrease in the oxygenated blood flow 
rate and a consequent decrease in brain oxygen levels (Olivera et al., 2010; 
Nayak et al., 2014). In present study we demonstrate that LP-211 treatment 
rescues the pulse distension deficit in RTT mice, restoring it to wt levels. These 
data are in agreement with previous work suggesting that the 5-HT7 receptor 
mediates 5-HT induced dilation of the carotid artery (Villalon et al., 1997; 
Terron and Martinez-Garcia, 2007). Carotid stenosis is an important risk factor 
for stroke and it was associated with the presence of cognitive dysfunction and 
psychiatric symptomatology in humans (Sours, 1964; Kim et al., 2007) and 
mice (Jiwa et al., 2010). In this line, restoration of pulse distention impairment 
by LP-211 treatment was accompanied by a substantial rescue of behavioural 
alterations in RTT mice (Table 1, in bold the new results). Even though further 
studies are necessary to elucidate the correlation between the effects of 
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possible carotid stenosis and the severity of RTT symptomatology, present 
results provide further support to the therapeutic value of this pharmacological 
approach. 
Given the promising behavioural results so far obtained (Table 1), we 
have further explored the molecular mechanisms underlying the reported 
beneficial effects of the LP-211 treatment in RTT mouse brain. Notably, we 
found that the LP-211 treatment was able to counterbalance histone H3 
acetylation abnormalities in RTT mouse brain in comparison to veh treated 
RTT mice, suggesting H3 acetylation modulation as a good target to ameliorate 
RTT phenotype. Indeed, compelling evidence demonstrate a tight link between 
histone acetylation abnormalities and poor synaptic plasticity and memory 
(Alarcon et al., 2004; Levenson et al., 2004; Yeh et al., 2004; Fischer et al., 
2007; Vecsey et al., 2007; Stefanko et al., 2009). Moreover, epigenetic 
modifications play a fundamental role in the pathogenesis of different 
neurocognitive and neurodegenerative disorders, including autism spectrum 
disorders, intellectual disability disorders, schizophrenia, and epilepsy 
(Koshibu et al., 2009; Miller et al., 2010; Graff et al., 2012). Of note, several 
evidences also suggest that the histone acetylation is important for the control 
of lipid homeostasis and mitochondria activity (Shen et al., 2015), both of 
which are altered in RTT (Kyle et al., 2016; Valenti et al., 2017). 
Interestingly, however, different brain areas presented opposite 
profiles, with the RTT hippocampus presenting the expected hyperacetylation 
of H3, while the cortex showing lower levels of histone acetylation in RTT 
mice compared to wt mice. 
The decrease in global acetylation levels of the histone H3 we found in 
the cortex of RTT mice was in fact surprising, as previous work reported a 
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cortical histone H3 hyperacetylation in the same RTT mouse model 
(Shahbazian et al., 2002). One possible explanation for this discrepancy may 
derive from the sex of the animals. Indeed, in the present study, we quantified 
for the first time the histone H3 acetylation level in two different brain regions 
of MeCP2-308 heterozygous female mice. Differences between male and 
female in the modulation of gene expression involving histone methylation and 
acetylation have been hypothesized in previous studies, suggesting a key role 
of the sex-hormones in the regulation of epigenetic modification in complex 
diseases, such as autism and depression (Kaminsky et al., 2006). Another 
important difference from the study of Shahbazian and colleagues was the age 
of the mice (3-5 months vs 12 months of age in the present study) which could 
explain, at least in part, the different H3 acetylation levels in cortical brain 
areas. Indeed, previous works showed differences of acetylation levels of H3 
and H4 in the visual cortex of 1 month of age mice compared to adult mice 
(about 3 months of age), demonstrating the impact of visual experience on 
acetylation (Vierci et al., 2016). In addition, in previous studies no cortical 
hyperacetylation of histone H3 and H4 was found  on 2 months old female 
RTT-null mice (Urdinguio et al., 2007), suggesting that acetylation process 
may be dependent, beside the age, also on the type of MeCP2 mutation 
occurring in RTT mouse models. 
To understand the causes leading to this unexpected acetylation profile 
in RTT mouse brain and LP-211 treatment thereon, we verified whether brain-
area specific differences in the levels of SIN3α, NCoR, HDAC1 and 3 might 
be found in RTT mouse brain. In fact, all these proteins are able to directly or 
indirectly associate with an array of DNA binding repressors, beyond MeCP2 
(Guenther et al., 2001). Interestingly, we found a hyper-expression of the 
NCoR and HDAC3 proteins in RTT mouse cortex, that was completely 
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normalized by LP-211 treatment. These results are consistent with the 
possibility that NCoR/HDAC3 complex in this brain area might be responsible 
for the H3 histone hypo-acetylation. Indeed, HDAC3 regulates many 
biological processes in a variety of tissues, such as lipid metabolism in liver 
and heart and the cell cycle progression of fibroblasts (Sun et al., 2013), which 
may be relevant for RTT. Moreover, neuronal deletion of Hdac3 in mice elicits 
abnormal locomotor coordination, defective sociability, and cognition (Nott et 
al., 2016). The observation that lower levels of histone acetylation are 
accompanied by the overexpression of HDAC3 in RTT mouse cortex thus 
suggests that MeCP2-independent catalytic activity of NCoR/HDAC3 may be 
abnormal in this brain areas and that the LP-211-induced restoration of 
HDAC3 may at least partially account for the beneficial effects exerted by the 
pharmacological treatment under investigation on behavioural parameters. 
Considering the complexity of the epigenetic regulation of gene expression and 
the involvement of numerous actors in this process, such as the histones 
acetyltransferase (HAT), the Acetyl-CoA, NAD+ and HDACs (Shen et al., 
2015), we cannot exclude that LP-211 treatment may exert its beneficial effects 
on histone H3 acetylation in the brain of RTT mice by modulating the levels 
and the functionality of other proteins. 
A different profile was found in the hippocampus of RTT mice, in 
which lower levels of NCoR protein, in the absence of changes in HDAC3, 
were found. Present molecular results, together with the observation that 
cortical and hippocampal brain areas present opposite H3 acetylation levels in 
RTT mice compared to wt controls, are consistent with the idea that MeCP2 
function differs between cell types and that the lack of fully functional MeCP2 
may differentially impact the complex regulation of gene transcription in a 
brain-area specific manner (Lyst and Bird, 2015).  
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Even though no alterations in SIN3α and HDAC1 protein levels were 
found in the hippocampus or the cortex of RTT mice, we found that the LP-
211 treatment significantly increased SIN3α and HDAC1 level in both brain 
areas selectively in RTT mice. These results suggest that the LP-211 treatment 
may have boosted MeCP2-independent catalytic activity of SIN3α in RTT 
mouse brain. In fact, SIN3α plays a key role in regulation of lifespan and health 
maintenance (Barnes et al., 2014) as well as in mitochondrial function 
regulation (Pile et al., 2003; Barnes et al., 2010; Barnes et al., 2014), thus 
representing an intriguing therapeutic target. Dysfunction in the bioenergetic 
metabolism and in brain mitochondria functionality has been consistently 
demonstrated in RTT mice (Valenti et al., 2014; De Filippis et al., 2015b) , that 
was completely normalized by the LP-211 treatment (Valenti et al., 2017). 
Further exploring LP-211 effects on Sin3a functionality could thus provide 
interesting results. 
In conclusion, the present study provides evidence that the LP-211 
treatment can rescue histone acetylation abnormalities, even though they are 
present in opposite directions in different brain areas. Moreover, present data 
extend previous behavioural results demonstrating the beneficial effects of LP-
211 treatment also on alterations in the social sphere and on the 
cardiocirculatory impairments detected in a female mouse model of RTT. Even 
though further studies are needed to understand the importance of histone 
acetylation in different brain area behaviourally relevant for RTT and to clarify 
whether LP-211 treatment can repristinate the MeCP2 functionality, present 
results shed some light on the molecular mechanisms underlying the beneficial 
effects of the LP-211 treatment and add further support to the translational 
value of this promising pharmacological approach.  
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3.1 Abstract 
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene cause 
CDKL5 Deficiency Disorder (CDD), a rare neurodevelopmental syndrome 
characterized by severe behavioural and physiological symptoms. No cure is 
available for CDD. CDKL5 is a kinase that is abundantly expressed in the brain 
and plays a critical role in neurodevelopmental processes, such as neuronal 
morphogenesis and plasticity. This study provides the first characterization of 
the neurobehavioural phenotype of 1-year old Cdkl5-null mice and 
demonstrates that stimulation of the serotonin receptor 7 (5-HT7R) with the 
agonist molecule LP-211 (0.25 mg/kg once/day for 7 days) partially rescues 
the abnormal phenotype and brain molecular alterations in Cdkl5-null male 
mice. In particular, LP-211 treatment completely normalizes the prepulse 
inhibition defects observed in Cdkl5-null mice and, at a molecular level, 
restores the abnormal cortical phosphorylation of rpS6, a downstream target of 
mTOR and S6 kinase, which plays a direct role in regulating protein synthesis. 
Moreover, we demonstrate for the first time that mitochondria show prominent 
functional abnormalities in Cdkl5-null mouse brains that can be restored by 
pharmacological stimulation of brain 5-HT7R.   
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3.2 Introduction 
CDKL5 Deficiency Disorder (CDD) (OMIM #300672) is a rare 
neuropathological condition that is caused by mutations in the X-linked cyclin-
dependent kinase-like 5 (CDKL5) gene (Kalscheuer et al., 2003). This disorder 
is characterized by a variety of behavioural and physiological symptoms that 
include the onset of seizures in the first months of life, severe global 
developmental delay resulting in intellectual disability (ID) and poor motor 
control, and the presence of peculiar hand stereotypies (Bahi-Buisson et al., 
2008; Fehr et al., 2016). No cure exists for patients affected by CDD. 
CDKL5 encodes a serine/threonine kinase expressed in various tissues, 
with the brain showing the highest levels of expression (Rusconi et al., 2008; 
Kilstrup-Nielsen et al., 2012). Available data point to a crucial role of Cdkl5 
in fundamental neurodevelopmental processes such as activity-dependent 
regulation of neuronal morphogenesis and plasticity (Fuchs et al., 2014; Zhou 
et al., 2017). These processes require a fine-tune regulation of Cdkl5 
localization in neurons, with the shuttling between the cytoplasm and the 
nucleus being regulated by the activation of extra-synaptic NMDA receptors 
(Rusconi et al., 2011), and protein localization on the post-synaptic side of 
excitatory synapses being regulated by the association of the kinase with PSD-
95 (Ricciardi et al., 2012). These neuronal alterations are accompanied by a 
number of behavioural deficits in mice lacking Cdkl5, including motor 
dysfunction, autistic-like behaviours and memory deficits (Jhang et al., 2017; 
Okuda et al., 2018).  
The serotonin receptor 7 (5-HT7R) is a G protein-coupled receptor 
broadly expressed in the central nervous system that is involved in a variety of 
neurophysiological phenomena relevant for CDD, such as sleep, cognitive 
processes and synaptic plasticity (Hedlund et al., 2003; Cifariello et al., 2008; 
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Matthys et al., 2011). Pharmacological stimulation of the 5-HT7R by the brain 
penetrant agonist LP-211 has provided promising results in preclinical studies 
for disorders associated with syndromic IDs, such as Fragile X syndrome and 
Rett syndrome (RTT) (Costa et al., 2012; De Filippis et al., 2014a; De Filippis 
et al., 2015b). Of note, the beneficial effects of LP-211 treatment extend 
beyond intellectual deficits and impact other domains, such as motor function 
and autistic-like behaviours in a mouse model of RTT (De Filippis et al., 
2014a; De Filippis et al., 2015b), a syndrome that presents several symptoms 
in common with CDD (Fehr et al., 2013). Moreover, 5-HT7R stimulation by 
LP-211 impacts a number of behavioural domains and molecular pathways that 
have been demonstrated to be altered in Cdkl5-null mouse brain and in 
induced-pluripotent stem cell (iPSCs)-derived neurons from CDKL5 patients 
(Ricciardi et al., 2012; Amendola et al., 2014), as it promotes a rearrangement 
of neuronal morphology, facilitates synaptogenesis and modulates the 
activation of the Akt/mTOR/S6 pathway (De Filippis et al., 2014a; Speranza 
et al., 2017). 
Based on these pieces of evidence, in the present study we evaluated 
whether the stimulation of 5-HT7R might represent a potential therapeutic 
approach for CDD. To test this hypothesis, 9-12-months old Cdkl5-null male 
mice and wild-type littermate controls received a repeated systemic 
intraperitoneal (i.p.) treatment with LP-211 (0.25 mg/kg once/day for 7 days) 
(De Filippis et al., 2015b). We reasoned that the translational relevance of the 
treatment under investigation might be increased if the relief of symptoms was 
demonstrated at an advanced and more severely affected stage of the disease 
(1-year-old mice). Male mice were used based on clinical evidences of CDD 
in males (Elia et al., 2008) and on the effects of mosaic CDKL5 expression due 
to random X-chromosome inactivation in females. To evaluate therapeutic 
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efficacy, a battery of behavioural analyses was carried out at the end of the 
treatment specifically tailored to detect CDD-related behavioural alterations. 
Behavioural testing started at least 7 days after the end of the i.p. treatment and 
the brains of the experimental mice were collected two months after the last 
i.p. injection, based on previous data suggesting long-term effects of a seven-
day-long treatment with LP-211 (De Filippis et al., 2015b).  
In the brain of Cdkl5-null mice treated with either LP-211 or vehicle, 
Rac1 activation and mitochondrial functionality were evaluated, since recent 
data suggest a role for 5-HT7R in the activation of brain Rho GTPases and in 
the regulation of the oxidative phosphorylation (OXPHOS) apparatus, the 
mitochondrial molecular machinery responsible for the majority of cell energy 
production (De Filippis et al., 2015c; De Filippis et al., 2015d; Valenti et al., 
2017), central players in several pathological conditions associated with ID 
(De Filippis et al., 2014b; Valenti et al., 2014). We also verified whether the 
expression and the activation of Rho GTPase-dependent pathways are 
abnormal in Cdkl5-null mouse brain and LP-211 treatment effects thereon, 
based on previous data pointing to a pathogenic role of a disrupted interaction 
between Cdkl5 and the Rho GTPases Rac1 (Chen et al., 2010; Barbiero et al., 
2017). In particular, we explored whether the LP-211 treatment impacts group 
I PAKs, the leading molecules by which Rho GTPases affect actin 
cytoskeleton dynamics (De Filippis et al., 2014b), and the activation of the 
rpS6 and its upstream regulator Akt, a pathway that is modulated by Rho 
GTPases and is involved in protein synthesis (Ricciardi et al., 2011; De Filippis 
et al., 2014a).   
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3.3 Materials and methods 
3.3.1 Subjects 
The experimental subjects were 9-12-months old Cdkl5-null male mice 
and wild-type littermates (wt) backcrossed to C57BL/6N mice for at least 10 
generations (Amendola et al., 2014). Experimental mice were obtained by 
crossing Cdkl5 heterozygous (-/+) female mice and wt male mice and weaned 
at postnatal day 25. After weaning, mice were housed according to sex in 
groups of two or three in polycarbonate transparent cages (33 x 13 x 14 cm) 
with sawdust bedding and kept on a 12-h light-dark schedule (lights off at 8:00 
a.m.). Temperature was maintained at 21 ±1 °C and relative humidity at 
60±10%. Animals were provided ad libitum with tap water and a complete 
pellet diet (Altromin, 1324 - 10mm pellets, Germany). All experimental 
procedures were conducted in conformity with the European Directive 
2010/63/EU and the Italian legislation on animal experimentation, D.Lgs. 
26/2014. 
3.3.2 Genotyping  
DNA has been prepared from a small tail-tip biopsy taken at weaning, 
as previously described (De Filippis et al., 2014a). The Cdkl5 alleles have been 
identified by PCR using two sets of primers (for further details see 
Supplementary materials). PCR products were electrophoresed through a 2% 
NuSieve 3:1 agarose gel (Cambrex Bio Science, Rockland, ME, USA) 
containing 0.1 µl/ml GelRed™ and examined under UV light. 
3.3.3 Drug and Treatment 
LP-211 was prepared following the same synthetic procedure described 
in (Leopoldo et al., 2008). The compound, which has a half-life 65 minutes, 
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was dissolved in a vehicle solution of 1% dimethyl sulfoxide (DMSO) in saline 
(0.9% NaCl). Cdkl5-null mice and wt littermate controls were randomly 
assigned to be daily i.p. injected (between 9.00 and 11.00 am) for 7 consecutive 
days with either LP-211 (0.25 mg/kg) or vehicle (1% of DMSO in saline).  
3.3.4 Behavioural testing  
A comprehensive test battery was carried out aimed at assessing 
treatment effects on the behavioural domains that are compromised in CDD. 
The selection of the tests to be performed was based on previous literature 
addressing the neurobehavioural phenotype of Cdkl5-null mice (Amendola et 
al., 2014; Okuda et al., 2018) and on our lasting experience on the study of 
mouse models of RTT, a syndrome that has many symptoms in common with 
CDD (De Filippis et al., 2010; De Filippis et al., 2015a). Mice were 
experimentally naïve at the start of the behavioural test battery. All behavioural 
testing took place during the dark phase of the L/D cycle, between 9.00 am and 
3.00 pm, and was carried out by experimenters blind to the mouse genotypes. 
A minimum of 24 h was left between tests.  
3.3.4.1 Prepulse inhibition (PPI) paradigm 
Sensorimotor gating was evaluated 7 days after the last i.p. with the 
prepulse inhibition (PPI) paradigm (Swerdlow et al., 2001). The apparatus 
consisted of two Plexiglas rectangular boxes (startle cages) (9 x 7 cm), placed 
in sound-attenuated chambers with a red light and a fan ventilator (Med 
associates inc. St Albans, VT, United States of America). Background white 
(62 db) noise and acoustic bursts were conveyed by two separate speakers, 
properly spaced from the startle cage so as to produce a fine-tuned regulation 
of sound. Both speakers and startle cages were connected to a main PC 
computer, which detected and analyzed all chamber variables by means of a 
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specific software. Two slightly different protocols were adopted on two 
cohorts of mice, that differed in the range of prepulse intensities under 
investigation. On the first cohort of mice, prepulse intensities were as follows: 
67, 70, 73 or 76 db (Macri et al., 2015). On the second cohort, 78, 82 or 84 dB 
pre-pulse intensities were applied (Chao et al., 2010). To evaluate sensorimotor 
gating capabilities in Cdkl5-null mice, the % PPI was calculated as follows: 
(100-[(mean startle amplitude for prepulse + pulse trials/mean startle 
amplitude for pulse-alone trials) x 100]) (for further details see Supplementary 
materials). 
3.3.4.2 General health score 
The general health of the experimental mice was qualitatively evaluated 
1 and 28 days after the last injection, by a trained observer, blind to the 
genotype of the experimental mice, according to a method that has been 
developed to assess the health status of RTT mice (Guy et al., 2007; De Filippis 
et al., 2014a). Briefly, mice received a score (ranging from 0 – normal 
appearance- to 4- highly compromised) for each of the following parameters: 
gait, mobility, breathing, kyphosis, fur, hind limb clasping, tremors and general 
conditions. The individual scores for each category were subsequently 
averaged to obtain a semi-quantitative measure of the general health status. 
3.3.4.3 Nest Building evaluation 
Nest building ability was scored 21 days from the last i.p. injection to 
assess purposeful and coordinated forepaw use to unravel whether Cdkl5-null 
mice display alterations and LP-211 effects thereon, as previously described 
(De Filippis et al., 2015a). The quality of the nests was evaluated 24 h after 
nest material provision (for further details see Supplementary materials). 
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3.3.4.4 Home cage locomotor activity 
To verify whether LP-211 treatment affects the daily locomotor activity 
in Cdkl5-null mice, spontaneous locomotor activity in the home-cages was 
evaluated 33 days after the last i.p. injection. Levels of activity were monitored 
continuously by means of an automatic device using small passive infrared 
sensors positioned on the top of each cage (ACTIVISCOPE system, 
NewBehaviour Inc., Zurich, Switzerland) as previously described (De Filippis 
et al., 2013) (for further details see Supplementary materials). To avoid 
confounding effects due to cage clean procedures and/or room entrances, the 
analysis was performed during two 6-hours intervals, during the dark and the 
light phase, in which animals were left undisturbed. 
3.3.4.5 Open Field test 
Locomotor activity was assessed in the Open Field test 30 days after 
the last i.p injection, to complement the home-cage recording (Ricceri et al., 
2011) (for further details see Supplementary materials). 
3.3.4.6 Fear conditioning task 
The fear conditioning task was carried out 14 days after the last i.p. 
injection to evaluate cognitive abilities in Cdkl5-null mice and LP-211 effect 
thereon (Wang et al., 2012). An automated system was used (UgoBasile 
S.R.L.), which consisted in a soundproof cubic apparatus with inside a mouse 
cage (21(d) x 24(w) x 30(h) cm) with electrified grid floor. The task consisted 
of a two-days-long protocol in which freezing frequency and duration were 
measured with an automatic freezing detector (UgoBasile S.R.L.). Throughout 
the task, mice were exposed to a white noise (WN- 60db, 2000 Hz). On the 
first day (training), animals were placed in the fear conditioning apparatus for 
180s (baseline, BL) and then exposed for three times to the acoustic 
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conditioned stimulus (CS; 2000 Hz – 68db, 30s). Each CS on the first day was 
paired with a 0.7 mA shock released during the last 2s (unconditioned stimulus; 
US). A 95s inter trial interval (ITI) was used. On the second day(test), mice 
were placed in the same chamber and, after a 180s BL, were exposed to fifteen 
trials consisting in 30s of CS plus 10s of ITI. Contextual fear memory was 
established by measuring the time spent in freezing behaviour during the 
baseline on the testing day compared to levels shown during the baseline on 
the training day. Freezing behaviour in response to the CSs on the test day was 
also evaluated. Before the starting of each session the grid floor of the 
apparatus was cleaned with 70% ethanol. 
3.3.5 Neurobiological analyses  
Two months after the last i.p. injection, the brains of the experimental 
mice were dissected and cortices, a behaviourally relevant brain area in which 
5-HT7R (Hedlund, 2009) and Cdkl5 (Wang et al., 2012) are highly expressed, 
were immediately frozen in dry ice for G-LISA Assay and western blot 
analyses (De Filippis et al., 2015b).  
For mitochondrial analyses, the hemispheres from additional subjects 
were cryopreserved, as previously described (Valenti et al., 2017). Previous 
data in fact demonstrate that cryopreserved brain tissues show mitochondrial 
membrane potential, outer and inner membrane integrity and mitochondrial 
ATP production capacity comparable to mitochondria isolated from fresh 
brains (Valenti et al., 2014b). 
3.3.5.1 RAC-1 G-LISA Assay 
Rac1 G-Lisa Activation Assay BiochemkitTM (Cytoskeleton, Denver, 
CO) (n = 4-5) was used to measure Rac1 activity in mouse cortices according 
to the manufacturer’s recommendations. 
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3.3.5.2 Western blot analysis 
Cortices were homogenized in lysis buffer and centrifuged. Then the 
supernatant was collected and the protein content was quantified by 
bicinchonic acid assay. For western blotting analysis, 20 g of total proteins 
were separated on a 12% SDS-PAGE and membranes incubated with the 
appropriate primary and secondary antibodies. Images of the membranes were 
acquired by a CCD camera (Syngene, G-Box Chemi XRQ) and optical 
densities (O.D.) of the protein signals calculated for each sample with Image J 
software and normalized with the corresponding housekeeping signal (Fig. 4 
A, C); the O.D. ratios were then compared and expressed as the average fold 
increase, with 1 (wt control) as baseline (for further details see Supplementary 
materials). 
3.3.5.3 Mitochondrial analysis  
Measurement of mitochondrial respiratory chain complex (MRC) 
activities. MRC activities were evaluated in mitochondrial membrane-enriched 
fractions obtained from isolated mitochondria. Measurement of MRC complex 
activities were performed essentially as in (Manente et al., 2013), by three 
assays which rely on the sequential addition of reagents to measure the 
activities of: i) NADH: ubiquinone oxidoreductase (complex I) followed by 
ATP synthase (complex V), ii) succinate: ubiquinone oxidoreductase (complex 
II) and iii) cytochrome c oxidase (complex IV) followed by cytochrome c 
oxidoreductase (complex III) (for further details see Supplementary materials). 
Measurement of mitochondrial ATP production rate. The rate of ATP 
production by OXPHOS was determined in isolated mitochondria, as 
previously described in (Valenti et al., 2010) (for further details see 
Supplementary materials).  
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Measurement of mouse brain ATP levels. Half brain was weighted 
(approx. 20 mg) and subjected to perchloric acid extraction as described in 
(Khan, 2003) (for further details see Supplementary materials). The amount of 
tissue ATP was determined enzymatically in KOH neutralized extracts, as 
described in (Valenti et al., 2010). 
3.3.6 Statistical analysis 
Data were analyzed using the two-way ANOVA model, including 
genotype and treatment as between-subjects factors, or applying repeated 
measures ANOVAs if there was a within-subjects factor, using Statview vers. 
5.0 (Sas, Institute Inc., Cary, NC). The alpha level was set to 5%. To unravel 
the presence of outliers, the Grubbs' test was applied. Post-hoc comparisons 
were performed using Tukey HSD (Wilcox, 1987).  
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3.4 Results 
3.4.1 LP-211 treatment selectively rescues PPI deficit in mice lacking 
Cdkl5 at an advanced stage of the disease 
To evaluate the efficacy of the LP-211 treatment for CDD, a broad test 
battery was carried out.  
Prepulse inhibition (PPI). The evaluation of the sensorimotor gating 
showed significant deficits in PPI capacity in Cdkl5-null mice compared to 
wild–type (wt) controls, in the absence of changes in the acoustic startle 
response (see Fig.S1A-B). This genotype effect was replicated on two cohorts 
of animals using protocols adopting different ranges of prepulse intensities 
[Fig.1A cohort 1: Genotype*Treatment interaction: F(1,22) = 12.2, p = 0.021; 
post-hoc: p < 0.01; Fig.1B cohort 2: Genotype*Treatment interaction: F(1,33) = 
7.3, p = 0.011; post-hoc: p < 0.01].The LP-211 treatment significantly 
improved this abnormal behaviour in Cdkl5-null mice compared to vehicle 
(veh)-treated Cdkl5-null mice in both cohorts of animals [Fig.1A, 
Genotype*Treatment; post-hoc: p < 0.01; Fig.1B; Genotype*Treatment; post-
hoc: p < 0.05]. No significant prepulse intensities*genotype*treatment 
interactions were found (Fig.S1C-D).  
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Fig.1: LP-211 treatment selectively rescues prepulse inhibition (PPI) deficit in 
Cdkl5-null mice at an advanced stage of the disease. PPI evaluation was carried out 
on two cohorts of animals using protocols adopting different ranges of prepulse 
intensities; (A-B) Cdkl5-null mice show a severe impairment in PPI compared to wt 
mice. LP-211 treatment rescues the abnormal sensory motor gating in Cdkl5-null mice 
(cohort 1: wt, Veh = 4; wt, LP-211 =7; Cdkl5-null, Veh = 8; Cdkl5-null, LP-211 = 9; 
cohort 2: wt, Veh = 11; wt, LP-211 =12; Cdkl5-null, Veh = 7; Cdkl5-null, LP-211 = 
7). The histograms show the average of all prepulse intensities. Data are mean ± SEM. 
Statistical significance was calculated by two-way ANOVA. **p<0,01; *p<0,05 after 
Tukey’s post-hoc tests.  
General health status. We found that fully symptomatic Cdkl5-null mice 
showed worse general health conditions in comparison to wt mice [Fig.2A; 
Genotype: F(1,35) = 7.8; p = 0.008]. The LP-211 treatment did not significantly 
improve general health status in Cdkl5-null mice (Fig.2A). No differences 
between the first and the second evaluation (1 and 28 days from the last i.p.), 
and no interaction of the repeated measures with genotype and treatment were 
found. Figure 2A represents the genotype*treatment interaction, in which the 
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general health scores obtained at 1 and 28 days after the last i.p. injections were 
averaged.  
 
Fig.2: Cdkl5-null mice show severe general health status at an advanced stage of 
the disease. (A) Cdkl5-null mice present a higher general health score compared to wt 
controls, thus confirming a worse general health status (score= 0-4). No treatment 
effects are found (wt, Veh = 11; wt, LP-211 = 12; Cdkl5-null, Veh = 8; Cdkl5-null, 
LP-211 = 8). Data are mean ± SEM. Statistical significance was calculated by two-
way ANOVA. **p < 0.01; *p < 0.05 after Tukey’spost-hoc tests.  
 
Nest building ability. Nest building ability was slightly, but significantly 
impaired in Cdkl5-null mice in comparison to wt controls [Genotype: F(1,35) = 
4.9; p = 0.032], thus confirming defective coordination of forepaws (De 
Filippis et al., 2015a; Fuchs et al., 2018b). The LP-211 treatment did not affect 
the quality of the nests built by Cdkl5-null mice (wt veh: 2.3  1.2; Cdkl5-null 
veh: 1.8  1.4; wt LP-211: 2.5  1.2; Cdkl5-null LP-211: 1.3  1.0). 
Home cage locomotor activity. The evaluation of spontaneous home cage 
locomotor activity highlighted a hypoactive profile in Cdkl5-null mice 
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compared to wt controls, as demonstrated by the lower number of beam breaks 
they performed during the dark/active phase of the Light/Dark cycle [Fig.2B; 
Phase*Genotype*Treatment interaction: F(1,28) = 3.3; p =n0.082; post-hoc: p 
< 0.05]. The LP-211 treatment did not affect the abnormal locomotor profile 
shown by Cdkl5-null mice in the home cage. 
 
Fig.2: Cdkl5-null mice show hypo-active profile during the dark phase of the 
circadian rhythm at an advanced stage of the disease (B) Cdkl5-null mice show 
hypoactivity in the home cage in comparison to wt mice during the dark/active phase 
of the circadian cycle. The LP-211 treatment does not affect this parameter. The 
infrared sensors detect any movement of mice with a frequency of 20 events per 
second (20 Hz). Scores are obtained as counts per hour (cph) expressed during 1-hour 
periods, and the profile of daily activity is obtained by averaging 6-hours of 
continuous registration per phase (Dark vs Light; 1-6pm - 2-8am) (wt, Veh = 8; wt, 
LP-211 = 10; Cdkl5-null, Veh = 7; Cdkl5-null, LP-211 = 7). Data are mean ± SEM. 
Statistical significance was calculated by two-way ANOVA. **p < 0.01; *p < 0.05 
after Tukey’spost-hoc tests.  
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Open field test. We found that Cdkl5-null mice show hyperactivity when 
exposed to a novel environment compared to wt controls, as demonstrated by 
the increased distance they moved in the open field [Fig.2C; Genotype: F(1,33) 
= 13.6; p < 0.001] as well as the number of entrances in the central zone of the 
arena [Genotype: F(1,33) = 5.9, p < 0.021]. Increased locomotion was confirmed 
throughout the 60-min Open Field test, with no differences between the initial 
and the last 5-min blocks (Fig.S2). LP-211 treatment did not exert any effects 
on the total distance moved (Fig.2C) as well as the number of entrances in the 
central zone of the arena (wt veh:191.5  65.1; Cdkl5-null mice veh: 222.4  
83.9; wt LP-211: 176.6  55.2; Cdkl5-null mice LP-211: 252.6  60.7). No 
difference between Cdkl5-null mice and wt controls was found in time spent 
in the central/intimidating zone of the arena, an index of anxiety-like 
behaviours (data not shown).  
 
Fig.2: Cdkl5-null mice show hyper-active profile in the open field task at an 
advanced stage of the disease (C) A hyperactive profile is evident in the open field 
task, with Cdkl5-null mice moving more than wt controls, that is not affected by the 
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LP-211 treatment. (wt, Veh = 11; wt, LP-211 = 12; Cdkl5-null, Veh = 8; Cdkl5-null, 
LP-211 = 8). Data are mean ± SEM. Statistical significance was calculated by two-
way ANOVA. **p<0,01; *p<0,05 after Tukey’spost-hoc tests.  
 
Fear conditioning test. Defective contextual fear memory was found in 
Cdkl5-null mice, as demonstrated by the reduced freezing levels they displayed 
compared to wt controls when exposed to the context in which they received 
the footshock on the previous day [Fig.2D; Day*Genotype*Treatment 
interaction: F(1,35) = 3.1; p = 0.086; post-hoc: p < 0.01]; no significant LP-211 
treatment effect was highlighted on this hippocampus-dependent cognitive 
deficit. Reduced freezing in response to the presentation of the 15 CSs on the 
second day of testing compared to wt controls was also evident in Cdkl5-null 
mice [Genotype: F(1,35) = 11.6; p < 0.001]. The LP-211 treatment did not 
improve this abnormal freezing response shown by Cdkl5-null mice (wt 
veh:27.9  10.2; Cdkl5-null mice veh: 16.3  12.0; wt LP-211: 24.1  11.8; 
Cdkl5-null mice LP-211: 16.5  12.8). 
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Fig.2: Cdkl5-null mice show reduced freezing behaviour in the fear conditioning 
paradigm at an advanced stage of the disease (D) Cdkl5-null mice show reduced 
freezing behaviour in comparison to wt mice in the fear conditioning task, suggesting 
defective contextual fear memory. The LP-211 treatment does not affect the 
performance in this cognitive test (wt, Veh = 11; wt, LP-211 = 12; Cdkl5-null, Veh = 
8; Cdkl5-null, LP-211 = 8). Data are mean ± SEM. Statistical significance was 
calculated by two-way ANOVA. **p < 0.01; *p < 0.05 after Tukey’spost-hoc tests.  
 
3.4.2 The LP-211 treatment activates Rac1 and rescues the abnormal 
activation of rpS6 in the cortex of Cdkl5-null mice 
Based on available data suggesting that Rac1 signaling may be 
defective in CDD (Chen et al., 2010), the activation of Rac1 and of the Rho 
GTPases downstream molecules PAKs and rpS6 was evaluated in Cdkl5-null 
mouse cortex, to verify whether they are abnormal and whether 
pharmacological stimulation of the 5-HT7R may recover them.  
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Rac1 activation. No genotype difference was found in the activation of 
Rac1 in Cdkl5-null mouse cortex. The LP-211 treatment significantly 
increased Rac1 activation in both genotypes [Fig.3, Treatment: F(1,15) = 5.8; p 
= 0.028]. 
 
Fig.3: The LP-211 treatment significantly increases Rac1 activation in both 
genotypes. The activation of Rac1 protein was evaluated in mouse cortical brain areas 
by G-Lisa Activation Assay. No differences were found between Cdkl5-null mice and 
wt littermates. LP-211 treatment increases Rac1 activation levels in both genotypes 
(wt, Veh = 5; wt, LP-211 = 5; Cdkl5-null, Veh = 5; Cdkl5-null, LP-211 = 4). Data are 
mean ± SEM. Statistical significance was calculated by two-way ANOVA.  
 
Expression and activation of RhoGTPase-dependent signaling 
pathways. We found that phospho-PAK(p-PAK)/total PAK ratio, which 
provides an index of the net functionality of the kinase, was shifted toward 
increased activation in Cdkl5-null mouse cortex compared to wt controls 
[Fig.4A,B; Genotype: F(1,17) = 15.7; p < 0.001]. The LP-211 treatment 
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increased PAK activation in the cortex of both genotypes, as demonstrated by 
increased p-PAK/total PAK ratio [Fig.4B, Treatment: F(1,17) = 11.7; p = 0.003]. 
 
 
Fig.4: The LP-211 treatment increases the activation of PAK in the cortex of Cdkl5-
null mice. Representative Western blot analysis (summarized view corresponding to 
one or three animals per group) of (A) phospho-PAK (p-PAK) and PAK tot in cortical 
brain areas. (B) The LP-211 treatment increases the activation of group I PAKs, 
measured as p-PAK/PAK tot ratio in the cortex of Cdkl5-null and wt mice. This leads 
to an exacerbation of the overactivation of PAK in Cdkl5-null mouse cortex (wt, Veh 
= 4; wt, LP-211 = 6; Cdkl5-null, Veh = 6; Cdkl5-null, LP-211 = 6). Data are expressed 
as percentage of wt veh controls (100). Data are mean ± SEM. Statistical significance 
was calculated by two-way ANOVA. **p < 0.01; *p < 0.05 after Tukey’s post-hoc 
tests.  
 
In Cdkl5-null mouse cortex, we also observed increased ribosomal 
protein S6 (rpS6) activation (Fig. 4C representative blots), as demonstrated by 
increased phospho-rpS6 (240/244)(p-rpS6)/total rpS6 ratio, which was 
normalized by the LP-211 treatment [Fig.4D; Genotype*Treatment 
interaction: F(1,18) = 3.2, p = 0.089; post-hoc: p < 0.05]. No genotype or 
treatment effects were found on the phosphorylation levels of the rpS6 at 
Ser235/236 in the cortex (Fig.4E). 
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Fig.4: The LP-211 treatment rescues the abnormal activation of rpS6 in the cortex 
of Cdkl5-null mice. Representative Western blot analysis (summarized view 
corresponding to one or three animals per group) (C) rpS6 p240/244, rpS6 p235/236 
and rpS6 tot proteins in cortical brain areas. (D) The LP-211 treatment normalizes the 
abnormal level of the p-rpS6(240/244)/ rpS6tot ratio inCdkl5-null mouse cortex. The 
LP-211 treatment does not affect cortical levels of the p-rpS6(235/236)/ rpS6 tot ratio 
(E) (wt, Veh = 4; wt, LP-211 = 6; Cdkl5-null, Veh = 6; Cdkl5-null, LP-211 = 6). Data 
are expressed as percentage of wt veh controls (100). Data are mean ± SEM. Statistical 
significance was calculated by two-way ANOVA. **p < 0.01; *p < 0.05 after Tukey’s 
post-hoc tests.  
 
Akt activation levels. In the cortex of Cdkl5-null mice, no genotype 
difference and no LP-211 treatment was detected for the activation of Akt 
quantified as the ratio phospho-Akt (p-Akt)/Akt total (Fig.S3). 
Cdkl5 levels. Interestingly, the LP-211 treatment slightly, but 
significantly increased Cdkl5 protein levels in the cortex of LP-211-treated wt 
mice, in comparison to wt controls [Genotype*Treatment interaction: F(1,18) = 
11.6, p = 0.003; post-hoc: p < 0.01; wt, veh: 1000.2 and wt, LP-211: 1400.2 
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(% relative to wt)]. As expected, Cdkl5 was not detected in the brain of mutant 
mice.  
5-HT7R levels. We also evaluated whether the levels of the 5-HT7R 
differ in the brain of Cdkl5-null mice compared to wt controls and LP-211 
effects thereon. No significant genotype or treatment effects were found in 
cortex (Fig.S4).  
3.4.3 Cdkl5-null mouse brain shows defective mitochondrial 
functionality that is rescued by the LP-211 treatment  
Based on recent evidence suggesting a role for 5-HT7R and Rho 
GTPases in the regulation of brain mitochondrial functionality (De Filippis et 
al., 2015a; De Filippis et al., 2015b; Valenti et al., 2017), we analyzed 
mitochondrial functionality in Cdkl5-null mouse brains.  
Activity of Mitochondrial Respiratory Chain (MRC) complexes. We 
found reduced activity of the MRC complexes III, IV and V in Cdkl5-null 
mouse brains compared to wt controls [Fig.5A; Repeated 
measure*Genotype*Treatment interaction: F(4,32) = 13.4; p < 0.001; post-hoc: 
p < 0.01]. No difference was found in the activity of complexes I and II 
(Fig.5A). A complete restoration in the activity of the defective MRC 
complexes in LP-211-treated Cdkl5-null mice was found [Fig.5A; Repeated 
measure*Genotype*Treatment interaction; post-hoc: p < 0.01 compared to 
vehicle-treated Cdkl5-null mice for complexes IV and V and p < 0.05 
compared to vehicle-treated Cdkl5-null mice for complex III]. 
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Fig.5: Cdkl5-null mouse brain shows defective mitochondrial functionality that is 
rescued by the LP-211 treatment. (A) Reduced activity of mitochondrial respiratory 
chain (MRC) complexes III, IV, V is evident in Cdkl5-null mouse brain compared to 
wt controls. LP-211 treatment rescues these alterations (wt, Veh = 3; wt, LP-211 = 3; 
Cdkl5-null, Veh = 3; Cdkl5-null, LP-211 = 3). Data are mean ± SEM. Statistical 
significance was calculated by two-way ANOVA. **p < 0.01; *p < 0.05 after Tukey’s 
post-hoc test. 
 
Brain energy status evaluation. To evaluate if normalization of the activity 
of MRC complexes was associated with a normalization of their bioenergetic 
efficiency, the ATP production rate and ATP whole brain levels were 
measured (Fig.5B,C). In line with the results on complexes activity, Cdkl5-null 
mouse mitochondria showed a significant reduction in mitochondrial ATP 
production rate when supplied with the substrate for complex IV 
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(ascorbate/TMDP), as energy source [Fig. 5B; Repeated 
measure*Genotype*Treatment interaction: F(2,16) = 3.2; p = 0.066; post-hoc: 
p < 0.05]. No changes were found when substrates for complexes I and II were 
used (Fig.5B). Importantly, whole brain ATP levels were also reduced in 
Cdkl5-null mouse brain in comparison to wt controls [Fig.5C; 
Genotype*Treatment interaction: F(1,12) = 20.2; p < 0.001; post-hoc: p < 0.01]. 
LP-211 treatment completely rescued the defective mitochondrial ATP 
production and the reduced brain ATP levels in Cdkl5-null mice [Fig.5B; ATP 
production: Repeated measure*Genotype*Treatment interaction; post-hoc: p 
< 0.05; Fig.5C; whole brain ATP level: Genotype*Treatment interaction; post-
hoc: p < 0.01].  
 
Fig.5: Cdkl5-null mouse brain shows defective mitochondrial functionality that is 
rescued by the LP-211 treatment. (B) Mitochondrial ATP production rate and (C) 
ATP level are lower in the brain of Cdkl5-null mice. The LP-211 rescues the defective 
energy status in the brain of Cdkl5-null mice (B, C) (wt, Veh = 3; wt, LP-211 = 3; 
Cdkl5-null, Veh = 3; Cdkl5-null, LP-211 = 3). Data are mean ± SEM. Statistical 
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significance was calculated by two-way ANOVA. **p  <0.01; *p < 0.05 after Tukey’s 
post-hoc test.  
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3.5 Discussion 
This study provides the first characterization of the behavioural 
phenotype of Cdkl5-null mice at an advanced stage of the disease and 
demonstrates that 5-HT7R modulation, with the 5-HT7R agonist LP-211, 
partially rescues the abnormal neurobehavioural phenotype of fully 
symptomatic Cdkl5-null male mice. In particular, in Cdkl5-null mice receiving 
the LP-211 treatment we found a normalization of PPI deficits and a complete 
restoration of rpS6 activation in cortical brain areas. Moreover, we 
demonstrate for the first time that mitochondria, the powerhouses of the cells, 
show important abnormalities at the functional level in Cdkl5-null brain and 
that such functional alterations can be persistently restored by modulation of 
brain 5-HT7R.  
In spite of the progressive nature of CDD, mouse studies have been so 
far focused on young animals (i.e. 2-4 months of age) and no information is 
available on behavioural as well as brain molecular alterations in Cdkl5-null 
mice at an advanced stage of the disease. The present study provides the first 
comprehensive characterization of the behavioural phenotype displayed by 9-
12-months old Cdkl5-null male mice. In particular, we found marked 
alterations in the general health status and in the locomotor profile, with Cdkl5-
null mice showing an hypo-locomotor profile in the home cage and 
hyperlocomotion in the open field, thus confirming previous data in young 
animals (Amendola et al., 2014; Jhang et al., 2017). An abnormal profile was 
also observed in the fear conditioning task, suggestive of a profound cognitive 
impairment in fully symptomatic Cdkl5-null mice. We cannot however 
exclude that the hyperactive profile shown by Cdkl5-null mice when exposed 
to novel contexts may account for the reduced freezing behavior in this 
cognitive task (Amendola et al., 2014; Jhang et al., 2017).  
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Furthermore, the comprehensive battery of behavioural tests we carried 
out allowed us to identify the presence of severe PPI deficits in fully 
symptomatic Cdkl5-null mice, a measure of sensorimotor gating of the startle 
reflex (Swerdlow et al., 2001) that is known to be affected in patients with 
several neuropsychiatric disorders including schizophrenia (Braff et al., 2001), 
and in rodent models (Schwabe and Krauss, 2017). As PPI can be easily 
assessed in patients (Braff et al., 2001), present results provide to the clinical 
setting an innovative, non-invasive tool to test the efficacy of potential 
treatments for CDD. Further studies are however needed to uncover the 
developmental course of this behavioural alteration as a reduction in PPI was 
previously reported in two-months old Cdkl5-null mice, that just missed 
statistical significance (Okuda et al., 2018). 
Of note, the LP-211 treatment rescued this behavioural alteration in 
Cdkl5-null mice. A link between PPI deficits and abnormal serotonin 
signalling has been clearly established, with either an increase or a decrease in 
serotonin signalling leading to PPI disruption (Fletcher et al., 2001). Moreover, 
based on human studies demonstrating that 5-HT7R mRNA is downregulated 
in the dorsolateral prefrontal cortex of schizophrenics (East et al., 2002), 
several works have addressed and demonstrated the involvement of 5-HT7R in 
regulation of the PPI response in rodents (Pouzet et al., 2002b; Semenova et 
al., 2008). Our results similarly suggest that 5-HT7R may be critically involved 
in serotonin-dependent regulation of the sensorimotor gating processing. Since 
we did not observe any change in the levels of the 5-HT7R in Cdkl5-null mouse 
brain, our results suggest that stimulation of the 5-HT7R might have indirectly 
rescued 5-HT7R-independent defects in Cdkl5-null mouse brain. Indeed, 
several serotonin receptors have been found to be involved in the regulation of 
PPI (Pouzet et al., 2002a; Mitchell and Neumaier, 2008; Pogorelov et al., 
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2017). Moreover, other neurotransmitter systems including glutamate and 
dopamine play a role in regulating sensorimotor gating (reviewed in (Geyer et 
al., 2001)).  
Another important finding of the present study concerns the 
demonstration that Cdkl5-null mouse brains display impaired mitochondrial 
OXPHOS and a consequent decrease in brain energy status. We found reduced 
activity of the complexes III, IV, V and decreased ATP production and whole 
brain levels. How the lack of Cdkl5 produces such a mitochondrial dysfunction 
in mouse brain is not yet clear. Both transcriptional and post-translational 
mechanisms may be involved (De Filippis et al., 2015b). Of note, high levels 
of oxidative stress markers have been found in CDKL5 patients (Pecorelli et 
al., 2011), that have been proposed to be due to mitochondrial dysfunction 
(Pecorelli et al., 2015). We clearly demonstrate here the occurrence of 
multilevel dysfunctions of brain mitochondria in Cdkl5-null mice, thus 
providing support to this hypothesis. 
Interestingly, reactivation of mitochondrial respiratory chain 
complexes in Cdkl5-null mouse brain by the LP-211 treatment rescued the 
defective brain energy status. Present results are in line with previous studies 
reporting the beneficial effect of the LP-211 treatment on brain mitochondrial 
function of two mouse models of RTT (Valenti et al., 2017). Taken together, 
these data strengthen the suggested link between 5-HT7R and mitochondria in 
mouse brain and add relevant information to previous studies demonstrating a 
role for the serotonergic system in the regulation of mitochondria homeostasis 
(Chen et al., 2007; de Oliveira, 2016).  
In the present study, we focused on RhoGTPases signaling, based on 
previous evidence suggesting that these pathways may be altered in CDD 
(Chen et al., 2010). Contrary to our expectation, we found normal activation 
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levels of Rac1 in Cdkl5-null mouse cortex at the tested age. These results are 
in contrast with previous in vitro studies suggesting that defective Rac1 
activation may play a role in CDD pathogenesis (Chen et al., 2010; Barbiero 
et al., 2017). Since no data on younger animals are currently available we 
cannot however exclude that such inconsistency may be due to the advanced 
age of the experimental mice. Indeed, a recent study aimed at evaluating Rac1 
signaling in the brain of Fragile X mouse model has uncovered an age-
dependent effect, with the observed Rac1 overactivation disappearing in older 
animals (Pyronneau et al., 2017).  
Evidence that CDKL5 pathogenesis changes as the disease progresses 
is in fact provided by the increased activation of rpS6 (p 240/244) and the lack 
of genotype differences in Akt activation we found in Cdkl5-null mouse cortex 
at an advanced stage of the disease, which are in contrast with the previously 
reported reductions in younger animals (9-12 months of age vs postnatal day 
27 and 60) (Amendola et al., 2014; Della Sala et al., 2016). Moreover, recent 
evidence demonstrated age-dependent efficacy of pharmacological treatment 
strategies in Cdkl5-null mice, with drugs exerting promising beneficial effects 
in two-month old Cdkl5-null mice losing their effectiveness at an advanced 
stage of the disease (Fuchs et al., 2018a). Altogether, these data highlight the 
need for studies aimed at evaluating the developmental progression of the 
disease and for innovative therapeutic strategies to be applied at an advanced 
stage of the disease, when previously efficacious therapies may lose their 
effectiveness. 
We found that the LP-211 treatment normalized the unexpected 
overactivation of rpS6 in Cdkl5-null cortex, in addition to PPI deficits and 
mitochondrial dysfunction. Given that Rac1 and AkT activation were found to 
be normal and were not affected by the LP-211 treatment, present results 
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suggest that different upstream molecules of rpS6 are altered in Cdkl5-null 
mouse brain at an advanced stage of the disease, that may account for the 
beneficial effects of the treatment under investigation (Bokoch, 2003; Biever 
et al., 2015). Indeed, the 5-HT7R activation is known to stimulate several 
signalling cascades (Speranza et al., 2013; Guseva et al., 2014). Interestingly, 
among them, PKA activation has been intriguingly linked to de-
phosphorylation of rpS6 at Ser240/244 (Bonito-Oliva et al., 2013) and to 
regulation of PPI (Kelly et al., 2007).  
Besides the overactivation of rpS6, increased activation of group I 
PAKs was also evident in Cdkl5-null mouse brain, that was exacerbated by the 
LP-211 treatment. This family of proteins is crucially involved in several 
neuronal processes potentially relevant for CDD. In fact, group I PAKs play a 
crucial role in modulating ultrastructural neuronal morphology in vivo and in 
regulating activity-dependent actin dynamics, underlying synaptic plasticity 
(Hayashi-Takagi et al., 2010; De Filippis et al., 2014b; Duffney et al., 2015). 
Moreover, overactivation of the Rac/Pak pathway affects fear memory (Das et 
al., 2017), social learning (Molosh et al., 2014) and synaptic plasticity 
(Hayashi et al., 2004; Hayashi et al., 2007; Martinez and Tejada-Simon, 2011). 
Taken together, these results highlight the overactivation of Group I PAKs as 
a potential innovative target for the treatment of CDD at an advanced stage of 
the disease. Group I PAKs inhibitors are in fact increasingly recognized as 
promising candidates for the treatment of Fragile X and schizophrenia (Dolan 
et al., 2013; Hayashi-Takagi et al., 2014). 
In conclusion, the present study provides the first evidence that the LP-
211 treatment partially rescues the abnormal neurobehavioural phenotype of 
clearly symptomatic Cdkl5-null male mice. Abnormal PPI and reduced brain 
energy status due to mitochondrial dysfunction were also uncovered, for the 
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first time, in Cdkl5-null mice at an advanced stage of the disease, thus 
providing innovative endophenotypes for CDD. Moreover, we provide here 
the first in vivo evidence that Cdkl5 in mouse cortex is involved in regulation 
of group I PAKs, a family of proteins that are crucially involved in several 
neuronal processes potentially relevant for CDD. Altogether, the present data 
highlight innovative endophenotypes and druggable molecular targets for this 
devastating disorder. 
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Supplementary materials 
Genotyping  
DNA has been prepared from a small tail-tip biopsy taken at weaning, 
as previously described (De Filippis et al., 2010). The Cdkl5 alleles have been 
identified by PCR using two sets of primers. Primer set 1 (5′ primer: 5’- ACG-
ATA-GAA-ATA-GAG-GAT-CAA-CCC-3′ and 3′ primer: 5’-CCC-AAG-
TAT-ACC-CCT-TTC-CA-3’) yields a product of 240 bp identifying the wild 
type allele. Primer set 2 (5′ primer same as for primer set 1 and 3′ primer: 5’-
CTG-TGA-CTA-GGG-GCT-AGA-GA 3’) yields a product of apparent size 
344 bp identifying the null allele. PCR products were electrophoresed through 
a 2% NuSieve 3:1 agarose gel (Cambrex Bio Science, Rockland, ME, USA) 
containing 0.1 µl/ml GelRed™ and examined under UV light. 
Behavioural testing  
Prepulse Inhibition 
Sensorimotor gating was evaluated 7 days after the last i.p. with the 
prepulse inhibition (PPI) paradigm (Swerdlow et al., 2001). The apparatus 
consisted of two Plexiglas rectangular boxes (startle cages) (9 x 7 cm), placed 
in sound-attenuated chambers with a red light and a fan ventilator (Med 
associates inc. St Albans, VT, United States of America). Background white 
noise and acoustic bursts were conveyed by two separate speakers, properly 
spaced from the startle cage so as to produce a fine-tuned regulation of sound. 
Both speakers and startle cages were connected to a main PC computer, which 
detected and analyzed all chamber variables by means of a specific software. 
Before every testing session, acoustic stimuli and mechanical responses were 
calibrated via specific devices supplied by Med Associates. One day before the 
164 
experiment, all mice were left undisturbed in the apparatus in the presence of 
the background noise for 5 minutes (habituation). On the following day (test), 
mice were positioned inside the startle chamber and exposed to a continuous 
white noise (62 db) for 5 min, followed by three blocks of trials. The first and 
third blocks consisted of 10 pulses (40ms, 120 db) interspaced by an average 
inter-trial interval of 15s. The second block of trials displayed a pseudorandom 
sequence of 28 trials. Each trial started with a 50ms null period, followed by a 
20ms pre-pulse noise bursts. The delay between the pre-pulses and the startle 
was 100ms. Two slightly different protocols were adopted on two cohorts of 
mice, that differed in the range of prepulse intensities under investigation. On 
the first cohort of mice, prepulse intensities were as follows: 67, 70, 73 or 76 db 
and the following types of trials were entailed: prepulse plus startle (four trials 
per prepulse intensity), prepulse alone (four trials per prepulse intensity), 
startle alone (four trials) and no stimulation (four trials) (Macri et al., 2015). 
On the second cohort, 78, 82 or 84 dB pre-pulse intensities were applied (Chao 
et al., 2010), with the following trials: prepulse plus startle (eight trials per 
prepulse intensity), prepulse alone (eight trials per prepulse intensity), startle 
alone (eight trials) and no stimulation (eight trials). To prevent habituation, the 
inter-trial interval randomly varied between 10s and 20s. Before each animal 
testing the apparatus was cleaned with 70% ethanol solution. To evaluate 
sensorimotor gating capabilities in Cdkl5-null mice, the % PPI was calculated 
as follows: (100-[(mean startle amplitude for prepulse +pulse trials/mean 
startle amplitude for pulse-alone trials) x100]). 
Nest building evaluation 
One piece of filter paper (5 cm × 5 cm) was provided to each singly 
housed mouse. Mice were singly housed on the day before nest material 
provision. The quality of the nests was scored by a trained observer, according 
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to the following five-point qualitative scale: 0: nest material untouched; 1: nest 
material nearly untouched; 2: nest material scattered, no clear shape evident; 
3: nest of intermediate quality; 4: nest round and well built. 
Home cage locomotor activity 
To verify whether LP-211 treatment affects the daily locomotor activity 
in Cdkl5-null mice, spontaneous locomotor activity in the home cages was 
evaluated. Levels of activity were monitored continuously by means of an 
automatic device using small passive infrared sensors positioned on the top of 
each cage (ACTIVISCOPE system, NewBehaviour Inc., Zurich, Switzerland). 
The sensors (20 Hz) detected any movement of mice with a frequency of 20 
events per second. Data were recorded by a computer with dedicated software. 
No movements were detected by the sensors when mice were sleeping, 
inactive, or performing moderate self-grooming. Scores were obtained during 
60 min intervals and expressed as counts per hour. The position of cages in the 
rack was such that mice of each group were equally distributed in rows and 
columns. 
Open field test 
The apparatus consisted of a black plastic cubical arena (40 × 40 × 40 
cm) with a grey floor subdivided by black line into 8 × 8 cm squares. The 
session started by placing the animal in one corner of the arena and lasted 60 
min. Activity was recorded by a suspended video camera and analyzed using 
Ethovision software (Noldus, Netherlands). A central square zone (30 x 30 cm) 
was defined to evaluate anxiety-related responses. Total distance moved, speed 
and number of entries into the central zone of the arena were automatically 
scored throughout the 60-min session. The floor of the apparatus was cleaned 
with 70% ethanol before each testing session. 
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Neurobiological analyses 
Western blot analysis 
Tissues, hippocampi and cortices, from 4 mice for WT-Vehicle group 
and from 6 mice for the other groups were collected 2 months after the last i.p. 
and immediately frozen in dry ice. To prepare the lysate, tissue were defrosted 
in ice and soon after homogenized with a glass-glass ice-cold dounce 
homogenizer in lysis buffer (Tris-HCl pH 8, 50 mM; NaCl, 150 mM; EDTA, 
2 mM) supplemented with protease and phosphatase inhibitor cocktails (PIC, 
cod. P8340, Sigma Aldrich and PhosSTOP, cod. 04 906 837 001, Roche, 
respectively). To the homogenized tissues, a final concentration of 1% NP40 
and 0,1% SDS were added to promote membrane solubilization. After a 30-
minute incubation in ice, samples were sonicated to fragment nucleic acids and 
centrifuged at 16000g for 15’ at 4°C. Cellular debris were discarded and the 
supernatants collected, dosed with the bicinchonic acid assay (Pierce) and 
stored in laemmli buffer. For western blotting analysis, 20 mg of total proteins 
were separated on a 12% SDS-PAGE and blotted to nitrocellulose membrane. 
The following primary antibodies were used: rabbit polyconal anti-rpS6 
(1:1000, cod. 2217, Cell Signaling), rabbit polyclonal anti-phospho-rpS6 
(1:1000, cod. 2211 (Ser 235/236) and cod. 2215 (Ser 240/244), Cell Signaling), 
rabbit polyclonal anti phospho S473 Akt (1:1000, cod. 9271, Cell Signaling),  
rabbit polyclonal anti Akt total (1:1000, cod. 9272, Cell Signaling), rabbit 
polyclonal anti-phospho PAK Ser 141 (1:500, cod. 44940G, Invitrogen), rabbit 
polyclonal anti-PAK (C-19) (1:1000, cod. sc-881, Santa Cruz), rabbit 
polyclonal anti-CDKL5 (1:1000, cod. HPA002847) and mouse monoclonal 
anti-neuronal class III b-tubulin (clone TUJ1, cod. MMS-435P, Covance). 
Images of the membranes were acquired by a CCD camera (Syngene, G-Box 
Chemi XRQ) and optical densities (O.D.) of the protein signals calculated for 
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each sample with Image J software and normalized with the corresponding 
TUJ1 signal; the O.D. ratios were then compared and expressed as the average 
fold increase, with 1 (wt control) as baseline. 
Mitochondrial analysis  
Brain tissue cryopreservation. Brains were submerged in a dry-ice-cold 
cryopreservation solution consisting of 50 mM K-MES (pH 7.1), 3 mM 
K2HPO4, 9.5 mM MgCl2, 3 mM ATP plus 20% glycerol and 10 mg/ml BSA 
and stored at -80°C until assayed.  
Measurement of mitochondrial ATP production rate. Mitochondria 
isolated from total brain were incubated at 37°C in 2 ml of respiratory medium 
consisting of 210 mM mannitol, 70 mM sucrose, 20 mM Tris/HCl, 5 mM 
KH2PO4/K2HPO4, (pH 7.4) plus 5 mg/ml BSA, 3 mM MgCl2, in the presence 
of the ATP detecting system consisting of glucose (2.5 mM), hexokinase (HK, 
2 e.u.), glucose 6-phosphate dehydrogenase (G6P-DH, 1 e.u.) and NADP+ 
(0.25 mM) in the presence of glutamate (GLU) plus malate (MAL) (5 mM 
each) or succinate (SUCC, 5 mM) plus rotenone (ROT, 3 µM), or ascorbate 
(ASC, 0.5 mM) plus N,N,N',N'- tetramethyl-p-phenylenediamine (TMPD, 
0.25 mM), as energy sources. The reduction of NADP+ in the 
extramitochondrial phase, which reveals ATP formation from externally added 
ADP (0.5 mM), was monitored as an increase in absorbance at 340 nm. Care 
was taken to use enough HK/G6P-DH coupled enzymes to ensure a non-
limiting ADP-regenerating system for the measurement of ATP production.  
Measurement of mouse brain ATP levels. Half brain was weighted 
(approx. 20 mg) and subjected to perchloric acid extraction: tissues were 
homogenized in 600 µl of pre-cooled 10% perchloric acid neutralized with 2.5 
M KOH and then centrifuged at 14000 rpm for 10 min, 4°C. The amount of 
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tissue ATP was determined enzymatically in KOH neutralized extracts, as 
described in (Valenti et al., 2010). 
Measurement of mitochondrial respiratory chain complex (MRC) 
activities. For isolation of mitochondrial membrane-enriched fractions, 
mitochondrial pellets were first frozen at -80° C, then thawed at 2-4°C, 
suspended in 1 ml of 10 mM Tris-HCl (pH 7.5) plus 1mg/ml BSA and exposed 
to ultrasound energy for 8s at 0°C (11 pulse 0.7 sec on, 0.7 sec off) at 20 kHz, 
intensity 2. The ultrasound-treated mitochondria were centrifuged at 600 rpm 
for 10 min, 4°C. The supernatant was centrifuged again at 14000 rpm for 10 
min, 4°C and the resulting pellet was kept at -80°C until use. Measurement of 
MRC complex activities were performed essentially as in (Manente et al., 
2013), by three assays which rely on the sequential addition of reagents to 
measure the activities of: i) NADH: ubiquinone oxidoreductase (complex I) 
followed by ATP synthase (complex V), ii) succinate: ubiquinone 
oxidoreductase (complex II) and iii) cytochrome c oxidase (complex IV) 
followed by cytochrome c oxidoreductase (complex III). 
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4.1 Abstract 
Rett syndrome (RTT) is a rare neurodevelopmental disorder, 
characterized by severe behavioural and physiological symptoms. RTT is 
caused by mutations in the MECP2 gene in about 95% of cases and to date no 
cure is available. The endocannabinoid system modulates several 
physiological processes and behavioural responses that are impaired in RTT 
and its deregulation has been associated with neuropsychiatric disorders which 
have symptoms in common with RTT. The present study evaluated the 
potential therapeutic efficacy for RTT of cannabidivarin (CBDV), a non-
psychotropic phytocannabinoid from Cannabis sativa that presents 
antagonistic properties on the G protein-coupled receptor 55 (GPR55), the 
most recently identified cannabinoid receptor. Present results demonstrate that 
systemic treatment with CBDV (2, 20, 100 mg/Kg ip for 14 days) rescues 
behavioural and brain alterations in MeCP2-308 male mice, a validated RTT 
model. The CBDV treatment restored the compromised general health status, 
the sociability and the brain weight in RTT mice. A partial restoration of motor 
coordination was also observed. Moreover, increased levels of GPR55 were 
found in RTT mouse hippocampus, suggesting this G protein-coupled receptor 
as new potential target for the treatment of this disorder. Present findings 
highlight for the first time for RTT the translational relevance of CBDV, an 
innovative therapeutic agent that is under active investigation in the clinical 
setting.  
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4.2 Introduction 
Rett syndrome (RTT) is a rare neurodevelopmental disorder, 
characterized by severe behavioural and physiological symptoms (Hagberg et 
al., 2002; Rett, 1966; Ricceri et al., 2012). One essential feature of RTT is the 
apparently normal perinatal development until about 6-18 months of age, when 
RTT patients start losing their acquired cognitive, social, and motor skills and 
develop a wide variety of symptoms (Hagberg, 2002). Classic RTT is caused 
in about 90–95% of cases by de novo mutations in the X-linked MECP2 gene, 
which encodes the methyl CpG-binding protein 2 (MECP2), a multifunctional 
protein that binds to methylated DNA and mainly acts as a key transcriptional 
regulator (Guy et al., 2011). Despite extensive effort in this research field, how 
mutations in MECP2 lead to the symptomatology of RTT is still unknown and 
no effective therapy is currently available for this devastating syndrome.  
The endocannabinoid system (ECS) is a complex neuromodulatory 
system found in all vertebrate classes, involved in the regulation of numerous 
physiological functions (Kano et al., 2009). At the central level, ECS 
modulates several physiological processes and behavioural responses that are 
impaired in RTT (Di Marzo et al., 2015), such as social behaviour (Wei et al., 
2017), anxiety and stress response (Jenniches et al., 2016) and motor control 
(El Manira and Kyriakatos, 2010). Moreover, ECS deregulation has been 
associated with many neuropsychiatric disorders such as anxiety and 
depression (Jenniches et al., 2016; Micale et al., 2013), Fragile X syndrome 
(Jung et al., 2012), schizophrenia (Clarke et al., 2017) and with 
neurodegenerative disorders characterized by cognitive and motor 
dysfunctions such as Alzheimer’s, Huntington’s and Parkinson’s disease 
(Dowie et al., 2009; Maroof et al., 2014; Pisani et al., 2011). Recent data also 
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suggest an involvement of the ECS in Autism Spectrum disorders (Chakrabarti 
et al., 2015).  
A growing number of molecules able to directly or indirectly modulate 
the ECS have been identified to date. Pioneering studies increased the ECS 
response using agonists of the CB1 receptor, one of the two well characterized 
G-coupled receptors for endocannabinoids (Berrendero and Maldonado, 2002; 
Jiang et al., 2005; Patel et al., 2003). However, CB1 agonists may cause 
psychotropic side effects, similar to those reported with cannabis use in 
recreational settings. Such effects are now known to be due to the assimilation 
of Δ9-tetrahydrocannabinol (THC), the main compound of Cannabis sativa. To 
avoid these undesirable effects, most recent preclinical studies focussed on the 
identification of molecules that modulate the ECS without the psychotropic 
effects of THC, such as Rimonabant and URB597 (see e.g.(Griebel et al., 2005; 
Marco et al., 2015)). In addition, much attention has been devoted to non-
psychotropic molecules from Cannabis sativa, which contains more than 120 
substances (Morales et al., 2017). This has led to the identification of few non-
psychotropic phytocannabinoids (phCBs) with a potential as novel drugs. 
These include Cannabigerol (CBG) and Cannabidiol (CBD), the second and 
the third most abundant chemical class types contained in Cannabis sativa 
respectively. In particular CBD bears a high potential in the treatment of 
muscular spasms and rigidity (Di Marzo, 2011), epilepsy (Chiu et al., 1979; 
Devinsky et al., 2017), mood disorders (Linge et al., 2016) and Alzheimer’s 
disease (Cheng et al., 2014). Moreover, recent evidences suggest a potential 
application for CBD in paediatric conditions such as autistic-related syndromes 
(Kaplan et al., 2017) and in children with refractory epilepsy (Brodie and Ben-
Menachem, 2018; Geffrey et al., 2015).  
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Another promising phCB is Cannabidivarin (CBDV), the n-propyl 
analog of CBD. Recent evidence proves that in vitro and in vivo treatment with 
CBDV in mouse and rat exerts anticonvulsant effects (Hill et al., 2012) and 
prevents neuronal hyperexcitability (Iannotti et al., 2014). However, the 
studies focussed on this compound are still very limited and the mechanisms 
of action of CDBV have not been clarified so far. Current evidences suggest 
that at physiologically relevant concentrations of CBDV show no affinity for 
CB1 and CB2 receptors (Hill et al., 2012) and presents antagonistic properties 
on the G protein-coupled receptor 55 (GPR55) receptor, the leading candidate 
for the CB3 receptor name (Anavi-Goffer et al., 2012; Iannotti et al., 2014; 
Marichal-Cancino et al., 2017; Turner et al., 2017). This lipid-activated G 
protein-coupled receptor has been suggested to regulate motor function, spatial 
memory and sociability (Bjursell et al., 2016; Kramar et al., 2017; Marichal-
Cancino et al., 2018), behavioural domains that are compromised in RTT (De 
Filippis et al., 2014; Moretti et al., 2006). Moreover, antagonism of GPR55 has 
been recently suggested as a potential therapeutic approach for Dravet 
syndrome (Kaplan et al., 2017), an autistic-like syndrome with several 
symptoms in common with RTT. 
Importantly, a clinical trial is currently listed aimed at evaluating the 
potential efficacy of a treatment with CBDV on children affected by Autism 
Spectrum Disorder (clinicaltrial.gov, NCT03202303). Based on the high 
translational potentiality of CBDV as an innovative therapeutic agent, in the 
present study MeCP2-308 hemizygous male mice, a highly validated mouse 
model of RTT (De Filippis et al., 2010), and wild-type littermate controls 
received a repeated systemic intraperitoneal (ip) treatment with CBDV (2, 20, 
100 mg/Kg ip for 14 days). Mice were treated at 5 months of age, an early 
symptomatic stage at which MeCP2-308 mice already present reduced 
178 
spontaneous home-cage motor activity, motor coordination impairments, and 
a more marked profile of D-amphetamine-released stereotyped behavioural 
syndrome than WT controls (De Filippis et al., 2010). A battery of behavioural 
analyses was carried out to evaluate treatment effects. Given CBDV 
antagonistic action on GPR55 (Marichal-Cancino et al., 2017), levels of this 
receptor were evaluated, to verify whether they are abnormal in RTT and 
CBDV treatment effects thereon. As markers of efficacy we also explored 
whether the CBDV treatment impacts the abnormal activation of the ribosomal 
protein (rp) S6, a downstream target of  mTOR, in the brain of MeCP2-308 
mice (De Filippis et al., 2014; Ricciardi et al., 2011), and the alterations in 
brain neurotrophins levels (Chang et al., 2006; Ricceri et al., 2011). Indeed, 
based on previous reports suggesting that ECS modulation in mouse brain can 
impact mTOR signalling (Busquets-Garcia et al., 2013; Puighermanal et al., 
2012) and neurotrophins levels (Keimpema et al., 2014), we hypothesised that 
the CBDV treatment may normalize these RTT-related brain molecular 
alterations. A focus was made on the hippocampus, a brain region critically 
involved in regulation of relevant behavioural domains (Kaplan et al., 2017; 
De Filippis et al., 2014). 
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4.3 Materials and methods 
4.3.1 Animals 
The experimental subjects were 5 month-old MeCP2-308 hemizygous 
male mice (RTT) and wild-type (WT) littermates (B6.129S-MeCP2tm1Heto/J 
from the Jackson Laboratories (USA), stock number: 005439) (De Filippis et 
al., 2010; Shahbazian et al., 2002), bred in our facility. Mice were weaned at 
postnatal day 25 and maintained in groups of 2-3 (according to sex) until 5 
months of age. Temperature was maintained at 21 ± 1 °C and relative humidity 
at 60 ± 10%. Animals were provided ad libitum with tap water and a complete 
pellet diet (Altromin, 1324 - 10mm pellets, Germany). All experimental 
procedures were conducted in conformity with the European Directive 
2010/63/EU and the Italian legislation on animal experimentation, D.Lgs. 
26/2014. 
4.3.2 Genotyping  
DNA has been prepared from a small tail-tip biopsy taken at weaning, 
as previously described (De Filippis et al., 2010). The MeCP2 alleles have been 
identified by PCR using two sets of primers. Primer set 1 (5′ primer: 5′-AAC 
GGG GTA GAA AGC CTG-3′ and 3′ primer: 5′-ATG CTC CAG ACT GCC TTG -
3′) yields a product of 396 bp identifying the wildtype allele. Primer set 2 (5′ 
primer same as for primer set 1 and 3′ primer: 5′- TGA TGG GGT CCTCAG 
AGC -3′) yields a product of apparent size 318 bp identifying the null allele. 
PCR products were electrophoresed through a 2% NuSieve 3:1 agarose gel 
(Cambrex Bio Science, Rockland, ME, USA) containing 0.5 μg/mL ethidium 
bromide, and examined under UV light. 
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4.3.3 Drug and treatment 
CBDV (purity by HPLC: 95.9%) was supplied by GW Research 
Limited (Salisbury, UK) and stored in a freezer (at approximately −20°C), 
protected from light and freshly prepared immediately prior to injection. Given 
that CBDV is a nonpolar molecule with very low solubility in water solution, 
the emulsion was prepared using Cremophor® mixed with EtOH and saline. 
RTT mice and WT littermate controls were injected daily i.p. (between 9.00 
and 11.00 am) for 14 consecutive days with CBDV (2, 20 or 100 mg/kg) or 
vehicle (veh) (Cremophor® EL:EtOH:saline in a ratio of 1:2:17). After a 24-
hour washout period from the 14th i.p. injection, mice were sacrificed by 
decapitation. Before the regions collection, whole brains (including olfactory 
bulbs) of experimental animals were rapidly weighted. Subsequently, brains 
were dissected and hippocampi were collected and rapidly frozen for 
biochemical analyses. 
4.3.4 Behavioural tests 
To unravel the effects of the CBDV treatment on RTT-related 
behavioural alterations, mice were subjected to a battery of behavioural tests 
(Figure 1). The following numerosity for each experimental group has been 
achieved in the behavioural analyses: WT, veh: 9; WT, CBDV 2 mg/Kg: 9; 
WT, CBDV 20 mg/Kg: 9; WT, CBDV 100 mg/Kg: 9; Hz, veh: 7; Hz, CBDV 
2 mg/Kg: 8; Hz, CBDV 20 mg/Kg: 8; Hz, CBDV 100 mg/Kg: 9. A total of 70 
animals were used for the study. 
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Fig. 1: Experimental schedule 
4.3.4.1 General health score 
The general health of the experimental mice was qualitatively evaluated 
by a trained observer, blind to the genotype of the experimental mice, at the 
end of behavioural testing after the 1st, the 7th and the 13th injection, as 
previously described (De Filippis et al., 2014; Guy et al., 2001). Briefly, mice 
received a score (ranging from 0 – normal appearance- to 4- highly 
compromised) for each of the following symptoms: gait, mobility, breathing, 
kyphosis, fur, hind limb clasping, tremors and general conditions. The 
individual scores for each category have been subsequently analysed to obtain 
a semi-quantitative measure of the general health status. Body weight was also 
recorded at each scoring session. 
4.3.4.2 Dowel Test 
To evaluate the effects of the treatment on motor learning capacities, 
the dowel test has been performed 1.5 hours after the 1st, the 7th i.p. and the 
13th injections as previously described (De Filippis et al., 2015a). The 
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hardwood round dowel is 9.0 mm in diameter and 35 cm long. The dowel has 
been mounted horizontally 50 cm above a 5 cm depth bedding of sawdust. At 
the beginning of the testing, each mouse has been placed in the middle of the 
dowel so that the length of its body was parallel to the dowel. Latency to fall 
from the dowel into a cage of bedding has been recorded (30-second criterion) 
and used as a measure of motor coordination abilities. Each mouse has repeated 
the test twice per each testing day, with an inter-trial interval of at least 15 
minutes. 
4.3.4.3 Home-cage spontaneous activity and its circadian variation 
Spontaneous locomotor activity in the home-cages has been monitored 
by means of an automatic device using small passive infrared sensors 
positioned on the top of each cage, as previously described (De Filippis et al., 
2012; De Filippis et al., 2010). Data presented in the Results section are 
referred to a selection of 5 hours per phase (dark: 2-6 pm; light: 2-6 am) 
recorded on the first and the seventh day of the treatment schedule. We in fact 
hypothesised that the arousal state of the experimental animals is highly 
influenced by the number and type of experiments that are performed on a 
particular day and may affect the locomotor activity in the home cages. We 
therefore selected two days of the treatment schedule on which mice were 
subjected to a comparable battery of behavioural evaluations which included a 
motor coordination test and the general health score evaluation (see Fig. 1) 
4.3.4.4 Three-chamber social test 
Sociability and social recognition were assessed in the three-chambered 
test, as previously described (Smith et al., 2007). The test started 1 hour after 
the 5th i.p. injection. The test consists of 4 consecutive phases of 10 minutes 
during which each mouse is individually placed in the apparatus: Phase 1 (S1): 
mice can freely explore the central chamber of the apparatus; Phase 2 (S2): 
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mice can explore the three empty chambers; Phase 3 (S3): mice can explore 
either the chamber containing an empty small wire cage or the other one 
containing a conspecific kept under an identical small wire cage; Phase 4 (S4): 
an unfamiliar mouse is located under the cage wire which was empty during 
S3. Allocation of mouse partners to specific chambers was counterbalanced 
within each experimental group. Time spent exploring the mouse versus the 
empty wire cage during S3 is considered as an index of sociability. Time spent 
exploring the unfamiliar mouse versus the familiar one during S4 is considered 
as an index of memory of the social stimuli. Naïve C57 adult male mice were 
used as partners in this test. They were first habituated to the small wire cages 
in the test environment for 2 consecutive days before the testing day. After 
each animal was tested, the three-chamber apparatus and the wire cages were 
thoroughly cleaned with 70% ethanol. 
4.3.4.5 Y-Maze test 
The effects of the treatment on short-term spatial memory were 
assessed on the cognitive, exploratory driven, spatial novelty preference task. 
This task was carried out 1 hour after the 11th i.p. injection, as previously 
described (De Filippis et al., 2015a; De Filippis et al., 2014). Mice were tested 
on a spontaneous, spatial novelty preference task as previously described 
(Lyon et al., 2011; Sanderson et al., 2007). The Y-maze was made from 
transparent Perspex, and consisted of three 30 cm long, 8 cm wide arms with 
20 cm high walls, connected by a central junction. A thin layer of sawdust 
covered the floor of the maze. The test was carried out as previously described 
(Lyon et al., 2011; Sanderson et al., 2007). Each mouse was assigned two arms 
(the ‘start arm’ and the ‘other arm’) to which they were exposed during the 
first phase of the task (the ‘exposure phase’). Allocation of arms to specific 
spatial locations was counterbalanced within each experimental group. During 
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the 5-min ‘exposure’ phase, the entrance to the third, ‘novel’, arm was closed 
off by the presence of a large Perspex white block. The mouse was placed at 
the end of the start arm, facing the experimenter, and allowed to explore the 
start arm and the other arm freely for 5 min, beginning as soon as the mouse 
left the start arm. At the end of 5min exposure phase, the mouse was removed 
from the maze and returned to the home cage for 1 min. During this time, the 
Perspex block closing off the novel arm was removed and the sawdust 
redistributed throughout the maze to minimize the use of odour cues. The 
mouse was then returned to the start arm, facing the experimenter, for the 2-
min ‘test phase’. This consisted of 2-min free exploration during which the 
mouse could enter all the three arms, beginning as soon as the mouse left the 
start arm. The test was video-recorded and the number of entries and the length 
of time spent into each arm, during both the exposure and the test phase, were 
subsequently scored by means of the Noldus Observer XT. For the test phase, 
a discrimination ratio [novel arm/(novel+other arm)]*100 was calculated for 
time spent in each arm. 
4.3.5 Neurobiological analyses 
4.3.5.1 Western Blot Analyses 
Hippocampal tissues were suspended in buffer containing 50 mM Tris–
HCl, pH 8.0, 150 mM NaCl, 1% Triton-X100, 2mM MgCl2 and phosphatase 
and protease inhibitors cocktail (PhosSTOP, Complete Mini, Roche) and then 
sonicated on ice. Lysates were centrifuged at 10000×g for 15 min at 4 °C. 
Protein concentration was determined by Bradford assay (BioRad). Samples 
containing 30µg of proteins were resolved by 7,5% SDS-PAGE under 
reducing and denaturing conditions and transferred to nitrocellulose membrane 
(Amersham Protran Premium). Membranes were blocked  in TBST (10 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Tween 20) with 5% non-fat dry milk 
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for 45 min at room temperature, and then incubated with rabbit anti-rpS6 
(1:1000,Cell Signaling), rabbit anti-phospho-rpS6 (Ser 240/244) (1:1000, Cell 
Signaling), rabbit anti-GPR55 (Abcam, 1:1000) and rabbit anti-beta actin (Cell 
Signaling, 1:1000) overnight at 4 °C. After washing, membranes were 
incubated with secondary anti- rabbit IgG HRP-conjugated antibodies (1:3000, 
Amersham) for 45 min at room temperature. Detection was performed by 
Immobilon Western Chemiluminescent HRP substrate (Millipore). 
Quantification of protein expression was performed by densitometry analysis 
using ImageLab software V.6.0 (Chemidoc, Biorad). Optical Density (OD) 
from at least 4 different experimental mice per group were calculated for each 
sample and normalized with the corresponding actin signal OD; the OD ratios 
were then compared and expressed as the average fold increase, with 100 (WT 
control) as the control value. 
4.3.5.2 Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was performed to quantify levels of different neurotrophins in 
the hippocampus of the experimental mice. Levels of BDNF, NGF, and IGF-1 
were analysed by using microtiter wells plates coated with anti-mouse 
neurotrophins antibodies (BDNF rapid, NGF rapid, Biosensis, Australia; IGF-
1 Elisa kit, Abcam, UK) according to the manufacturer's instructions. The 
absorbance was read on a spectro-photometer (Bio-Rad) using 450 nm as the 
primary wave length, with a sub-wave length of 650 nm. The quantity of 
neurotrophins was expressed as percentage average fold increase of WT 
control values (100). 
4.3.6 Statistical analyses 
Data were analyzed with two-way ANOVA models including genotype 
and treatment as between-subject factors and repeated measurements as 
within-subject factor. The alpha level was set to 5%. The Levene test was 
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applied to confirm the equality of variance. The presence of outliers was 
verified using ROUT method. Post-hoc comparisons were performed by 
Tukey HSD, even in the absence of statistically significant interactions 
(Wilcox, 1987).  
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4.4 Results 
4.4.1 Behavioural analyses 
4.4.1.1 General health score  
The evaluation of the general health status of the experimental mice 
confirmed that consistent gross phenotypic alterations can be detected in 5-
month-old RTT mice (Fig.2a, RTT, veh vs WT, veh, p < 0.01 after post-hoc 
comparison on Genotype*treatment interaction: F(3,60) = 2.906; p = 0.042). We 
found that 14 injections of CBDV at the doses of 20 and 100 mg/Kg can 
improve the general health status of RTT mice (Fig.2a, RTT, veh vs RTT, 
CBDV 20 mg/Kg, p<0.01 and RTT, veh vs RTT, CBDV, 100 mg/Kg, p < 0.01 
after post-hoc comparison on Genotype*treatment interaction). The ANOVA 
highlights significant effect of repeated measures (Days of the schedule 
number 1, 7 ,13: F(2,120) = 5.350; p < 0.006) and interaction of this factor with 
Genotype (F(2,120) = 3.930; p < 0.022) but no interaction with Treatment (F(2,120) 
= 0.839; p < 0.542). All these results are contained in Figure 2a which 
graphically shows the significant genotype*treatment interaction, thus the 
average of all time points (for further information on the profile of repeated 
measures see Supplementary Figure 1a). RTT mice weighed less compared to 
WT littermates (Genotype: F(1,60) = 12.048; p < 0.001). No treatment effects 
were found on this parameter (data not shown). 
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Figure 2: Cannabidivarin (CBDV) treatment rescues general health status in 5-
month-old RTT male mice; Vehicle-injected RTT mice (RTT, veh) showed worse 
health conditions compared to WT controls (WT, veh). Treatment with 
Cannabidivarin (CBDV) at 20 and 100 mg/Kg ameliorates the general health status of 
RTT mice; GH scores (AU: Arbitrary units) are mean values of the three time points 
in which the evaluation was carried out (Days of the schedule number 1, 7 ,13). Data 
are mean±SEM. Statistical significance was calculated by two-way ANOVA with 
Tukey’s post-hoc test. **p < 0.01; *p < 0.05. 
4.4.1.2 Dowel test 
Motor learning ability was assessed in the Dowel test (Fig.2b). In line with 
previous data, RTT mice showed shorter latency to fall from the bar compared 
to WT controls (RTT, veh vs WT, veh, p < 0.01 after post-hoc comparison on 
Day*trial*genotype*treatment interaction: F(6,120) = 2.512; p = 0.025). A worse 
performance of RTT mice was thus confirmed in this test (De Filippis et al., 
2012; De Filippis et al., 2010). Treatment with CBDV at the dose of 20 mg/kg 
significantly improved the motor learning ability of RTT mice and restored 
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WT-like levels of performance on the second testing day (the seventh of the 
experimental schedule). This profile was evident on both the first and the 
second trials (p < 0.01 and p < 0.05 after post-hoc comparisons on the 
Day*trial*genotype*treatment interaction, respectively). However, this 
treatment effect was no more evident on the 13th day of the treatment schedule. 
By contrast, at this latest time point, the dose of 100 mg/Kg significantly 
improved the motor learning ability of RTT mice (p < 0.05 after post-hoc 
comparison on the Day*trial* genotype*treatment interaction). 
 
Figure 2: Cannabidivarin (CBDV) treatment rescues motor alterations in 5-month-
old RTT male mice; (b) in the Dowel test, RTT mice displayed significantly shorter 
latencies to fall from a dowel compared to WT controls, confirming impaired motor 
learning capacities. CBDV at the dose of 20 mg/Kg improved the performance of RTT 
mice on day 7 and the 100mg/Kg dose improved the performance of RTT mice in the 
second trial of day 13; Mice were tested twice per day, with an inter-trial interval of 
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at least 15 minutes. Data are mean±SEM. Statistical significance was calculated by 
two-way ANOVA with Tukey’s post-hoc test. **p < 0.01; *p < 0.05. 
4.4.1.3 Spontaneous locomotor activity 
In line with previous reports, the evaluation of spontaneous locomotor 
activity in home cage revealed that RTT mice are generally less active than 
WT controls (Genotype*treatment interaction: F(3, 46) = 5.032; p = 0.004). This 
profile was mainly evident during the dark/active phase (Fig. 2c, p < 0.01 after 
post-hoc comparison on the Phase*genotype*treatment interaction: F(3,46) = 
4.757; p = 0.001). Levels of activity exhibited by RTT mice treated with 
CBDV at 2 mg/kg tended to be increased compared to those shown by vehicle-
injected ones. However, such a trend did not reach statistical significance. The 
ANOVA did not highlight any significant effect of repeated measures (Days 
of the schedule number 1 and 7: F(1,46) =3.147; p < 0.083) or interaction of this 
factor with Genotype (F(1,46) = 1.432; p < 0.238) or Treatment (F(3,46) = 0.818; 
p < 0.490). Figure 2c graphically shows the significant 
Phase*genotype*treatment interaction, thus the average of both days (for 
further information on the effects of repeated measures see Supplementary 
Figure1b).  
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Figure 2: Cannabidivarin (CBDV) treatment did not rescue spontaneous locomotor 
activity in 5-month-old RTT male mice; (c) RTT, veh mice are generally less active 
than WT controls in the home cages. This profile was mainly evident during the 
dark/active phase. CBDV treatment did not affect the hypoactive profile of RTT mice, 
despite a trend for the 2mg/kg dose of CBDV treatment; Activity was automatically 
monitored by passive infrared sensors. Number of beam breaks (cph: counts per hour) 
are referred to a selection of 5 hours per phase (dark: 2-6 pm; light: 2-6 am) recorded 
on the first and the seventh day of the treatment schedule. Data are mean±SEM. 
Statistical significance was calculated by two-way ANOVA with Tukey’s post-hoc 
test. **p < 0.01; *p < 0.05. 
4.4.1.4 Three-chamber social test 
The test was carried out in order to evaluate CBDV effect on social 
behaviour. As expected, the analysis of the S3 phase revealed a statistically 
significant difference between genotypes, with veh-injected RTT mice 
showing a reduced preference for the social stimulus (versus the inanimate 
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one) in comparison to veh-injected WT controls (Fig.2d, p < 0.01 after post-
hoc comparison on the Genotype*treatment interaction: F(3,58) = 3.527; p = 
0.020). Importantly, the CBDV treatment at the dose of 2 and 20 mg/Kg 
rescued this social deficit in RTT mice, restoring WT-like levels of social 
preference (Fig.2d, p < 0.05 after post-hoc comparison on the 
Genotype*treatment interaction). The analysis of the S4 phase did not 
highlight significant genotype or treatment effects in the recognition of a novel 
social stimulus (versus the familiar one) (Supplementary Figure 1c). 
 
Figure 2: Cannabidivarin (CBDV) treatment rescues social impairment in 5-month-
old RTT male mice; (d) in the three-chamber social test, RTT mice spent less time 
exploring the mouse versus the empty wire cage during sociability phase (S3) in 
comparison to WT controls. CBDV at the doses of 2 and 20 mg/Kg rescued this 
aberrant behaviour restoring normal level of sociability. Data are mean±SEM. 
Statistical significance was calculated by two-way ANOVA with Tukey’s post-hoc 
test. **p < 0.01; *p < 0.05. 
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4.4.1.5 Y-maze test 
No genotype effects were found in the discrimination ratio index at this 
early symptomatic age (Fig.2e); all the experimental mice recognized the novel 
arm versus the familiar one (discrimination ratio > 50). No treatment effects 
were evident.  
 
Figure 2: Cannabidivarin (CBDV) treatment rescues behavioural alterations in 5-
month-old RTT male mice; (e) in the Y-maze task, no genotype differences were found 
in the discrimination ratio index [time spent in novel arm/(novel+other arm)]*100 and 
no treatment effect was evident. Data are mean±SEM. Statistical significance was 
calculated by two-way ANOVA with Tukey’s post-hoc test. **p<0.01; *p<0.05. 
4.4.2 Neurobiological analyses 
4.4.2.1 Brain weight 
We found that the whole brain of veh-injected RTT mice weighted less 
compared to those of WT littermate controls (Fig.3, p < 0.05 after post-hoc 
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comparison on Genotype*treatment interaction: F(3,60) = 1.714; p = 0.174). 
Interestingly, the whole brain of RTT mice was increased at levels comparable 
to those of WT animals by 14 injections of CBDV at the doses of 2 and 100 
mg/Kg (Fig.3, RTT, veh vs RTT, CBDV 2 and 100 mg/Kg, p < 0.05 after post-
hoc comparisons on Genotype*treatment interaction).  
 
Figure 3: Cannabidivarin (CBDV) treatment normalizes the reduced brain weight of 
5 month-old RTT male mice; after sacrifice, the brain of experimental animals was 
collected and weighted before the hippocampal dissection; the brain of vehicle-
injected RTT mice (RTT, veh) weighted less in comparison to WT controls (WT, 
Veh); CBDV at the doses of 2mg/kg and 100 mg/Kg rescues the reduced brain weight 
of RTT mice. Data are mean±SEM. Statistical significance was calculated by two-
way ANOVA with Tukey’s post-hoc test. **p < 0.01; *p < 0.05. 
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4.4.2.2 Western Blot 
GPR55 has been described as a major target of CBDV (Anavi-Goffer 
et al., 2012; Marichal-Cancino et al., 2017). Based on this evidence, 
hippocampal levels of GPR55 were evaluated (Fig4a, Representative blots). 
We found a two-fold increase in GPR55 levels in RTT mice compared to WT 
littermates (Fig.4a-b, Genotype: F(1,24) = 18.880; p = 0.001). CBDV treatment 
did not exert significant effects on GPR55 level (Fig.4a-b, Genotype*treatment 
interaction: F(3,24) = 1.253; p = 0.313). 
 
Figure 4: 5-month-old RTT male mice present enhanced hippocampal levels of 
GPR55. (a) Representative Western blot analysis (summarized view corresponding to 
one animal per group) of GPR55 and actin. (b) Western blot analysis highlighted 
higher GPR55 level in hippocampus of RTT mice compared to WT mice. CBDV did 
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not alter GPR55 levels in both genotypes. (Data are mean±SEM. Statistical 
significance was calculated by two-way ANOVA with Tukey’s post-hoc test. **p < 
0.01; *p < 0.05. 
We explored whether the chronic treatment with CBDV affects the 
activation of the ribosomal protein (rp) S6 in the hippocampus of RTT mice. 
Neither genotype nor treatment effects were found as for total rpS6 protein 
level (S6tot) and no differences between genotypes were found as for the ratio 
between phospho-S6 (phS6) and S6tot, which expresses the functionality of 
the kinase. The CBDV treatment did not affect this parameter (Table 1). 
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Table 1. Levels of BDNF, IGF-1 and Ribosomal protein S6 activity in 
hippocampus  
Genotype Treatment BDNF  IGF-1   phS6/S6tot  
WT vehicle 100 ±58.0 100±11.7 100±0.0 
WT 
CBDV 
2mg/Kg 
149.7±50.6 108.4±6.7 96.2±31.5 
WT 
CBDV 
20mg/Kg 
89.5±59.3 92.3±43.9 103.9±44.6 
WT 
CBDV 
100mg/Kg 
132.6±77.0 94.088±5.2 117.9±41.6 
RTT vehicle 133.0±28.0 106.1±13.9 100.4±51.6 
RTT 
CBDV 
2mg/Kg 
173.8±63.4 101.996±8.3 95.8±26.6 
RTT 
CBDV 
20mg/Kg 
109.1±36.3 82.207±17.1 76.6±23.3 
RTT 
CBDV 
100mg/Kg 
89.8±24.2 96.0±3.7 85.8±48.2 
Data are mean±SEM. Hippocampal BDNF an IGF-1 levels were calculated 
performing ELISA assays and were expressed respect to WT=100. Western 
blot assay was used to quantify hippocampal levels of Ribosomal protein S6 
(S6tot) and its phosphorylated form (phS6). rpS6 activity was expressed as 
ratio phS6/S6tot levels, respect to WT=100. MeCP2-308 hemizygous male 
mice (RTT); wild-type littermates (WT); Cannabidivarin (CBDV).  
 
  
198 
4.4.2.3 ELISA 
The hippocampal levels of the neurotrophins BDNF, NGF and IGF-1 
were measured as markers of treatment efficacy. We found that hippocampal 
levels of BDNF and IGF1 did not significantly differ between RTT mice and 
WT controls at this testing age (Table 1), even though BDNF levels tended to 
be higher in RTT mouse brain. Conversely, NGF was significantly reduced in 
RTT mice (Fig.4c, p < 0.05 after post-hoc comparison on Genotype*treatment 
interaction: F(3,22) = 5.663; p = 0.005). CBDV did not produce any significant 
effect on neurotrophins levels in the hippocampus of RTT mice. However, the 
treatment with CBDV at the 100 mg/kg dose significantly increased NGF 
levels selectively in the hippocampus of WT mice (about 160% of veh-injected 
WT mice, Fig.4c, p < 0.01 after post-hoc comparison on Genotype*treatment 
interaction). 
 
Figure 4: 5-month-old RTT male mice present low hippocampal levels of NFG did 
not normalize by LP-211 treatment. (c) ELISA assays revealed that RTT mice display 
lower NGF levels in comparison to WT controls; CBDV did not rescue this alteration; 
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Data are mean±SEM. Statistical significance was calculated by two-way ANOVA 
with Tukey’s post-hoc test. **p < 0.01; *p < 0.05.  
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4.5 Discussion 
The present study demonstrates, for the first time, that 14 days of 
treatment with CBDV, a phCB extracted from Cannabis sativa, improves 
important aspects of the aberrant phenotype in a validated mouse model of 
RTT. The positive effects of CBDV treatment on RTT mice were specifically 
related to the general health status, the social sphere and the motor skills, 
phenotypic domains which are highly compromised in RTT patients (Morel 
and Demily, 2017; Stahlhut et al., 2017). Of note, the reduced brain weight of 
RTT mice was also normalized by the repeated CBDV treatment. Furthermore, 
the present study provides the first evidence of abnormal hippocampal levels 
of lipid-activated G protein-coupled receptor GPR55, a recently identified 
cannabinoid receptor, in a RTT mouse model. 
Present data provide convincing evidence that the CBDV treatment 
rescues a number of behavioural and phenotypic alterations in a validated RTT 
mouse model. In line with previous reports (Woods et al., 2012), we found that 
RTT mice show abnormal sociability in the three-chamber social test. These 
results are consistent with the increasing literature providing evidence of a link 
between cannabinoids and social behaviour in humans (Wei et al., 2017) and 
in animal models (Kaplan et al., 2017; Kramar et al., 2017; Marco et al., 2015). 
In particular, the ECS is suggested to control the molecular mechanisms 
underpinning social anxiety (Viveros et al., 2005; Wei et al., 2017). In this line, 
we found that RTT mice exhibited avoidance of the social stimulus, rather than 
a lack of preference for the social vs the inanimate one. This abnormal 
behavioural profile was largely attenuated by the CBDV treatment. 
Of note, a normalization of the compromised general health status in 
RTT mice was also observed. This effect was attributable to improvements in 
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a number of parameters which are relevant for this disorder such as mobility, 
gait, kyphosis and tremors. Moreover, these beneficial effects of the CBDV 
treatment were accompanied by a partial restoration of motor coordination and 
spontaneous locomotor activity in the home cage. Increasing evidence suggests 
the potential therapeutic efficacy of phCBs in a number of disorders 
characterized by motor dysfunctions, such as Alzheimer’s, Huntington’s and 
Parkinson’s disease (Dowie et al., 2009; Maroof et al., 2014; Pisani et al., 
2011). Taken together, present findings suggest that CBDV may provide 
significant beneficial effects on RTT-related motor defects. Further studies 
specifically tailored to confirm this hypothesis are however needed (De 
Filippis et al., 2015b). 
Another important finding of the present study concerns the 
normalization of brain atrophy in CBDV-treated RTT mice. Microcephaly is a 
peculiar feature of RTT and several studies have reported reduced brain weight 
in the mouse models (Zhou et al., 2017). It is generally acknowledged that such 
reduction is attributable to cell atrophy due to abnormalities in the 
cytoskeleton, rather than cell death (neurodegeneration is not observed in RTT 
mice or patients) (Guy et al., 2007). Given that the ECS is known to modulate 
the actin cytoskeleton (Njoo et al., 2015; Roland et al., 2014), one intriguing 
hypothesis concerns the possibility that the CBDV treatment may have 
restored the structural integrity of neurons and astrocytes or the 
cytoarchitecture of the cortex, which are abnormal in RTT mouse brain 
(Bittolo et al., 2016; Fukuda et al., 2005; Maezawa et al., 2009).  
In the present study, we provide the first evidence that GPR55 levels 
are increased in the hippocampus of early symptomatic RTT mice. Considering 
previous studies linking GPR55 with social behaviour (Kaplan et al., 2017; 
Kramar et al., 2017), motor function (Bjursell et al., 2016) and spatial memory 
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(Marichal-Cancino et al., 2018), it is conceivable that CBDV-mediated 
antagonism of GPR55 may account for the rescue of RTT-related alterations 
we report in the present study. Although further studies are needed to verify 
this possibility, our results provide a new pharmacological target for the 
treatment of RTT. In this line, it is worth noting that GPR55 has been suggested 
to be involved in the regulation of energetic metabolism (Simcocks et al., 
2014). Given that mitochondrial dysfunction is emerging as crucial in the 
pathogenesis of RTT (De Filippis et al., 2015c; Valenti et al., 2017), we suggest 
that further studies aimed at verifying whether abnormal GPR55 levels may 
account for defective mitochondrial energy production in RTT mouse brain 
should be performed. 
Interestingly, the CBDV treatment provided different effects in 
different paradigms depending on the dose used. The social defect was in fact 
contrasted by the low and the intermediate dose of CBDV (2 and 20 mg/kg), 
whereas the defective general health status and motor coordination appeared 
more efficaciously contrasted by the high and the intermediate dose (20 and 
100 mg/kg). Present results support the intermediate dose of 20 mg/kg as the 
most efficacious and highlight the need for further studies aimed at clarifying 
the molecular mechanisms underlying CBDV beneficial effects on RTT 
symptomatology. In fact, similar differential effects of low and high doses have 
been already reported for other molecules, including CBD, that were explained 
by actions on different molecular pathways (Han et al., 2014; Kaplan et al., 
2017).  
In the present study, using early symptomatic RTT mice we were not 
able to detect some behavioural and molecular alterations in veh-injected RTT 
mice that were previously reported in this RTT mouse model (De Filippis et 
al., 2012; De Filippis et al., 2014). One explanation for such discrepancies may 
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reside in the age of the experimental animals which were younger compared to 
previous experiments (5 months vs at least 7 months of age) (De Filippis et al., 
2014). This is the case for the cognitive abilities of RTT mice in the Y maze 
test as well as brain neurotrophins levels and the phosphorylation level of rpS6. 
Indeed, these cognitive and molecular deficits have been reported at 7-8 
months of age in this RTT mouse model compared to WT controls (De Filippis 
et al., 2014), but they have never been assessed at 5 months of age. In fact, 
most of the studies carried out so far in such RTT mouse model have focussed 
on clearly symptomatic mice (Moretti et al., 2006; Shahbazian et al., 2002) and 
only one study has addressed the progression of symptoms (De Filippis et al., 
2010). Present results provide new relevant information regarding the 
progression of RTT-related behavioural and molecular abnormalities in 
MeCP2-308 mice (De Filippis et al., 2010) and highlight the importance of 
studies aimed at testing the potential value of innovative therapeutic strategies 
for RTT at different stages of the disease. 
Increasing evidence suggests that modulation of neurotrophins, such as 
BDNF and IGF1, can improve RTT symptomatology and neuropathological 
signs in mouse models (Castro et al., 2014) and in patients (Katz, 2014; Pini et 
al., 2012). Besides this, numerous findings argue for a role of ECS in 
modulation of brain neurotrophin levels (Keimpema et al., 2014). Based on 
these evidences, we aimed at evaluating the effect of CBDV on the altered 
levels of relevant neurotrophins in the brain of RTT mice (Katz, 2014). In 
contrast to previous studies on older mice, in this study we could only identify 
abnormalities in the hippocampus of RTT mice concerning reduced NGF 
levels, which were not modulated by the CBDV treatment. Furthermore, no 
effects of the treatment on BDNF and IGF1 levels were evidenced. Even 
though we cannot exclude that the CBDV treatment might impact a defective 
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BDNF/IGF1 signalling at an advanced stage of the disease, present results 
suggest that the reported phenotypic improvement by CBDV treatment in RTT 
mice at the tested age involves different signalling pathways. 
We also evaluated CBDV treatment effects on the defects in mTOR/S6 
activation known to be characteristic of RTT mouse brain (De Filippis et al., 
2014; Ricciardi et al., 2011). Indeed, even though no studies have so far 
addressed CBDV effects on mTOR activation, this signalling pathway plays a 
crucial role in a number of neurodevelopmental disorders (Troca-Marín et al., 
2012) and is critically involved in regulation of synaptic plasticity and memory 
processes (Costa-Mattioli et al., 2009). Moreover, previous reports suggest that 
ECS modulation can impact mTOR signalling (Busquets-Garcia et al., 2013; 
Puighermanal et al., 2012). Based on these evidences, we reasoned that the 
CBDV treatment may normalize the defective activation of the mTOR 
pathway in RTT mouse brain. Unfortunately, at this early symptomatic stage 
of the disease we did not find any defect in the phosphorylation level of the 
rpS6, a downstream target of mTOR and S6 kinase, in the brain of MeCP2-
308 mice. This is consistent with the lack of cognitive defects in 5-month-old 
RTT mice we report in the present study. Present results do not allow us to 
exclude that the CBDV treatment might impact the defective mTOR pathway 
at a more advanced stage of the disease in the brain of RTT mice, thus restoring 
cognitive deficits.  
Conclusions 
No cure is currently available for patients suffering from RTT, a 
devastating neurodevelopmental disorder with a huge burden for families. 
Present data provide evidence that the CBDV treatment rescues several 
behavioural and phenotypic defects in a mouse model of RTT, thus 
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representing a potential therapeutic approach for this disorder. Moreover, 
GPR55 was herein for the first time suggested to be a potential target for the 
treatment of RTT. Even though further studies are needed to clarify the 
mechanisms of action of CBDV, present data highlight for the first time the 
potential therapeutic efficacy of a molecule which bears a high translational 
value. CBDV is in fact currently under investigation in the clinical setting and 
is involved in a clinical trial in children affected by Autism Spectrum 
Disorders. 
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5. Conclusion 
The present thesis aimed to search new pharmacological approaches for 
the cure of RTT and its variant CDD. No cure for these devastating disorders 
is in fact available and no completely efficacious pharmacological treatment is 
able to ameliorate full symptomatology characteristic of both RTT and CDD. 
For these reasons, the research in this field is focused on the identification of 
new therapeutic targets and new pharmacological approaches in order to at 
least ameliorate disorders symptoms and improve the quality of patient life.  
We propose two receptors as innovative pharmacological targets for the 
cure of RTT: the 5-HT7R, the most recently discovered serotonin receptor 
(Leopoldo et al., 2011), and the GPR55 (Ryberg et al., 2007), the leading 
candidate to be called cannabinoid receptor 3 (CB3) for its affinity with 
endocannabinoids and phytocannabinoids. To “hit” the two innovative targets, 
we used two different molecules: LP-211, a synthetic drug agonist of the 5-
HT7R, and CBDV, a non-psychotropic phytocannabinoid extracts from 
Cannabis sativa, antagonist of GPR55.  
In the present work we extended previous results obtained on MeCP2-
308 male and female mouse models (De Filippis et al., 2014; De Filippis et al., 
2015; Valenti et al., 2017) demonstrating that sub-chronic treatment with LP-
211 was able to rescue physiological and behavioural deficits (pulse distension 
and social impairments) and to normalize altered brain histone H3 acetylation 
and the levels of proteins forming a complex with MeCP2, the gene whose 
mutations are responsible for 95% of classical RTT cases (Vigli et al., in 
preparation); moreover, in CDD mouse model at an advanced stage of disease 
(12 months of age) the effects of LP-211 treatment were characterized for the 
first time, demonstrating that LP-211 treatment was able to normalize Prepulse 
222 
Inhibition deficit (proposing it as new tool for diagnosis of this pathology and 
to evaluate the drug efficacy) and to normalize cortical ribosomal protein S6 
and mitochondrial functionality (Vigli et al., 2018b), alterations previously 
detected also in RTT mouse models, suggesting the straight correlation 
between the two disorders. 
Regarding the use of phytocannabinoids extracts as new drugs, we 
demonstrated for the first time the positive effects of chronic treatment with 
CBDV on RTT male mouse model (MeCP2-308), showing CBDV wide 
beneficial effects on altered behavioural domains, such as worst general health 
status, motor impairments and social deficit. The reduced brain weight was 
also normalized. In addition, we demonstrated for the first time the higher 
expression of GPR55 in the hippocampus of RTT mice, proposing it as new 
pharmacological targets for the treatment of RTT (Vigli et al., 2018a).  
In conclusion, the present thesis provides compelling evidence that two 
pharmacological treatments targeting either the serotoninergic or 
endocannabinoid system ameliorate the symptomatology displayed by RTT 
and CDD mouse models, both on behavioural and molecular point of view, 
suggesting two innovative therapeutic approaches for the cure/treatment of two 
severe disorders for which no cure is available.  
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a b s t r a c t
Rett syndrome (RTT) is a rare neurodevelopmental disorder, characterized by severe behavioural and
physiological symptoms. RTT is caused by mutations in theMECP2 gene in about 95% of cases and to date
no cure is available. The endocannabinoid system modulates several physiological processes and
behavioural responses that are impaired in RTT and its deregulation has been associated with neuro-
psychiatric disorders which have symptoms in common with RTT. The present study evaluated the
potential therapeutic efficacy for RTT of cannabidivarin (CBDV), a non-psychotropic phytocannabinoid
from Cannabis sativa that presents antagonistic properties on the G protein-coupled receptor 55 (GPR55),
the most recently identified cannabinoid receptor. Present results demonstrate that systemic treatment
with CBDV (2, 20, 100 mg/Kg ip for 14 days) rescues behavioural and brain alterations in MeCP2-308 male
mice, a validated RTT model. The CBDV treatment restored the compromised general health status, the
sociability and the brain weight in RTT mice. A partial restoration of motor coordination was also
observed. Moreover, increased levels of GPR55 were found in RTT mouse hippocampus, suggesting this G
protein-coupled receptor as new potential target for the treatment of this disorder. Present findings
highlight for the first time for RTT the translational relevance of CBDV, an innovative therapeutic agent
that is under active investigation in the clinical setting.
© 2018 Elsevier Ltd. All rights reserved.
1. Introduction
Rett syndrome (RTT) is a rare neurodevelopmental disorder,
characterized by severe behavioural and physiological symptoms
(Hagberg et al., 2002; Rett, 1966; Ricceri et al., 2012). One essential
feature of RTT is the apparently normal perinatal development until
about 6e18 months of age, when RTT patients start losing their
acquired cognitive, social, and motor skills and develop a wide
variety of symptoms (Hagberg, 2002). Classic RTT is caused in about
90e95% of cases by de novomutations in the X-linkedMECP2 gene,
which encodes the methyl CpG-binding protein 2 (MECP2), a
multifunctional protein that binds to methylated DNA and mainly
acts as a key transcriptional regulator (Guy et al., 2011). Despite
extensive effort in this research field, howmutations inMECP2 lead
to the symptomatology of RTT is still unknown and no effective
therapy is currently available for this devastating syndrome.
The endocannabinoid system (ECS) is a complex neuro-
modulatory system found in all vertebrate classes, involved in the
regulation of numerous physiological functions (Kano et al., 2009).
At the central level, ECS modulates several physiological processes
and behavioural responses that are impaired in RTT (Di Marzo et al.,
2015), such as social behaviour (Wei et al., 2017), anxiety and stress
response (Jenniches et al., 2016) and motor control (El Manira and
Kyriakatos, 2010). Moreover, ECS deregulation has been associated
with many neuropsychiatric disorders such as anxiety and
depression (Jenniches et al., 2016; Micale et al., 2013), Fragile X
syndrome (Jung et al., 2012), schizophrenia (Clarke et al., 2017) and
with neurodegenerative disorders characterized by cognitive and
motor dysfunctions such as Alzheimer's, Huntington's and
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Parkinson's disease (Dowie et al., 2009; Maroof et al., 2014; Pisani
et al., 2011). Recent data also suggest an involvement of the ECS
in Autism Spectrum disorders (Chakrabarti et al., 2015).
A growing number of molecules able to directly or indirectly
modulate the ECS have been identified to date. Pioneering studies
increased the ECS response using agonists of the CB1 receptor, one
of the two well characterized G-coupled receptors for endocanna-
binoids (Berrendero and Maldonado, 2002; Jiang et al., 2005; Patel
et al., 2003). However, CB1 agonists may cause psychotropic side
effects, similar to those reported with cannabis use in recreational
settings. Such effects are now known to be due to the assimilation
of D9-tetrahydrocannabinol (THC), the main compound of Cannabis
sativa. To avoid these undesirable effects, most recent preclinical
studies focussed on the identification of molecules that modulate
the ECS without the psychotropic effects of THC, such as Rimona-
bant and URB597 (see e.g.(Griebel et al., 2005; Marco et al., 2015)).
In addition, much attention has been devoted to non-psychotropic
molecules from Cannabis sativa, which contains more than 120
substances (Morales et al., 2017). This has led to the identification of
few non-psychotropic phytocannabinoids (phCBs) with a potential
as novel drugs. These include Cannabigerol (CBG) and Cannabidiol
(CBD), the second and the thirdmost abundant chemical class types
contained in Cannabis sativa respectively. In particular CBD bears a
high potential in the treatment of muscular spasms and rigidity (Di
Marzo, 2011), epilepsy (Chiu et al., 1979; Devinsky et al., 2017),
mood disorders (Linge et al., 2016) and Alzheimer's disease (Cheng
et al., 2014). Moreover, recent evidences suggest a potential appli-
cation for CBD in pediatric conditions such as autistic-related
syndromes (Kaplan et al., 2017) and in children with refractory
epilepsy (Brodie and Ben-Menachem, 2018; Geffrey et al., 2015).
Another promising phCB is Cannabidivarin (CBDV), the n-propyl
analog of CBD. Recent evidence proves that in vitro and in vivo
treatment with CBDV in mouse and rat exerts anticonvulsant effects
(Hill et al., 2012) and prevents neuronal hyperexcitability (Iannotti
et al., 2014). However, the studies focussed on this compound are
still very limited and the mechanisms of action of CDBV have not
been clarified so far. Current evidences suggest that at physiologi-
cally relevant concentrations of CBDV show no affinity for CB1 and
CB2 receptors (Hill et al., 2012) and presents antagonistic properties
on the G protein-coupled receptor 55 (GPR55) receptor, the leading
candidate for the CB3 receptor name (Anavi-Goffer et al., 2012;
Iannotti et al., 2014; Marichal-Cancino et al., 2017; Turner et al.,
2017). This lipid-activated G protein-coupled receptor has been
suggested to regulate motor function, spatial memory and sociability
(Bjursell et al., 2016; Kramar et al., 2017; Marichal-Cancino et al.,
2018), behavioural domains that are compromised in RTT (De
Filippis et al., 2014; Moretti et al., 2006). Moreover, antagonism of
GPR55 has been recently suggested as a potential therapeutic
approach for Dravet syndrome (Kaplan et al., 2017), an autistic-like
syndrome with several symptoms in common with RTT.
Importantly, a clinical trial is currently listed aimed at evaluating
the potential efficacy of a treatment with CBDV on children affected
by Autism Spectrum Disorder (clinicaltrial.gov, NCT03202303).
Based on the high translational potentiality of CBDV as an innova-
tive therapeutic agent, in the present study MeCP2-308 hemizy-
gous male mice, a highly validated mouse model of RTT (De Filippis
et al., 2010), and wild-type littermate controls received a repeated
systemic intraperitoneal (i.p.) treatment with CBDV (2, 20, 100 mg/
Kg ip for 14 days). Mice were treated at 5 months of age, an early
symptomatic stage at which MeCP2-308 mice already present
reduced spontaneous home-cage motor activity, motor coordina-
tion impairments, and a more marked profile of D-amphetamine-
released stereotyped behavioural syndrome than WT controls (De
Filippis et al., 2010). A battery of behavioural analyses was carried
out to evaluate treatment effects. Given CBDV antagonistic action
on GPR55 (Marichal-Cancino et al., 2017), levels of this receptor
were evaluated, to verify whether they are abnormal in RTT and
CBDV treatment effects thereon. As markers of efficacy we also
explored whether the CBDV treatment impacts the abnormal
activation of the ribosomal protein (rp) S6, a downstream target of
mTOR, in the brain of MeCP2-308 mice (De Filippis et al., 2014;
Ricciardi et al., 2011), and the alterations in brain neurotrophins
levels (Chang et al., 2006; Ricceri et al., 2011). Indeed, based on
previous reports suggesting that ECS modulation in mouse brain
can impact mTOR signalling (Busquets-Garcia et al., 2013;
Puighermanal et al., 2012) and neurotrophins levels (Keimpema
et al., 2014), we hypothesised that the CBDV treatment may
normalize these RTT-related brain molecular alterations. A focus
was made on the hippocampus, a brain region critically involved in
regulation of relevant behavioural domains (Kaplan et al., 2017; De
Filippis et al., 2014).
2. Experimental procedures
2.1. Animals
The experimental subjects were 5 month-old MeCP2-308
hemizygous male mice (RTT) and wild-type (WT) littermates
(B6.129S-MeCP2tm1Heto/J from the Jackson Laboratories (USA),
stock number: 005439) (De Filippis et al., 2010; Shahbazian et al.,
2002), bred in our facility. Mice were weaned at postnatal day 25
and maintained in groups of 2e3 (according to sex) until 5 months
of age. Temperature was maintained at 21± 1 C and relative hu-
midity at 60± 10%. Animals were provided ad libitum with tap
water and a complete pellet diet (Altromin, 1324 - 10mm pellets,
Germany). All experimental procedures were conducted in con-
formity with the European Directive 2010/63/EU and the Italian
legislation on animal experimentation, D.Lgs. 26/2014.
2.2. Genotyping
DNA has been prepared from a small tail-tip biopsy taken at
weaning, as previously described (De Filippis et al., 2010). The
MeCP2 alleles have been identified by PCR using two sets of
primers. Primer set 1 (50 primer: 50-AAC GGG GTA GAA AGC CTG-30
and 30 primer: 50-ATG CTC CAG ACT GCC TTG -30) yields a product of
396 bp identifying the wildtype allele. Primer set 2 (50 primer same
as for primer set 1 and 30 primer: 50- TGA TGG GGT CCTCAGAGC -30)
yields a product of apparent size 318 bp identifying the null allele.
PCR products were electrophoresed through a 2% NuSieve 3:1
agarose gel (Cambrex Bio Science, Rockland, ME, USA) containing
0.5 mg/mL ethidium bromide, and examined under UV light.
2.3. Drug and treatment
CBDV (purity by HPLC: 95.9%) was supplied by GW Research
Limited (Salisbury, UK) and stored in a freezer (at
approximately 20 C), protected from light and freshly prepared
immediately prior to injection. Given that CBDV is a nonpolar
molecule with very low solubility in water solution, the emulsion
was prepared using Cremophor® mixed with EtOH and saline. RTT
mice and WT littermate controls were injected daily i.p. (between
9.00 and 11.00 a.m.) for 14 consecutive days with CBDV (2, 20 or
100mg/kg) or vehicle (veh) (Cremophor® EL:EtOH:saline in a ratio
of 1:2:17). After a 24-h washout period from the 14th i.p. injection,
mice were sacrificed by decapitation. Before the regions collection,
whole brains (including olfactory bulbs) of experimental animals
were rapidly weighted. Subsequently, brains were dissected and
hippocampi were collected and rapidly frozen for biochemical
analyses.
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2.4. Behavioural tests
To unravel the effects of the CBDV treatment on RTT-related
behavioural alterations, mice were subjected to a battery of
behavioural tests (Fig. 1). The following numerosity for each
experimental group has been achieved in the behavioural analyses:
WT, veh: 9; WT, CBDV 2 mg/Kg: 9; WT, CBDV 20 mg/Kg: 9; WT,
CBDV 100 mg/Kg: 9; Hz, veh: 7; Hz, CBDV 2 mg/Kg: 8; Hz, CBDV 20
mg/Kg: 8; Hz, CBDV 100 mg/Kg: 9. A total of 70 animals were used
for the study.
2.4.1. General health score
The general health of the experimental mice was qualitatively
evaluated by a trained observer, blind to the genotype of the
experimental mice, at the end of behavioural testing after the 1st,
the 7th and the 13th injection, as previously described (De Filippis
et al., 2014; Guy et al., 2001). Briefly, mice received a score (ranging
from 0e normal appearance-to 4- highly compromised) for each of
the following symptoms: gait, mobility, breathing, kyphosis, fur,
hind limb clasping, tremors and general conditions The individual
scores for each category have been subsequently analysed to obtain
a semi-quantitative measure of the general health status. Body
weight was also recorded at each scoring session.
2.4.2. Dowel test
To evaluate the effects of the treatment on motor learning ca-
pacities, the dowel test has been performed 1.5 h after the 1st, the
7th i.p. and the 13th injections as previously described (De Filippis
et al., 2015a). The hardwood round dowel is 9.0mm in diameter
and 35 cm long. The dowel has been mounted horizontally 50 cm
above a 5 cm depth bedding of sawdust. At the beginning of the
testing, each mouse has been placed in the middle of the dowel so
that the length of its body was parallel to the dowel. Latency to fall
from the dowel into a cage of bedding has been recorded (30-s
criterion) and used as a measure of motor coordination abilities.
Each mouse has repeated the test twice per each testing day, with
an inter-trial interval of at least 15min.
2.4.3. Home-cage spontaneous activity and its circadian variation
Spontaneous locomotor activity in the home-cages has been
monitored by means of an automatic device using small passive
infrared sensors positioned on the top of each cage, as previously
described (De Filippis et al., 2010, 2012). Data presented in the
Results section are referred to a selection of 5 h per phase (dark:
2e6 pm; light: 2e6 am) recorded on the first and the seventh day of
the treatment schedule. We in fact hypothesised that the arousal
state of the experimental animals is highly influenced by the
number and type of experiments that are performed on a particular
day and may affect the locomotor activity in the home cages. We
therefore selected two days of the treatment schedule on which
mice were subjected to a comparable battery of behavioural eval-
uations which included a motor coordination test and the general
health score evaluation (see Fig. 1).
2.4.4. Three-chamber social test
Sociability and social recognition were assessed in the three-
chambered test, as previously described (Smith et al., 2007). The
test started 1 h after the 5th i.p. injection. The test consists of 4
consecutive phases of 10min during which each mouse is indi-
vidually placed in the apparatus: Phase 1 (S1): mice can freely
explore the central chamber of the apparatus; Phase 2 (S2): mice
can explore the three empty chambers; Phase 3 (S3): mice can
explore either the chamber containing an empty small wire cage or
the other one containing a conspecific kept under an identical small
wire cage; Phase 4 (S4): an unfamiliar mouse is located under the
cagewirewhichwas empty during S3. Allocation of mouse partners
to specific chambers was counterbalanced within each experi-
mental group. Time spent exploring the mouse versus the empty
wire cage during S3 is considered as an index of sociability. Time
spent exploring the unfamiliar mouse versus the familiar one
during S4 is considered as an index of memory of the social stimuli.
Naïve C57 adult male mice were used as partners in this test. They
were first habituated to the small wire cages in the test environ-
ment for 2 consecutive days before the testing day. After each an-
imal was tested, the three-chamber apparatus and the wire cages
were thoroughly cleaned with 70% ethanol.
2.4.5. Y-maze test
The effects of the treatment on short-term spatial memory were
assessed on the cognitive, exploratory driven, spatial novelty
preference task. This task was carried out 1 h after the 11th i.p.
injection, as previously described (De Filippis et al., 2014, 2015a).
Mice were tested on a spontaneous, spatial novelty preference task
as previously described (Lyon et al., 2011; Sanderson et al., 2007).
The Y-maze was made from transparent Perspex, and consisted of
three 30 cm long, 8 cmwide arms with 20 cm highwalls, connected
by a central junction. A thin layer of sawdust covered the floor of
the maze. The test was carried out as previously described (Lyon
et al., 2011; Sanderson et al., 2007). Each mouse was assigned
two arms (the ‘start arm’ and the ‘other arm’) to which they were
Fig. 1. Experimental schedule; IP: intra-peritoneal.
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exposed during the first phase of the task (the ‘exposure phase’).
Allocation of arms to specific spatial locations was counterbalanced
within each experimental group. During the 5-min ‘exposure’
phase, the entrance to the third, ‘novel’, arm was closed off by the
presence of a large Perspex white block. The mouse was placed at
the end of the start arm, facing the experimenter, and allowed to
explore the start arm and the other arm freely for 5 min, beginning
as soon as themouse left the start arm. At the end of 5min exposure
phase, the mouse was removed from the maze and returned to the
home cage for 1 min. During this time, the Perspex block closing off
the novel arm was removed and the sawdust redistributed
throughout the maze to minimize the use of odor cues. The mouse
was then returned to the start arm, facing the experimenter, for the
2-min ‘test phase’. This consisted of 2-min free exploration during
which the mouse could enter all the three arms, beginning as soon
as themouse left the start arm. The test was video-recorded and the
number of entries and the length of time spent into each arm,
during both the exposure and the test phase, were subsequently
scored by means of the Noldus Observer XT. For the test phase, a
discrimination ratio [novel arm/(novel þ other arm)]*100 was
calculated for time spent in each arm.
2.5. Neurobiological analyses
2.5.1. Western blot analyses
Hippocampal tissues were suspended in buffer containing
50mM TriseHCl, pH 8.0, 150mM NaCl, 1% Triton-X100, 2mM
MgCl2 and phosphatase and protease inhibitors cocktail (PhosSTOP,
Complete Mini, Roche) and then sonicated on ice. Lysates were
centrifuged at 10000g for 15min at 4 C. Protein concentration
was determined by Bradford assay (BioRad). Samples containing
30 mg of proteins were resolved by 7,5% SDS-PAGE under reducing
and denaturing conditions and transferred to nitrocellulose mem-
brane (Amersham Protran Premium). Membranes were blocked in
TBST (10mM Tris-HCl pH 8.0, 150mM NaCl, 0.05% Tween 20) with
5% non-fat dry milk for 45min at room temperature, and then
incubated with rabbit anti-rpS6 (1:1000, Cell Signalling), rabbit
anti-phospho-rpS6 (Ser 240/244) (1:1000, Cell Signaling), rabbit
anti-GPR55 (Abcam, 1:1000) and rabbit anti-beta actin (Cell
Signaling, 1:1000) overnight at 4 C. After washing, membranes
were incubated with secondary anti-rabbit IgG HRP-conjugated
antibodies (1:3000, Amersham) for 45min at room temperature.
Detection was performed by Immobilon Western Chemilumines-
cent HRP substrate (Millipore). Quantification of protein expression
was performed by densitometry analysis using ImageLab software
V.6.0 (Chemidoc, Biorad). Optical Density (OD) from at least 4
different experimental mice per group were calculated for each
sample and normalizedwith the corresponding actin signal OD; the
OD ratios were then compared and expressed as the average fold
increase, with 100 (WT control) as the control value.
2.5.2. Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed to quantify levels of different neuro-
trophins in the hippocampus of the experimental mice. Levels of
BDNF, NGF, and IGF-1 were analysed by using microtiter wells
plates coated with anti-mouse neurotrophins antibodies (BDNF
rapid, NGF rapid, Biosensis, Australia; IGF-1 Elisa kit, Abcam, UK)
according to the manufacturer's instructions. The absorbance was
read on a spectro-photometer (Bio-Rad) using 450 nm as the pri-
mary wave length, with a sub-wave length of 650 nm. The quantity
of neurotrophins was expressed as percentage average fold in-
crease of WT control values (100).
2.5.3. Statistical analyses
Data were analysed with ANOVA models including genotype
and treatment as between-subject factors and repeated measure-
ments as within-subject factor. The alpha level was set to 5%. The
Levene test was applied to confirm the equality of variance. The
presence of outliers was verified using ROUT method. Post-hoc
comparisons were performed by Tukey HSD, even in the absence of
statistically significant interactions (Wilcox, 1987).
3. Results
3.1. Behavioural analyses
3.1.1. General health score
The evaluation of the general health status of the experimental
mice confirmed that consistent gross phenotypic alterations can be
detected in 5 month old RTT mice (Fig. 2a, RTT, veh vs WT, veh,
p< 0.01 after post-hoc comparison on Genotype*Treatment inter-
action: F(3,60)¼ 2.906; p¼ 0.042). We found that 14 injections of
CBDV at the doses of 20 and 100 mg/Kg can improve the general
health status of RTT mice (Fig. 2a, RTT, veh vs RTT, CBDV 20 mg/Kg,
p< 0.01 and RTT, veh vs RTT, CBDV, 100 mg/Kg, p< 0.01 after post-
hoc comparison on Genotype*Treatment interaction). The ANOVA
highlights significant effect of repeated measures (Days of the
schedule number 1, 7, 13: F(2,120)¼ 5.350; p< 0.006) and interaction
of this factor with Genotype (F(2,120)¼ 3.930; p< 0.022) but no
interaction with Treatment. Fig. 2a graphically shows the signifi-
cant Genotype*Treatment interaction, thus the average of all time
points (for further information on the effects of repeated measures
see Supplementary Fig.1a). RTTmiceweighed less compared toWT
littermates (Genotype: F(1,60)¼ 12.048; p< 0.001). No treatment
effects were found on this parameter (data not shown).
3.1.2. Dowel test
Motor learning ability was assessed in the Dowel test (Fig. 2b). In
line with previous data, RTT mice showed shorter latency to fall
down from the bar compared to WT controls (RTT, veh vs WT, veh,
p< 0.01 after post-hoc comparison on Day*Trial*Genotype*Treat-
ment interaction: F(6,120)¼ 2.512; p¼ 0.025). A worse performance
of RTT mice was thus confirmed in this test (De Filippis et al., 2010,
2012). Treatment with CBDV at the dose of 20mg/kg significantly
improved the motor learning ability of RTT mice and restored WT-
like levels of performance on the second testing day (the seventh of
the experimental schedule). This profile was evident on both the
first and the second trials (p< 0.01 and p< 0.05 after post-hoc
comparisons on the Day*Trial*Genotype*Treatment interaction,
respectively). However, this treatment effect was no more evident
on the 13th day of the treatment schedule. By contrast, at this latest
time point, the dose of 100 mg/Kg significantly improved themotor
learning ability of RTT mice (p < 0.05 after post-hoc comparison on
the Day*Trial* Genotype*Treatment interaction).
3.1.3. Spontaneous locomotor activity
In line with previous reports, the evaluation of spontaneous
locomotor activity in home cage revealed that RTT mice are
generally less active than WT controls (Genotype*Treatment
interaction: F(3,46)¼ 5.032; p¼ 0.004). This profile was mainly
evident during the dark/active phase (Fig. 2c, p< 0.01 after post-hoc
comparison on the Phase*Genotype*Treatment interaction:
F(3,46)¼ 4.757; p¼ 0.001). Levels of activity exhibited by RTT mice
treated with CBDV at 2mg/kg tended to be increased compared to
those shown by vehicle-injected ones. However, such a trend did
not reach statistical significance. The ANOVA did not highlight any
significant effect of repeated measures (Days of the schedule
number 1 and 7: F(1,46)¼ 3.147; p< 0.083) or interaction of this
factor with Genotype or Treatment. Fig. 2c graphically shows the
significant Phase*Genotype*Treatment interaction, thus the
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average of both days (for further information on the effects of
repeated measures see Supplementary Figure 1b).
3.1.4. Three-chamber social test
The test was carried out in order to evaluate CBDV effect on
social behaviour. As expected, the analysis of the S3 phase revealed
a statistically significant difference between genotypes, with veh-
injected RTT mice showing a reduced preference for the social
stimulus (versus the inanimate one) in comparison to veh-injected
WT controls (Fig. 2d, p< 0.01 after post-hoc comparison on the
Genotype*Treatment interaction: F (3,58)¼ 3.527; p¼ 0.020).
Importantly, the CBDV treatment at the dose of 2 and 20 mg/Kg
rescued this social deficit in RTT mice, restoring WT-like levels of
social preference (Fig. 2d, p< 0.05 after post-hoc comparison on the
Genotype*Treatment interaction). The analysis of the S4 phase did
not highlight significant genotype or treatment effects in the
recognition of a novel social stimulus (versus the familiar one)
(Supplementary Figure 1c).
3.1.5. Y-maze test
No genotype effects were found in the discrimination ratio
index at this early symptomatic age (Fig. 2e); all the experimental
mice recognized the novel arm versus the familiar one (discrimi-
nation ratio> 50). No treatment effects were evident.
3.2. Neurobiological analyses
3.2.1. Brain weight
We found that the whole brain of veh-injected RTT mice
weighted less compared to those of WT littermate controls (Fig. 3,
p< 0.05 after post-hoc comparison on Genotype*Treatment inter-
action: F(3,60)¼ 1.714; p¼ 0.174). Interestingly, the whole brain of
RTT mice was increased at levels comparable to those of WT ani-
mals by 14 injections of CBDV at the doses of 2 and 100 mg/Kg
(Fig. 3, RTT, veh vs RTT, CBDV 2 and 100 mg/Kg, p< 0.05 after post-
hoc comparisons on Genotype*Treatment interaction).
3.2.2. Western blot
GPR55 has been described as a major target of CBDV (Anavi-
Goffer et al., 2012; Marichal-Cancino et al., 2017). Based on this
evidence, hippocampal levels of GPR55 were evaluated (Fig. 4a,
Representative blots). We found a two-fold increase in GPR55 levels
Fig. 2. Cannabidivarin (CBDV) treatment rescues behavioural alterations in 5 month-old RTT male mice; Vehicle-injected RTT mice (RTT, veh) showed worse health conditions
compared to WT controls (WT, veh). Treatment with Cannabidivarin (CBDV) at 20 and 100 mg/Kg ameliorates the general health status of RTT mice; GH scores (AU: Arbitrary units)
are mean values of the three time points in which the evaluation was carried out (Days of the schedule number 1, 7, 13). (b) in the Dowel test, RTT mice displayed significantly
shorter latencies to fall from a dowel compared to WT controls, confirming impaired motor learning capacities. CBDV at the dose of 20 mg/Kg improved the performance of RTT
mice on day 7 and the 100 mg/Kg dose improved the performance of RTT mice in the second trial of day 13; Mice were tested twice per day, with an inter-trial interval of at least
15min (c) RTT, veh mice are generally less active than WT controls in the home cages. This profile was mainly evident during the dark/active phase. CBDV treatment did not affect
the hypoactive profile of RTT mice, despite a trend for the 2mg/kg dose of CBDV treatment; activity was automatically monitored by passive infrared sensors. Number of beam
breaks (cph: counts per hour) are referred to a selection of 5 h per phase (dark: 2e6 pm; light: 2e6 am) recorded on the first and the seventh day of the treatment schedule. (d) in
the three-chamber social test, RTT mice spent less time exploring the mouse versus the empty wire cage during sociability phase (S3) in comparison to WT controls. CBDV at the
doses of 2 and 20 mg/Kg rescued this aberrant behaviour restoring normal level of sociability; (e) in the Y-maze task, no genotype differences were found in the discrimination ratio
index [time spent in novel arm/(novel þ other arm)]*100 and no treatment effect was evident. Data are mean ± SEM. Statistical significance was calculated by two-way ANOVAwith
Tukey's post-hoc test. **p < 0.01; *p < 0.05.
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in RTT mice compared to WT littermates (Fig. 4aeb, Genotype:
F(1,24)¼ 18.880; p¼ 0.001). CBDV treatment did not exert signifi-
cant effects on GPR55 level (Fig. 4aeb, Genotype*Treatment inter-
action: F(3,24)¼ 1.253; p¼ 0.313).
We explored whether the chronic treatment with CBDV affects
the activation of the ribosomal protein (rp) S6 in the hippocampus
of RTT mice. Neither genotype nor treatment effects were found as
for total rpS6 protein level (S6tot) and no differences between ge-
notypes were found as for the ratio between phospho-S6 (phS6)
and S6tot, which expresses the functionality of the kinase. The
CBDV treatment did not affect this parameter (Table 1).
3.2.3. ELISA
The hippocampal levels of the neurotrophins BDNF, NGF and
IGF-1 were measured as markers of treatment efficacy. We found
that hippocampal levels of BDNF and IGF1 did not significantly
differ between RTT mice and WT controls at this testing age
(Table 1), even though BDNF levels tended to be higher in RTT
mouse brain. Conversely, NGF was significantly reduced in RTT
mice (Fig. 4c, p< 0.05 after post-hoc comparison on Genotype*-
Treatment interaction: F(3,22)¼ 5.663; p¼ 0.005). CBDV did not
produce any significant effect on neurotrophins levels in the hip-
pocampus of RTT mice. However, the treatment with CBDV at the
100mg/kg dose significantly increased NGF levels selectively in the
hippocampus of WT mice (about 160% of veh-injected WT mice,
Fig. 4c, p< 0.01 after post-hoc comparison on Genotype*Treatment
interaction).
4. Discussion
The present study demonstrates, for the first time, that 14 days
of treatment with CBDV, a phCB extracted from Cannabis sativa,
improves important aspects of the aberrant phenotype in a vali-
dated mouse model of RTT. The positive effects of CBDV treatment
on RTT mice were specifically related to the general health status,
the social sphere and the motor skills, phenotypic domains which
are highly compromised in RTT patients (Morel and Demily, 2017;
Stahlhut et al., 2017). Of note, the reduced brainweight of RTT mice
was also normalized by the repeated CBDV treatment. Furthermore,
the present study provides the first evidence of abnormal
hippocampal levels of lipid-activated G protein-coupled receptor
GPR55, a recently identified cannabinoid receptor, in a RTT mouse
model.
Present data provide convincing evidence that the CBDV treat-
ment rescues a number of behavioural and phenotypic alterations
Fig. 3. Cannabidivarin (CBDV) treatment normalizes the reduced brain weight of 5
month-old RTT male mice; after sacrifice, the brain of experimental animals was
collected and weighted before the hippocampal dissection; the brain of vehicle-
injected RTT mice (RTT, veh) weighted less in comparison to WT controls (WT, Veh);
CBDV at the doses of 2mg/kg and 100 mg/Kg rescues the reduced brain weight of RTT
mice. Data are mean± SEM. Statistical significance was calculated by two-way ANOVA
with Tukey's post-hoc test. *p < 0.05.
Fig. 4. 5 month-old RTT male mice present enhanced hippocampal levels of GPR55. (a)
Representative Western blot analysis (summarized view corresponding to one animal
per group) of GPR55 and actin. (b) Western blot analysis highlighted higher GPR55
level in hippocampus of RTT mice compared to WT mice. CBDV did not alter GPR55
levels in both genotypes. (c) ELISA assays revealed that RTT mice display lower NGF
levels in comparison to WT controls; CBDV did not rescue this alteration; Data are
mean± SEM. Statistical significance was calculated by two-way ANOVA with Tukey's
post-hoc test. **p < 0.01; *p < 0.05.
Table 1
Levels of BDNF, IGF-1 and Ribosomal protein S6 activity in hippocampus.
Genotype Treatment BDNF IGF-1 phS6/S6tot
WT vehicle 100± 58.0 100± 11.7 100± 0.0
WT CBDV 2mg/Kg 149.7± 50.6 108.4± 6.7 96.2± 31.5
WT CBDV 20mg/Kg 89.5± 59.3 92.3± 43.9 103.9± 44.6
WT CBDV 100mg/Kg 132.6± 77.0 94.088± 5.2 117.9± 41.6
RTT vehicle 133.0± 28.0 106.1± 13.9 100.4± 51.6
RTT CBDV 2mg/Kg 173.8± 63.4 101.996 ± 8.3 95.8± 26.6
RTT CBDV 20mg/Kg 109.1± 36.3 82.207± 17.1 76.6± 23.3
RTT CBDV 100mg/Kg 89.8± 24.2 96.0± 3.7 85.8± 48.2
Data are mean± SEM. Hippocampal BDNF an IGF-1 levels were calculated per-
forming ELISA assays and were expressed respect to WT¼ 100. Western blot assay
was used to quantify hippocampal levels of Ribosomal protein S6 (S6tot) and its
phosphorylated form (phS6). rpS6 activity was expressed as ratio phS6/S6tot levels,
respect to WT¼ 100. MeCP2-308 hemizygous male mice (RTT); wild-type litter-
mates (WT); Cannabidivarin (CBDV).
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in a validated RTT mouse model. In line with previous reports
(Woods et al., 2012), we found that RTT mice show abnormal so-
ciability in the three-chamber social test. These results are consis-
tent with the increasing literature providing evidence of a link
between cannabinoids and social behaviour in humans (Wei et al.,
2017) and in animal models (Kaplan et al., 2017; Kramar et al., 2017;
Marco et al., 2015). In particular, the ECS is suggested to control the
molecular mechanisms underpinning social anxiety (Viveros et al.,
2005; Wei et al., 2017). In this line, we found that RTT mice
exhibited avoidance of the social stimulus, rather than a lack of
preference for the social vs the inanimate one. This abnormal
behavioural profile was largely attenuated by the CBDV treatment.
Of note, a normalization of the compromised general health
status in RTTmice was also observed. This effect was attributable to
improvements in a number of parameters which are relevant for
this disorder such as mobility, gait, kyphosis and tremors. More-
over, these beneficial effects of the CBDV treatment were accom-
panied by a partial restoration of motor coordination and
spontaneous locomotor activity in the home cage. Increasing evi-
dence suggests the potential therapeutic efficacy of phCBs in a
number of disorders characterized by motor dysfunctions, such as
Alzheimer's, Huntington's and Parkinson's disease (Dowie et al.,
2009; Maroof et al., 2014; Pisani et al., 2011). Taken together, pre-
sent findings suggest that CBDV may provide significant beneficial
effects on RTT-related motor defects. Further studies specifically
tailored to confirm this hypothesis are however needed (De Filippis
et al., 2015b).
Another important finding of the present study concerns the
normalization of brain atrophy in CBDV-treated RTT mice. Micro-
cephaly is a peculiar feature of RTT and several studies have re-
ported reduced brain weight in the mouse models (Zhou et al.,
2017). It is generally acknowledged that such reduction is attrib-
utable to cell atrophy due to abnormalities in the cytoskeleton,
rather than cell death (neurodegeneration is not observed in RTT
mice or patients) (Guy et al., 2007). Given that the ECS is known to
modulate the actin cytoskeleton (Njoo et al., 2015; Roland et al.,
2014), one intriguing hypothesis concerns the possibility that the
CBDV treatment may have restored the structural integrity of
neurons and astrocytes or the cytoarchitecture of the cortex, which
are abnormal in RTT mouse brain (Bittolo et al., 2016; Fukuda et al.,
2005; Maezawa et al., 2009).
In the present study, we provide the first evidence that GPR55
levels are increased in the hippocampus of early symptomatic RTT
mice. Considering previous studies linking GPR55 with social
behaviour (Kaplan et al., 2017; Kramar et al., 2017), motor function
(Bjursell et al., 2016) and spatial memory (Marichal-Cancino et al.,
2018), it is conceivable that CBDV-mediated antagonism of GPR55
may account for the rescue of RTT-related alterations we report in
the present study. Although further studies are needed to verify this
possibility, our results provide a new pharmacological target for the
treatment of RTT. In this line, it is worth noting that GPR55 has been
suggested to be involved in the regulation of energetic metabolism
(Simcocks et al., 2014). Given that mitochondrial dysfunction is
emerging as crucial in the pathogenesis of RTT (De Filippis et al.,
2015c; Valenti et al., 2017), we suggest that further studies aimed
at verifying whether abnormal GPR55 levels may account for
defective mitochondrial energy production in RTT mouse brain
should be performed.
Interestingly, the CBDV treatment provided different effects in
different paradigms depending on the dose used. The social defect
was in fact contrasted by the low and the intermediate dose of
CBDV (2 and 20mg/kg), whereas the defective general health status
and motor coordination appeared more efficaciously contrasted by
the high and the intermediate dose (20 and 100mg/kg). Present
results support the intermediate dose of 20mg/kg as the most
efficacious and highlight the need for further studies aimed at
clarifying the molecular mechanisms underlying CBDV beneficial
effects on RTT symptomatology. In fact, similar differential effects of
lowand high doses have been already reported for other molecules,
including CBD, that were explained by actions on different molec-
ular pathways (Han et al., 2014; Kaplan et al., 2017).
In the present study, using early symptomatic RTTmice wewere
not able to detect some behavioural and molecular alterations in
veh-injected RTT mice that were previously reported in this RTT
mouse model (De Filippis et al., 2012, 2014). One explanation for
such discrepancies may reside in the age of the experimental ani-
mals which were younger compared to previous experiments (5
months vs at least 7 months of age) (De Filippis et al., 2014). This is
the case for the cognitive abilities of RTT mice in the Y maze test as
well as brain neurotrophins levels and the phosphorylation level of
rpS6. Indeed, these cognitive and molecular deficits have been re-
ported at 7e8 months of age in this RTT mouse model compared to
WT controls (De Filippis et al., 2014), but they have never been
assessed at 5 months of age. In fact, most of the studies carried out
so far in such RTT mouse model have focussed on clearly symp-
tomatic mice (Moretti et al., 2006; Shahbazian et al., 2002) and only
one study has addressed the progression of symptoms (De Filippis
et al., 2010). Present results provide new relevant information
regarding the progression of RTT-related behavioural and molecu-
lar abnormalities in MeCP2-308 mice (De Filippis et al., 2010) and
highlight the importance of studies aimed at testing the potential
value of innovative therapeutic strategies for RTT at different stages
of the disease.
Increasing evidence suggests that modulation of neurotrophins,
such as BDNF and IGF1, can improve RTT symptomatology and
neuropathological signs in mouse models (Castro et al., 2014) and
in patients (Katz, 2014; Pini et al., 2012). Besides this, numerous
findings argue for a role of ECS in modulation of brain neurotrophin
levels (Keimpema et al., 2014). Based on these evidences, we aimed
at evaluating the effect of CBDV on the altered levels of relevant
neurotrophins in the brain of RTT mice (Katz, 2014). In contrast to
previous studies on older mice, in this study we could only identify
abnormalities in the hippocampus of RTT mice concerning reduced
NGF levels, which were not modulated by the CBDV treatment.
Furthermore, no effects of the treatment on BDNF and IGF1 levels
were evidenced. Even though we cannot exclude that the CBDV
treatment might impact a defective BDNF/IGF1 signalling at an
advanced stage of the disease, present results suggest that the re-
ported phenotypic improvement by CBDV treatment in RTT mice at
the tested age involves different signalling pathways.
We also evaluated CBDV treatment effects on the defects in
mTOR/S6 activation known to be characteristic of RTT mouse brain
(De Filippis et al., 2014; Ricciardi et al., 2011). Indeed, even though
no studies have so far addressed CBDV effects on mTOR activation,
this signalling pathway plays a crucial role in a number of neuro-
developmental disorders (Troca-Marín et al., 2012) and is critically
involved in regulation of synaptic plasticity and memory processes
(Costa-Mattioli et al., 2009). Moreover, previous reports suggest
that ECS modulation can impact mTOR signalling (Busquets-Garcia
et al., 2013; Puighermanal et al., 2012). Based on these evidences,
we reasoned that the CBDV treatment may normalize the defective
activation of the mTOR pathway in RTTmouse brain. Unfortunately,
at this early symptomatic stage of the disease we did not find any
defect in the phosphorylation level of the rpS6, a downstream
target of mTOR and S6 kinase, in the brain of MeCP2-308 mice. This
is consistent with the lack of cognitive defects in 5 month-old RTT
mice we report in the present study. Present results do not allow us
to exclude that the CBDV treatment might impact the defective
mTOR pathway at a more advanced stage of the disease in the brain
of RTT mice, thus restoring cognitive deficits.
D. Vigli et al. / Neuropharmacology 140 (2018) 121e129 127
5. Conclusions
No cure is currently available for patients suffering from RTT, a
devastating neurodevelopmental disorder with a huge burden for
families. Present data provide evidence that the CBDV treatment
rescues several behavioural and phenotypic defects in a mouse
model of RTT, thus representing a potential therapeutic approach
for this disorder. Moreover, GPR55 was herein for the first time
suggested to be a potential target for the treatment of RTT. Even
though further studies are needed to clarify the mechanisms of
action of CBDV, present data highlight for the first time the po-
tential therapeutic efficacy of a molecule which bears a high
translational value. CBDV is in fact currently under investigation in
the clinical setting and is involved in a clinical trial in children
affected by Autism Spectrum Disorders.
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H I G H L I G H T S
• Characterization of behavioural phenotype in fully symptomatic Cdkl5-null mice.
• The 5HT7R agonist LP-211 normalizes prepulse inhibition defects in Cdkl5-null mice.
• LP-211 treatment rescues brain mitochondrial dysfunction in Cdkl5-null mice.
• The abnormal phosphorylation of rpS6 in Cdkl5-null cortex is restored by LP-211.
A B S T R A C T
Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5) gene cause CDKL5 Deficiency Disorder (CDD), a rare neurodevelopmental syndrome characterized by
severe behavioural and physiological symptoms. No cure is available for CDD. CDKL5 is a kinase that is abundantly expressed in the brain and plays a critical role in
neurodevelopmental processes, such as neuronal morphogenesis and plasticity. This study provides the first characterization of the neurobehavioural phenotype of 1
year old Cdkl5-null mice and demonstrates that stimulation of the serotonin receptor 7 (5-HT7R) with the agonist molecule LP-211 (0.25mg/kg once/day for 7 days)
partially rescues the abnormal phenotype and brain molecular alterations in Cdkl5-null male mice. In particular, LP-211 treatment completely normalizes the
prepulse inhibition defects observed in Cdkl5-null mice and, at a molecular level, restores the abnormal cortical phosphorylation of rpS6, a downstream target of
mTOR and S6 kinase, which plays a direct role in regulating protein synthesis. Moreover, we demonstrate for the first time that mitochondria show prominent
functional abnormalities in Cdkl5-null mouse brains that can be restored by pharmacological stimulation of brain 5-HT7R.
1. Introduction
CDKL5 Deficiency Disorder (CDD) (OMIM #300672) is a rare neu-
ropathological condition that is caused by mutations in the X-linked
cyclin-dependent kinase-like 5 (CDKL5) gene (Kalscheuer et al., 2003).
This disorder is characterized by a variety of behavioural and physio-
logical symptoms that include the onset of seizures in the first months
of life, severe global developmental delay resulting in intellectual dis-
ability (ID) and poor motor control, and the presence of peculiar hand
stereotypies (Bahi-Buisson et al., 2008; Fehr et al., 2016). No cure exists
for patients affected by CDD.
CDKL5 encodes a serine/threonine kinase expressed in various tis-
sues, with the brain showing the highest levels of expression (Rusconi
et al., 2008; Kilstrup-Nielsen et al., 2012). Available data point to a
crucial role of Cdkl5 in fundamental neurodevelopmental processes
such as activity-dependent regulation of neuronal morphogenesis and
plasticity (Fuchs et al., 2014; Zhou et al., 2017). These processes require
a fine-tune regulation of Cdkl5 localization in neurons, with the
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shuttling between the cytoplasm and the nucleus being regulated by the
activation of extra-synaptic NMDA receptors (Rusconi et al., 2011), and
protein localization on the post-synaptic side of excitatory synapses
being regulated by the association of the kinase with PSD-95 (Ricciardi
et al., 2012). These neuronal alterations are accompanied by a number
of behavioural deficits in mice lacking Cdkl5, including motor dys-
function, autistic-like behaviours and memory deficits (Jhang et al.,
2017; Okuda et al., 2018).
The serotonin receptor 7 (5-HT7R) is a G protein-coupled receptor
broadly expressed in the central nervous system that is involved in a
variety of neurophysiological phenomena relevant for CDD, such as
sleep, cognitive processes and synaptic plasticity (Hedlund et al., 2003;
Cifariello et al., 2008; Matthys et al., 2011). Pharmacological stimula-
tion of the 5-HT7R by the brain penetrant agonist LP-211 has provided
promising results in preclinical studies for disorders associated with
syndromic IDs, such as Fragile X syndrome and Rett syndrome (RTT)
(Costa et al., 2012; De Filippis et al., 2014a, 2015b). Of note, the
beneficial effects of LP-211 treatment extend beyond intellectual defi-
cits and impact other domains, such as motor function and autistic-like
behaviours in a mouse model of RTT (De Filippis et al., 2014a, 2015b),
a syndrome that presents several symptoms in common with CDD (Fehr
et al., 2013). Moreover, 5-HT7R stimulation by LP-211 impacts a
number of behavioural domains and molecular pathways that have
been demonstrated to be altered in Cdkl5-null mouse brain and in in-
duced-pluripotent stem cell (iPSCs)-derived neurons from CDKL5 pa-
tients (Ricciardi et al., 2012; Amendola et al., 2014), as it promotes a
rearrangement of neuronal morphology, facilitates synaptogenesis and
modulates the activation of the Akt/mTOR/S6 pathway (De Filippis
et al., 2014a; Speranza et al., 2017).
Based on these pieces of evidence, in the present study we evaluated
whether the stimulation of 5-HT7R might represent a potential ther-
apeutic approach for CDD. To test this hypothesis, 9–12-months old
Cdkl5-null male mice and wild-type littermate controls received a re-
peated systemic intraperitoneal (i.p.) treatment with LP-211 (0.25 mg/
kg once/day for 7 days) (De Filippis et al., 2015b). We reasoned that the
translational relevance of the treatment under investigation might be
increased if the relief of symptoms was demonstrated at an advanced
and more severely affected stage of the disease (1-year-old mice). Male
mice were used based on clinical evidences of CDD in males (Elia et al.,
2008) and on the effects of mosaic CDKL5 expression due to random X-
chromosome inactivation in females. To evaluate therapeutic efficacy, a
battery of behavioural analyses was carried out at the end of the
treatment specifically tailored to detect CDD-related behavioural al-
terations. Behavioural testing started at least 7 days after the end of the
i.p. treatment and the brains of the experimental mice were collected
two months after the last i.p. injection, based on previous data sug-
gesting long-term effects of a seven-day-long treatment with LP-211 (De
Filippis et al., 2015b).
In the brain of Cdkl5-null mice treated with either LP-211 or vehicle,
Rac1 activation and mitochondrial functionality were evaluated, since
recent data suggest a role for 5-HT7R in the activation of brain Rho
GTPases and in the regulation of the oxidative phosphorylation
(OXPHOS) apparatus, the mitochondrial molecular machinery re-
sponsible for the majority of cell energy production (De Filippis et al.,
2015a, 2015d; Valenti et al., 2017), central players in several patho-
logical conditions associated with ID (De Filippis et al., 2014b; Valenti
et al., 2014). We also verified whether the expression and the activation
of Rho GTPase-dependent pathways are abnormal in Cdkl5-null mouse
brain and LP-211 treatment effects thereon, based on previous data
pointing to a pathogenic role of a disrupted interaction between Cdkl5
and the Rho GTPases Rac1 (Chen et al., 2010; Barbiero et al., 2017). In
particular, we explored whether the LP-211 treatment impacts group I
PAKs, the leading molecules by which Rho GTPases affect actin cytos-
keleton dynamics (De Filippis et al., 2014b), and the activation of the
rpS6 and its upstream regulator Akt, a pathway that is modulated by
Rho GTPases and is involved in protein synthesis (Ricciardi et al., 2011;
De Filippis et al., 2014a).
2. Materials and methods
2.1. Subjects
The experimental subjects were 9–12-months old Cdkl5-null male
mice and wild-type littermates (wt) backcrossed to C57BL/6N mice for
at least 10 generations (Amendola et al., 2014). Experimental mice
were obtained by crossing Cdkl5 heterozygous (−/+) female mice and
wt male mice and weaned at postnatal day 25. After weaning, mice
were housed according to sex in groups of two or three in polycarbonate
transparent cages (33 × 13 × 14 cm) with sawdust bedding and kept
on a 12-h light-dark schedule (lights off at 8:00 am). Temperature was
maintained at 21 ± 1 °C and relative humidity at 60 ± 10%. Animals
were provided ad libitum with tap water and a complete pellet diet
(Altromin, 1324 - 10mm pellets, Germany). All experimental proce-
dures were conducted in conformity with the European Directive 2010/
63/EU and the Italian legislation on animal experimentation, D.Lgs. 26/
2014.
2.2. Genotyping
DNA has been prepared from a small tail-tip biopsy taken at
weaning, as previously described (De Filippis et al., 2014a). The Cdkl5
alleles have been identified by PCR using two sets of primers (for fur-
ther details see Supplementary materials). PCR products were electro-
phoresed through a 2% NuSieve 3:1 agarose gel (Cambrex Bio Science,
Rockland, ME, USA) containing 0.1 μl/ml GelRed™ and examined under
UV light.
2.3. Drug and treatment
LP-211 was prepared following the same synthetic procedure de-
scribed in (Leopoldo et al., 2008). The compound, which has a half-life
65min, was dissolved in a vehicle solution of 1% dimethyl sulfoxide
(DMSO) in saline (0.9% NaCl). Cdkl5-null mice and wt littermate con-
trols were randomly assigned to be daily i.p. injected (between 9.00 and
11.00 a.m.) for 7 consecutive days with either LP-211 (0.25mg/kg) or
vehicle (1% of DMSO in saline).
2.4. Behavioural testing
A comprehensive test battery was carried out aimed at assessing
treatment effects on the behavioural domains that are compromised in
CDD. The selection of the tests to be performed was based on previous
literature addressing the neurobehavioural phenotype of Cdkl5-null
mice (Amendola et al., 2014; Okuda et al., 2018) and on our lasting
experience on the study of mouse models of RTT, a syndrome that has
many symptoms in common with CDD (De Filippis et al., 2010, 2015c).
Mice were experimentally naïve at the start of the behavioural test
battery. All behavioural testing took place during the dark phase of the
L/D cycle, between 9.00 a.m. and 3.00 p.m., and was carried out by
experimenters blind to the mouse genotypes. A minimum of 24 h was
left between tests.
2.4.1. Prepulse inhibition (PPI) paradigm
Sensorimotor gating was evaluated 7 days after the last i.p. with the
prepulse inhibition (PPI) paradigm (Swerdlow et al., 2001). The ap-
paratus consisted of two Plexiglas rectangular boxes (startle cages)
(9×7 cm), placed in sound-attenuated chambers with a red light and a
fan ventilator (Med associates inc. St Albans, VT, United States of
America). Background white (62 db) noise and acoustic bursts were
conveyed by two separate speakers, properly spaced from the startle
cage so as to produce a fine-tuned regulation of sound. Both speakers
and startle cages were connected to a main PC computer, which
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detected and analyzed all chamber variables by means of a specific
software. Two slightly different protocols were adopted on two cohorts
of mice, that differed in the range of prepulse intensities under in-
vestigation. On the first cohort of mice, prepulse intensities were as
follows: 67, 70, 73 or 76 db (Macri et al., 2015). On the second cohort,
78, 82 or 84 dB pre-pulse intensities were applied (Chao et al., 2010).
To evaluate sensorimotor gating capabilities in Cdkl5-null mice, the %
PPI was calculated as follows: (100-[(mean startle amplitude for pre-
pulse + pulse trials/mean startle amplitude for pulse-alone trials) x
100]) (for further details see Supplementary materials).
2.4.2. General health score
The general health of the experimental mice was qualitatively
evaluated 1 and 28 days after the last injection, by a trained observer,
blind to the genotype of the experimental mice, according to a method
that has been developed to assess the health status of RTT mice (Guy
et al., 2007; De Filippis et al., 2014a). Briefly, mice received a score
(ranging from 0 – normal appearance-to 4- highly compromised) for
each of the following parameters: gait, mobility, breathing, kyphosis,
fur, hind limb clasping, tremors and general conditions. The individual
scores for each category were subsequently averaged to obtain a semi-
quantitative measure of the general health status.
2.4.3. Nest building evaluation
Nest building ability was scored 21 days from the last i.p. injection
to assess purposeful and coordinated forepaw use to unravel whether
Cdkl5-null mice display alterations and LP-211 effects thereon, as pre-
viously described (De Filippis et al., 2015a). The quality of the nests
was evaluated 24 h after nest material provision (for further details see
Supplementary materials).
2.4.4. Home cage locomotor activity
To verify whether LP-211 treatment affects the daily locomotor
activity in Cdkl5-null mice, spontaneous locomotor activity in the
home-cages was evaluated 33 days after the last i.p. injection. Levels of
activity were monitored continuously by means of an automatic device
using small passive infrared sensors positioned on the top of each cage
(ACTIVISCOPE system, NewBehaviour Inc., Zurich, Switzerland) as
previously described (De Filippis et al., 2013) (for further details see
Supplementary materials). To avoid confounding effects due to cage
clean procedures and/or room entrances, the analysis was performed
during two 6-h intervals, during the dark and the light phase, in which
animals were left undisturbed.
2.4.5. Open field test
Locomotor activity was assessed in the Open Field test 30 days after
the last i.p injection, to complement the home-cage recording (Ricceri
et al., 2011) (for further details see Supplementary materials).
2.4.6. Fear conditioning task
The fear conditioning task was carried out 14 days after the last i.p.
injection to evaluate cognitive abilities in Cdkl5-null mice and LP-211
effect thereon (Wang et al., 2012). An automated system was used
(UgoBasile S.R.L.), which consisted in a soundproof cubic apparatus
with inside a mouse cage (21(d) x 24(w) x 30(h) cm) with electrified
grid floor. The task consisted of a two-days-long protocol in which
freezing frequency and duration were measured with an automatic
freezing detector (UgoBasile S.R.L.). Throughout the task, mice were
exposed to a white noise (WN- 60 db, 2000 Hz). On the first day
(training), animals were placed in the fear conditioning apparatus for
180s (baseline, BL) and then exposed for three times to the acoustic
conditioned stimulus (CS; 2000 Hz–68 db, 30s). Each CS on the first day
was paired with a 0.7mA shock released during the last 2s (uncondi-
tioned stimulus; US). A 95s inter trial interval (ITI) was used. On the
second day(test), mice were placed in the same chamber and, after a
180s BL, were exposed to fifteen trials consisting in 30s of CS plus 10s of
ITI. Contextual fear memory was established by measuring the time
spent in freezing behaviour during the baseline on the testing day
compared to levels shown during the baseline on the training day.
Freezing behaviour in response to the CSs on the test day was also
evaluated. Before the starting of each session the grid floor of the ap-
paratus was cleaned with 70% ethanol.
2.5. Neurobiological analyses
Two months after the last i.p. injection, the brains of the experi-
mental mice were dissected and cortices, a behaviourally relevant brain
area in which 5-HT7R (Hedlund, 2009) and Cdkl5 (Wang et al., 2012)
are highly expressed, were immediately frozen in dry ice for G-LISA
Assay and western blot analyses (De Filippis et al., 2015b).
For mitochondrial analyses, the hemispheres from additional sub-
jects were cryopreserved, as previously described (Valenti et al., 2017).
Previous data in fact demonstrate that cryopreserved brain tissues show
mitochondrial membrane potential, outer and inner membrane in-
tegrity and mitochondrial ATP production capacity comparable to mi-
tochondria isolated from fresh brains (Valenti et al., 2014).
2.5.1. RAC-1 G-LISA assay
Rac1 G-Lisa Activation Assay BiochemkitTM (Cytoskeleton, Denver,
CO) (n=4–5) was used to measure Rac1 activity in mouse cortices
according to the manufacturer's recommendations.
2.5.2. Western blot analysis
Cortices were homogenized in lysis buffer and centrifuged. Then the
supernatant was collected and the protein content was quantified by
bicinchonic acid assay. For western blotting analysis, 20 μg of total
proteins were separated on a 12% SDS-PAGE and membranes incubated
with the appropriate primary and secondary antibodies. Images of the
membranes were acquired by a CCD camera (Syngene, G-Box Chemi
XRQ) and optical densities (O.D.) of the protein signals calculated for
each sample with Image J software and normalized with the corre-
sponding housekeeping signal (Fig. 4 A, C); the O.D. ratios were then
compared and expressed as the average fold increase, with 1 (wt con-
trol) as baseline (for further details see Supplementary materials).
2.5.3. Mitochondrial analysis
Measurement of mitochondrial respiratory chain complex (MRC) ac-
tivities. MRC activities were evaluated in mitochondrial membrane-en-
riched fractions obtained from isolated mitochondria. Measurement of
MRC complex activities were performed essentially as in (Manente
et al., 2013), by three assays which rely on the sequential addition of
reagents to measure the activities of: i) NADH: ubiquinone oxidor-
eductase (complex I) followed by ATP synthase (complex V), ii) succi-
nate: ubiquinone oxidoreductase (complex II) and iii) cytochrome c
oxidase (complex IV) followed by cytochrome c oxidoreductase (com-
plex III) (for further details see Supplementary materials).
Measurement of mitochondrial ATP production rate. The rate of ATP
production by OXPHOS was determined in isolated mitochondria, as
previously described in (Valenti et al., 2010) (for further details see
Supplementary materials).
Measurement of mouse brain ATP levels. Half brain was weighted
(approx. 20 mg) and subjected to perchloric acid extraction as de-
scribed in (Khan, 2003) (for further details see Supplementary mate-
rials). The amount of tissue ATP was determined enzymatically in KOH
neutralized extracts, as described in (Valenti et al., 2010).
2.6. Statistical analysis
Data were analyzed using the ANOVA model, including genotype
and treatment as between-subjects factors, or applying repeated mea-
sures ANOVAs if there was a within-subjects factor, using Statview vers.
5.0 (Sas, Institute Inc., Cary, NC). The alpha level was set to 5%. To
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unravel the presence of outliers, the Grubbs' test was applied. Post-hoc
comparisons were performed using Tukey HSD (Wilcox, 1987).
3. Results
3.1. LP-211 treatment selectively rescues PPI deficit in mice lacking Cdkl5
at an advanced stage of the disease
To evaluate the efficacy of the LP-211 treatment for CDD, a broad
test battery was carried out.
Prepulse inhibition (PPI). The evaluation of the sensorimotor gating
showed significant deficits in PPI capacity in Cdkl5-null mice compared
to wild–type (wt) controls, in the absence of changes in the acoustic
startle response (see Fig. S1 A-B). This genotype effect was replicated on
two cohorts of animals using protocols adopting different ranges of
prepulse intensities [Fig. 1A cohort 1: Genotype*Treatment interaction:
F (1,22) = 12.2, p = 0.021; post-hoc: p < 0.01; Fig. 1B cohort 2:
Genotype*Treatment interaction: F (1,33) = 7.3, p = 0.011; post-hoc:
p < 0.01].The LP-211 treatment significantly improved this abnormal
behaviour in Cdkl5-null mice compared to vehicle (veh)-treated Cdkl5-
null mice in both cohorts of animals [Fig. 1A, Genotype*Treatment;
post-hoc: p < 0.01; Fig. 1B; Genotype*Treatment; post-hoc: p < 0.05].
No significant prepulses intensities*genotype*treatment interactions
were found (Fig. S1 C-D).
General health status. We found that fully symptomatic Cdkl5-null
mice showed worse general health conditions in comparison to wt mice
[Fig. 2A; Genotype: F (1,35)= 7.8; p=0.008]. The LP-211 treatment
did not significantly improve general health status in Cdkl5-null mice
(Fig. 2A). No differences between the first and the second evaluation (1
and 28 days from the last i.p.), and no interaction of the repeated
measures with genotype and treatment were found. Fig. 2A represents
the genotype*treatment interaction, in which the general health scores
obtained at 1 and 28 days after the last i.p. injections were averaged.
Nest building ability. Nest building ability was slightly, but sig-
nificantly impaired in Cdkl5-null mice in comparison to wt controls
[Genotype: F (1,35)= 4.9; p=0.032], thus confirming defective co-
ordination of forepaws (De Filippis et al., 2015a; Fuchs et al., 2018b).
The LP-211 treatment did not affect the quality of the nests built by
Cdkl5-null mice (wt veh: 2.3 ± 1.2; Cdkl5-null veh: 1.8 ± 1.4; wt LP-
211: 2.5 ± 1.2; Cdkl5-null LP-211: 1.3 ± 1.0).
Home cage locomotor activity. The evaluation of spontaneous home
cage locomotor activity highlighted a hypoactive profile in Cdkl5-null
mice compared to wt controls, as demonstrated by the lower number of
beam breaks they performed during the dark/active phase of the Light/
Dark cycle [Fig. 2B; Phase*Genotype*Treatment interaction: F
(1,28) = 3.3; p = 0.082; post-hoc: p < 0.05]. The LP-211 treatment
did not affect the abnormal locomotor profile shown by Cdkl5-null mice
in the home cage.
Open field test. We found that Cdkl5-null mice show hyperactivity
when exposed to a novel environment compared to wt controls, as
demonstrated by the increased distance they moved in the open field
[Fig. 2C; Genotype: F (1,33)= 13.6; p < 0.001] as well as the number
of entrances in the central zone of the arena [Genotype: F (1,33)= 5.9,
p < 0.021]. Increased locomotion was confirmed throughout the 60-
min Open Field test, with no differences between the initial and the last
5-min blocks (Fig. S2). LP-211 treatment did not exert any effects on the
total distance moved (Fig. 2C) as well as the number of entrances in the
central zone of the arena (wt veh:191.5 ± 65.1; Cdkl5-null mice veh:
222.4 ± 83.9; wt LP-211: 176.6 ± 55.2; Cdkl5-null mice LP-211:
252.6 ± 60.7). No difference between Cdkl5-null mice and wt controls
was found in time spent in the central/intimidating zone of the arena,
an index of anxiety-like behaviours (data not shown).
Fear conditioning test. Defective contextual fear memory was found
in Cdkl5-null mice, as demonstrated by the reduced freezing levels they
displayed compared to wt controls when exposed to the context in
which they received the footshock on the previous day [Fig. 2D;
Day*Genotype*Treatment interaction: F (1,35) = 3.1; p = 0.086; post-
hoc: p < 0.01]; no significant LP-211 treatment effect was highlighted
on this hippocampus-dependent cognitive deficit. Reduced freezing in
response to the presentation of the 15 CSs on the second day of testing
compared to wt controls was also evident in Cdkl5-null mice [Genotype:
F (1,35)= 11.6; p < 0.001]. The LP-211 treatment did not improve
this abnormal freezing response shown by Cdkl5-null mice (wt
veh:27.9 ± 10.2; Cdkl5-null mice veh: 16.3 ± 12.0; wt LP-211:
24.1 ± 11.8; Cdkl5-null mice LP-211: 16.5 ± 12.8).
3.2. The LP-211 treatment activates Rac1 and rescues the abnormal
activation of rpS6 in the cortex of Cdkl5-null mice
Based on available data suggesting that Rac1 signaling may be de-
fective in CDD (Chen et al., 2010), the activation of Rac1 and of the Rho
GTPases downstream molecules PAKs and rpS6 was evaluated in Cdkl5-
null mouse cortex, to verify whether they are abnormal and whether
pharmacological stimulation of the 5-HT7R may recover them.
Rac1 activation. No genotype difference was found in the activation
of Rac1 in Cdkl5-null mouse cortex. The LP-211 treatment significantly
Fig. 1. LP-211 treatment selectively res-
cues prepulse inhibition (PPI) deficit in
Cdkl5-null mice at an advanced stage of
the disease. PPI evaluation was carried out
on two cohorts of animals using protocols
adopting different ranges of prepulse in-
tensities; (A-B) Cdkl5-null mice show a se-
vere impairment in PPI compared to wt
mice. LP-211 treatment rescues the ab-
normal sensory motor gating in Cdkl5-null
mice (cohort 1: wt, Veh= 4; wt, LP-
211= 7; Cdkl5-null, Veh=8; Cdkl5-null,
LP-211= 9; cohort 2: wt, Veh=11; wt, LP-
211= 12; Cdkl5-null, Veh= 7; Cdkl5-null,
LP-211 = 7). The histograms show the
average of all prepulse intensities. Data are
mean ± SEM. Statistical significance was
calculated by two-way ANOVA.
**p < 0,01; *p < 0,05 after Tukey's post-
hoc tests.
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increased Rac1 activation in both genotypes [Fig. 3, Treatment: F
(1,15)= 5.8; p= 0.028].
Expression and activation of RhoGTPase-dependent signaling pathways.
We found that phospho-PAK(p-PAK)/total PAK ratio, which provides an
index of the net functionality of the kinase, was shifted toward in-
creased activation in Cdkl5-null mouse cortex compared to wt controls
[Fig. 4A and B; Genotype: F (1,17)= 15.7; p < 0.001]. The LP-211
treatment increased PAK activation in the cortex of both genotypes, as
demonstrated by increased p-PAK/total PAK ratio [Fig. 4B, Treatment:
F (1,17)= 11.7; p= 0.003].
In Cdkl5-null mouse cortex, we also observed increased ribosomal
protein S6 (rpS6) activation (Fig. 4C representative blots), as demon-
strated by increased phospho-rpS6 (240/244) (p-rpS6)/total rpS6 ratio,
which was normalized by the LP-211 treatment [Fig. 4D; Genotype*-
Treatment interaction: F (1,18) = 3.2, p = 0.089; post-hoc: p < 0.05].
No genotype or treatment effects were found on the phosphorylation
levels of the rpS6 at Ser235/236 in the cortex (Fig. 4E).
Akt activation levels. In the cortex of Cdkl5-null mice, no genotype
difference and no LP-211 treatment was detected for the activation of
Akt quantified as the ratio phospho-Akt (p-Akt)/Akt total (Fig. S3).
Cdkl5 levels. Interestingly, the LP-211 treatment slightly, but sig-
nificantly increased Cdkl5 protein levels in the cortex of LP-211-treated
wt mice, in comparison to wt controls [Genotype*Treatment interac-
tion: F (1,18) = 11.6, p = 0.003; post-hoc: p < 0.01; wt, veh:
100 ± 0.2 and wt, LP-211: 140 ± 0.2 (% relative to wt)]. As expected,
Cdkl5 was not detected in the brain of mutant mice.
5-HT7R levels. We also evaluated whether the levels of the 5-HT7R
differ in the brain of Cdkl5-null mice compared to wt controls and LP-
211 effects thereon. No significant genotype or treatment effects were
found in cortex (Fig. S4).
Fig. 2. Cdkl5-null mice show severe behavioural alterations at an advanced stage of the disease. (A) Cdkl5-null mice present a higher general health score
compared to wt controls, thus confirming a worse general health status (score= 0–4). No treatment effects are found (wt, Veh=11; wt, LP-211=12; Cdkl5-null,
Veh= 8; Cdkl5-null, LP-211=8). (B) Cdkl5-null mice show hypoactivity in the home cage in comparison to wt mice during the dark/active phase of the circadian
cycle. The LP-211 treatment does not affect this parameter. The infrared sensors detect any movement of mice with a frequency of 20 events per second (20 Hz).
Scores are obtained as counts per hour (cph) expressed during 1-h periods, and the profile of daily activity is obtained by averaging 6-h of continuous registration per
phase (Dark vs Light; 1–6pm - 2–8am) (wt, Veh=8; wt, LP-211= 10; Cdkl5-null, Veh= 7; Cdkl5-null, LP-211= 7). (C) A hyperactive profile is evident in the open
field task, with Cdkl5-null mice moving more than wt controls, that is not affected by the LP-211 treatment. (wt, Veh= 11; wt, LP-211= 12; Cdkl5-null, Veh= 8;
Cdkl5-null, LP-211=8). (D) Cdkl5-null mice show reduced freezing behaviour in comparison to wt mice in the fear conditioning task, suggesting defective contextual
fear memory. The LP-211 treatment does not affect the performance in this cognitive test (wt, Veh= 11; wt, LP-211= 12; Cdkl5-null, Veh= 8; Cdkl5-null, LP-
211 = 8). Data are mean ± SEM. Statistical significance was calculated by two-way ANOVA. **p < 0,01; *p < 0,05 after Tukey'spost-hoc tests.
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3.3. Cdkl5-null mouse brain shows defective mitochondrial functionality
that is rescued by the LP-211 treatment
Based on recent evidence suggesting a role for 5-HT7R and Rho
GTPases in the regulation of brain mitochondrial functionality (De
Filippis et al., 2015c, 2015d; Valenti et al., 2017), we analyzed mi-
tochondrial functionality in Cdkl5-null mouse brains.
Activity of Mitochondrial Respiratory Chain (MRC) complexes. We
Fig. 3. The LP-211 treatment significantly increases
Rac1 activation in both genotypes. The activation of
Rac1 protein was evaluated in mouse cortical brain areas
by G-Lisa Activation Assay. No differences were found
between Cdkl5-null mice and wt littermates. LP-211
treatment increases Rac1 activation levels in both geno-
types (wt, Veh=5; wt, LP-211= 5; Cdkl5-null, Veh= 5;
Cdkl5-null, LP-211= 4). Data are mean ± SEM.
Statistical significance was calculated by two-way
ANOVA.
Fig. 4. The LP-211 treatment rescues the abnormal activation of rpS6 in the cortex of Cdkl5-null mice. Representative Western blot analysis (summarized view
corresponding to one or three animals per group) of (A) phospho-PAK (p-PAK) and PAK tot, (C) rpS6 p240/244, rpS6 p235/236 and rpS6 tot proteins in cortical brain
areas. (B) The LP-211 treatment increases the activation of group I PAKs, measured as p-PAK/PAK tot ratio in the cortex of Cdkl5-null and wt mice. This leads to an
exacerbation of the overactivation of PAK in Cdkl5-null mouse cortex. (D) The LP-211 treatment normalizes the abnormal level of the p-rpS6(240/244)/rpS6tot ratio
inCdkl5-null mouse cortex. The LP-211 treatment does not affect cortical levels of the p-rpS6(235/236)/rpS6 tot ratio (E) (wt, Veh=4; wt, LP-211=6; Cdkl5-null,
Veh= 6; Cdkl5-null, LP-211 = 6). Data are expressed as percentage of wt veh controls (100). Data are mean ± SEM. Statistical significance was calculated by two-
way ANOVA. **p < 0,01; *p < 0,05 after Tukey's post-hoc tests.
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found reduced activity of the MRC complexes III, IV and V in Cdkl5-null
mouse brains compared to wt controls [Fig. 5A; Repeated measur-
e*Genotype*Treatment interaction: F (4,32) = 13.4; p < 0.001; post-
hoc: p < 0.01]. No difference was found in the activity of complexes I
and II (Fig. 5A). A complete restoration in the activity of the defective
MRC complexes in LP-211-treated Cdkl5-null mice was found [Fig. 5A;
Repeated measure*Genotype*Treatment interaction; post-hoc:
p < 0.01 compared to vehicle-treated Cdkl5-null mice for complexes
Fig. 5. Cdkl5-null mouse brain shows defective mitochondrial functionality that is rescued by the LP-211 treatment. (A) Reduced activity of mitochondrial
respiratory chain (MRC) complexes III, IV, V is evident in Cdkl5-null mouse brain compared to wt controls. LP-211 treatment rescues these alterations. (B)
Mitochondrial ATP production rate and (C) ATP level are lower in the brain of Cdkl5-null mice. The LP-211 rescues the defective energy status in the brain of Cdkl5-
null mice (B, C) (wt, Veh= 3; wt, LP-211=3; Cdkl5-null, Veh= 3; Cdkl5-null, LP-211 = 3). Data are mean ± SEM. Statistical significance was calculated by two-
way ANOVA. **p < 0,01; *p < 0,05 after Tukey's post-hoc test.
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IV and V and p < 0.05 compared to vehicle-treated Cdkl5-null mice for
complex III].
Brain energy status evaluation. To evaluate if normalization of the
activity of MRC complexes was associated with a normalization of their
bioenergetic efficiency, the ATP production rate and ATP whole brain
levels were measured (Fig. 5 B, C). In line with the results on complexes
activity, Cdkl5-null mouse mitochondria showed a significant reduction
in mitochondrial ATP production rate when supplied with the substrate
for complex IV (ascorbate/TMDP), as energy source [Fig. 5B; Repeated
measure*Genotype*Treatment interaction: F (2,16) = 3.2; p = 0.066;
post-hoc: p < 0.05]. No changes were found when substrates for
complexes I and II were used (Fig. 5B). Importantly, whole brain ATP
levels were also reduced in Cdkl5-null mouse brain in comparison to wt
controls [Fig. 5C; Genotype*Treatment interaction: F(1,12) = 20.2;
p < 0.001; post-hoc: p < 0.01]. LP-211 treatment completely rescued
the defective mitochondrial ATP production and the reduced brain ATP
levels in Cdkl5-null mice [Fig. 5B; ATP production: Repeated measur-
e*Genotype*Treatment interaction; post-hoc: p < 0.05; Fig. 5C; whole
brain ATP level: Genotype*Treatment interaction; post-hoc: p < 0.01].
4. Discussion
This study provides the first characterization of the behavioural
phenotype of Cdkl5-null mice at an advanced stage of the disease and
demonstrates that 5-HT7R modulation, with the 5-HT7R agonist LP-211,
partially rescues the abnormal neurobehavioural phenotype of fully
symptomatic Cdkl5-null male mice. In particular, in Cdkl5-null mice
receiving the LP-211 treatment we found a normalization of PPI deficits
and a complete restoration of rpS6 activation in cortical brain areas.
Moreover, we demonstrate for the first time that mitochondria, the
powerhouses of the cells, show important abnormalities at the func-
tional level in Cdkl5-null brain and that such functional alterations can
be persistently restored by modulation of brain 5-HT7R.
In spite of the progressive nature of CDD, mouse studies have been
so far focused on young animals (i.e. 2–4 months of age) and no in-
formation is available on behavioural as well as brain molecular al-
terations in Cdkl5-null mice at an advanced stage of the disease. The
present study provides the first comprehensive characterization of the
behavioural phenotype displayed by 9–12-months old Cdkl5-null male
mice. In particular, we found marked alterations in the general health
status and in the locomotor profile, with Cdkl5-null mice showing an
hypolocomotor profile in the home cage and hyperlocomotion in the
open field, thus confirming previous data in young animals (Amendola
et al., 2014; Jhang et al., 2017). An abnormal profile was also observed
in the fear conditioning task, suggestive of a profound cognitive im-
pairment in fully symptomatic Cdkl5-null mice. We cannot however
exclude that the hyperactive profile shown by Cdkl5-null mice when
exposed to novel contexts may account for the reduced freezing beha-
viour in this cognitive task (Amendola et al., 2014; Jhang et al., 2017).
Furthermore, the comprehensive battery of behavioural tests we
carried out allowed us to identify the presence of severe PPI deficits in
fully symptomatic Cdkl5-null mice, a measure of sensorimotor gating of
the startle reflex (Swerdlow et al., 2001) that is known to be affected in
patients with several neuropsychiatric disorders including schizo-
phrenia (Braff et al., 2001), and in rodent models (Schwabe and Krauss,
2017). As PPI can be easily assessed in patients (Braff et al., 2001),
present results provide to the clinical setting an innovative, non-in-
vasive tool to test the efficacy of potential treatments for CDD. Further
studies are however needed to uncover the developmental course of this
behavioural alteration as a reduction in PPI was previously reported in
two-months old Cdkl5-null mice, that just missed statistical significance
(Okuda et al., 2018).
Of note, the LP-211 treatment rescued this behavioural alteration in
Cdkl5-null mice. A link between PPI deficits and abnormal serotonin
signaling has been clearly established, with either an increase or a
decrease in serotonin signaling leading to PPI disruption (Fletcher et al.,
2001). Moreover, based on human studies demonstrating that 5-HT7R
mRNA is downregulated in the dorsolateral prefrontal cortex of schi-
zophrenics (East et al., 2002), several works have addressed and de-
monstrated the involvement of 5-HT7R in regulation of the PPI response
in rodents (Pouzet et al., 2002b; Semenova et al., 2008). Our results
similarly suggest that 5-HT7R may be critically involved in serotonin-
dependent regulation of the sensorimotor gating processing. Since we
did not observe any change in the levels of the 5-HT7R in Cdkl5-null
mouse brain, our results suggest that stimulation of the 5-HT7R might
have indirectly rescued 5-HT7R-independent defects in Cdkl5-null
mouse brain. Indeed, several serotonin receptors have been found to be
involved in the regulation of PPI (Pouzet et al., 2002a; Mitchell and
Neumaier, 2008; Pogorelov et al., 2017). Moreover, other neuro-
transmitter systems including glutamate and dopamine play a role in
regulating sensorimotor gating (reviewed in (Geyer et al., 2001)).
Another important finding of the present study concerns the de-
monstration that Cdkl5-null mouse brains display impaired mitochon-
drial OXPHOS and a consequent decrease in brain energy status. We
found reduced activity of the complexes III, IV, V and decreased ATP
production and defective whole brain energy status. How the lack of
Cdkl5 produces such a mitochondrial dysfunction in mouse brain is not
yet clear. Both transcriptional and post-translational mechanisms may
be involved (De Filippis et al., 2015b). Of note, high levels of oxidative
stress markers have been found in CDKL5 patients (Pecorelli et al.,
2011), that have been proposed to be due to mitochondrial dysfunction
(Pecorelli et al., 2015). We clearly demonstrate here the occurrence of
multilevel dysfunctions of brain mitochondria in Cdkl5-null mice, thus
providing support to this hypothesis.
Interestingly, reactivation of mitochondrial respiratory chain com-
plexes in Cdkl5-null mouse brain by the LP-211 treatment rescued the
defective brain energy status. Present results are in line with previous
studies reporting the beneficial effect of the LP-211 treatment on brain
mitochondrial function of two mouse models of RTT (Valenti et al.,
2017). Taken together, these data strengthen the suggested link be-
tween 5-HT7R and mitochondria in mouse brain and add relevant in-
formation to previous studies demonstrating a role for the serotonergic
system in the regulation of mitochondria homeostasis (Chen et al.,
2007; de Oliveira, 2016).
In the present study, we focused on RhoGTPases signaling, based on
previous evidence suggesting that these pathways may be altered in
CDD (Chen et al., 2010). Contrary to our expectation, we found normal
activation levels of Rac1 in Cdkl5-null mouse cortex at the tested age.
These results are in contrast with previous in vitro studies suggesting
that defective Rac1 activation may play a role in CDD pathogenesis
(Chen et al., 2010; Barbiero et al., 2017). Since no data on younger
animals are currently available we cannot however exclude that such
inconsistency may be due to the advanced age of the experimental
mice. Indeed, a recent study aimed at evaluating Rac1 signaling in the
brain of Fragile X mouse model has uncovered an age-dependent effect,
with the observed Rac1 overactivation disappearing in older animals
(Pyronneau et al., 2017).
Evidence that CDKL5 pathogenesis changes as the disease pro-
gresses is in fact provided by the increased activation of rpS6 (p 240/
244) and the lack of genotype differences in Akt activation we found in
Cdkl5-null mouse cortex at an advanced stage of the disease, which are
in contrast with the previously reported reductions in younger animals
(9–12 months of age vs postnatal day 27 and 60) (Amendola et al.,
2014; Della Sala et al., 2016). Moreover, recent evidence demonstrated
age-dependent efficacy of pharmacological treatment strategies in
Cdkl5-null mice, with drugs exerting promising beneficial effects in
two-month old Cdkl5-null mice losing their effectiveness at an advanced
stage of the disease (Fuchs et al., 2018a). Altogether, these data high-
light the need for studies aimed at evaluating the developmental pro-
gression of the disease and for innovative therapeutic strategies to be
applied at an advanced stage of the disease, when previously efficacious
therapies may lose their effectiveness.
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We found that the LP-211 treatment normalized the unexpected
overactivation of rpS6 in Cdkl5-null cortex, in addition to PPI deficits
and mitochondrial dysfunction. Given that Rac1 and AkT activation
were found to be normal and were not affected by the LP-211 treat-
ment, present results suggest that different upstream molecules of rpS6
are altered in Cdkl5-null mouse brain at an advanced stage of the dis-
ease, that may account for the beneficial effects of the treatment under
investigation (Bokoch, 2003; Biever et al., 2015). Indeed, the 5-HT7R
activation is known to stimulate several signaling cascades (Speranza
et al., 2013; Guseva et al., 2014). Interestingly, among them, PKA ac-
tivation has been intriguingly linked to de-phosphorylation of rpS6 at
Ser240/244 (Bonito-Oliva et al., 2013) and to regulation of PPI (Kelly
et al., 2007).
Besides the overactivation of rpS6, increased activation of group I
PAKs was also evident in Cdkl5-null mouse brain, that was exacerbated
by the LP-211 treatment. This family of proteins is crucially involved in
several neuronal processes potentially relevant for CDD. In fact, group I
PAKs play a crucial role in modulating ultrastructural neuronal mor-
phology in vivo and in regulating activity-dependent actin dynamics,
underlying synaptic plasticity (Hayashi-Takagi et al., 2010; De Filippis
et al., 2014b; Duffney et al., 2015). Moreover, overactivation of the
Rac/Pak pathway affects fear memory (Das et al., 2017), social learning
(Molosh et al., 2014) and synaptic plasticity (Hayashi et al., 2004,
2007; Martinez and Tejada-Simon, 2011). Taken together, these results
highlight the overactivation of Group I PAKs as a potential innovative
target for the treatment of CDD at an advanced stage of the disease.
Group I PAKs inhibitors are in fact increasingly recognized as promising
candidates for the treatment of Fragile X and schizophrenia (Dolan
et al., 2013; Hayashi-Takagi et al., 2014).
In conclusion, the present study provides the first evidence that the
LP-211 treatment partially rescues the abnormal neurobehavioural
phenotype of clearly symptomatic Cdkl5-null male mice. Abnormal PPI
and reduced brain energy status due to mitochondrial dysfunction were
also uncovered, for the first time, in Cdkl5-null mice at an advanced
stage of the disease, thus providing innovative endophenotypes for
CDD. Moreover, we provide here the first in vivo evidence that Cdkl5 in
mouse cortex is involved in regulation of group I PAKs, a family of
proteins that are crucially involved in several neuronal processes po-
tentially relevant for CDD. Altogether, the present data highlight in-
novative endophenotypes and druggable molecular targets for this de-
vastating disorder.
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Glossary
CDKL5 Deficiency Disorder: CDD
Cyclin-dependent kinase-like 5: CDKL5
Serotonin receptor 7: 5-HT7R
Intellectual disability: ID
Rett syndrome: RTT
Induced-pluripotent stem cells: iPSCs
Ribosomal protein: rp
Intraperitoneal: i.p.
Oxidative phosphorylation: OXPHOS
Wild-type: wt
Prepulse inhibition: PPI
Mitochondrial Respiratory Chain: MRC
Dimethyl sulfoxide: DMSO
White noise: WN
BL: baseline
CS: conditioned stimulus
US: unconditioned stimulus
Inter trial interval: ITI
Nomenclature
LP-211: N-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide
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